Patent Application
20190359589
The present invention relates to pyridine compounds and the N-oxides and the salts thereof for combating phytopathogenic fungi, and to the use and methods for combating phytopathogenic fungi and to seeds coated with at least one such compound. The invention also relates to processes for preparing these compounds, intermediates, processes for preparing such intermediates, and to compositions comprising at least one compound I.
In many cases, in particular at low application rates, the fungicidal activity of the known fungicidal compounds is unsatisfactory. Based on this, it was an object of the present invention to provide compounds having improved activity and/or a broader activity spectrum against phytopathogenic harmful fungi.
Surprisingly, this object is achieved by the use of the inventive pyridine compounds of formula I having favorable fungicidal activity against phytopathogenic fungi.
Accordingly, the present invention relates to the compounds of formula I
The numbering of the ring members in the compounds of the present invention is as given in formula I above:
Compounds of formula I, when R12 is not proton, can be accessed e.g. starting from compounds of the formula I-1 (R12 is proton) A skilled person will realize that compounds of type I can be reached via reaction with a reactive group R12—X. Reactive groups are preferably alkyl halides, alkenyl halides, alkynyl halides, benzyl halides, aldehydes, ester, acid chlorides, amides, sulfates, silyl halides or phosphates, e.g. carboxylic acid (X═CO2H), aldehydes (X═COH), acid chloride (X═COCl), or halides (X=halogen), phosphates (X═PO(OCH3)2), or amides (X═CONH(OR′)R″), wherein R′ and R″ are selected from (C1-C4)-alkyl, most preferably being methyl. If X═CO2H, the addition of an activating reagent, preferably a carbodiimide, may be preferred
Typically the reaction is performed in a range between 0° C. and ambient temperature in the presence of a reactive group and an organic base. Suitable base preferably NEt3, pyridine NaOH, TEBAC, K2CO3, NaCO3 or KOH. Most preferably solvents are THF, DMF, DMSO, MeOH or water (see for example, Journal of Medicinal Chemistry, 1989, 32(6), 1242-1248; European Journal of Medicinal Chemistry, 2009, 44(10), 4034-4043).
Compounds of formula I-1 can be accessed e.g. starting from compounds of the formula II via a reduction agent in an organic solvent (see for example WO2009095253, WO2008143263). Reduction agent can be for example NaBH4 or NaCNBH3.Typically the reaction is performed in a range between 0° C., room temperature and 60° C. in an organic solvent, such as THF, dichloromethane or acetonitrile, most preferably MeOH or EtOH.
Compounds of formula II can be also reduced to I-1 via hydrogenation by using a metal catalyst in an organic solvent, water or a mix of water and organic solvent (see for example ChemCatChem, 5(10), 2939-2945; 2013; Organic Letters, 17(12), 2878-2881; 2015). As metal catalyst can be used for example Ru, Ir, and Pd, with or without ligands such as phosphines, phosphates, cyclooctadiene, diamines and imidazoles. The reaction can take place at temperature from 0° C. to 100° C. Preferable organic solvent are methanol, acetone, dichloromethane, 2,2,2-trifluoroethanol or DMF. The reaction can also take place the presence of an acid for example HCO2H, trifluoro acetic acid and acetic acid.
Compounds of formula II can be easily access by a skilled person following literature procedure (see for example WO 2017016915).
It may be preferred to access compounds I, where R5 and R6 are F (named compounds I-2) from corresponding compounds II-1 via reduction and optionally reaction with a reactive group R12—X.
Compounds II-1 can be synthesized from the respective keto compound (named compounds IIA) as follows based on a literature precedent (US 2008/0275242). A skilled person will realize that compounds II-1 can be formed using a suitable halogenation agent, preferably diethyl aminosulfur trifluoride, HF/SF4 or phosphorus trihalides in or without an organic solvent, preferably a chlorinated hydrocarbon such as dichloromethane at, e.g., room temperature. If appropriate, the reaction can be performed from −10° C. to elevated temperatures.
Compounds of type IIA can be accessed by reacting compounds of type II-2 (where R5 and R6 are halogen substituents (Hal′), in particular bromo) under aqueous or mildly acidic conditions in an organic solvent.
Said compounds II-2 (where Hal are both bromo) can be prepared from compounds II-3 (where R5 and R6 are both hydrogen) by reaction with a halide source, preferably N-bromosuccinimide or 1,3-dibromo-5,5-dimethylhydantoin, in an organic solvent, preferably a hydrocarbon such as toluene or benzene, in the presence of an initiator, preferably azobis-isobutyronitrile, at elevated temperatures (see for example WO 2008/035379).
Alternatively, as described elsewhere (WO 2013/047749), compounds II-1 can be prepared directly from compounds II-3. To this end, compounds II-2 are reacted with hydrogen fluoride triethyl amine (HF NEt3) in an organic solvent, preferably an aromatic hydrocarbon and at elevated temperatures (example WO 2013/047749). In addition, compounds II-1 can also be prepared by compound II-2 and then fluorination (see for example WO 2017016915). Alternatively, compounds of formula II-1 can also be obtained through compounds of formula III-2, (see for example WO 2017016915).
Compounds of the formula II-3 can be provided e.g. starting from alcohols of type III with nitriles of type IV in the presence of an acid in an organic solvent (see for example US 2008/0275242 or WO2005/070917). Preferably, sulfuric acid or a sulfonic acid, in particular triflic acid, are used as acid. Most suitable solvents are hydrocarbons, preferably benzene or dichloromethane.
Depending on the nature of the starting materials, the reaction is performed at a temperature from −40° C. to 200° C., in particular from −10° C. to 120° C., more specifically from 0° C. to 100° C., even more specifically from room or ambient temperature (about 23° C.) to 80° C.
Nitriles of type IV are either commercially available or can be prepared by a skilled person from the corresponding halides following literature procedures (see, for example Journal of Organic Chemistry, 76(2), 665-668; 2011; Angewandte Chemie, International Edition, 52(38), 10035-10039; 2013; WO2004/013094).
Alcohols of type III can be prepared as described below. A skilled person will realize that compounds of type V can be reacted with organometallic reagents, preferably alkyl Grignard or alkyl-Lithium reagents, in ethereal solvents, preferably THF at low temperatures and under inert conditions to furnish compounds of type III.
Alternatively, alcohols of type III can be prepared from epoxides Va and compounds VI (see below):
The metalation reaction may preferably be carried out using Lithium-organic compounds, such as for example n-butyl lithium, sec-butyl lithium or tert-butyl lithium to result in an exchange of halogen by lithium. Also suitable is the reaction with magnesium resulting in the formation of the respective Grignard reagents. A further possibility is the use of other Grignard reagents such as isopropyl-magnesium-bromide instead of Mg.
A typical preparation of compounds of type III can be achieved by reacting compounds of type VII with organometallic reagents, preferably alkyl Grignard or alkyl-Lithium reagents, in ethereal solvents, preferably THF at low temperatures and under inert conditions as previously reported (see for example WO2012051036; WO2011042918).
Compounds of type VII can be accessed by reacting a carbonyl compound of type VIII, preferably a carboxylic acid (X═OH) or an acid chloride (X═Cl), with NH(OR′)R″, wherein R′ and R″ are selected from (C1-C4)-alkyl, most preferably being methyl, in an organic solvent, preferably THF or dichloromethane. Typically the reaction is performed in a range between 0° C. and ambient temperature in the presence of an organic base, preferably NEt3 or pyridine (see e.g. US 20130324506; Tetrahedron: Asymmetry, 17(4), 508-511; 2006). If X═OH, the addition of an activating reagent, preferably a carbodiimide, may be preferred (see for example ChemMedChem, 7(12), 2101-2112; 2012; 2011038204; Journal of Organic Chemistry, 76(1), 164-169; 2011).
If required, compounds of type VIII can be prepared from the corresponding aryl halides of type VI (Hal is halogen, preferably Br or I). As described (Tetrahedron, 68(9). 2113-2120; 2012; Chemical Communications (Cambridge, United Kingdom), 49(60), 6767-6769; 2013), aryl halides VI will react with compounds of type IX in the presence of a transition metal catalyst, preferably a copper(I) salt, in an organic solvent, preferably DMF or DMSO, at elevated temperatures. Typically a base, preferably potassium phosphate, is added.
If appropriate, compounds of type III can be prepared as follows. A known or commercially available carbonyl compound can be reacted with an organometallic reagent of type X, preferably a Grignard or an organolithium reagent, readily prepared by a skilled person. Preferably, the reaction is performed in a temperature range from −78° C. to room temperature under inert conditions in an ethereal solvent.
Alternatively compounds II-3 can also be accessed by reacting a nitrile IV with an olefin IIIa under acidic conditions as described elsewhere (U.S. Pat. No. 7,632,783, B2, page 60, method A).
Alternatively compounds II-3 and compounds II-2 can be prepared via intramolecular reaction of amide XI or XI′ with an electron-rich heterocycle or aryl group. The intramolecular cyclization will take place in the presence of a dehydrating agent in an organic solvent (WO 2008143263, Synthetic Communications 2007, 37, 1331-1338; Org. Letters; 2008, 10, 3485-3488; Tetrahedron Lett. 1980, 36, 1279-1300; J. Org. Chem. 1998, 63, 406-407; J. Org. Chem. 1991, 56, 6034-6038; Synlett. 2008, 2803-2806; J. Org. Chem. “012, 75, 5627-5634; Tetrahedron Lett. 2002, 43, 5089-5091). Preferably, phosphoryl chloride (POCl3), POCl3/P2O5, PCl5, PPA, POBr3, H3PO4/P2O5, SnCl4, Tf2O, SOCl2, CH3SO3H, or BF3 are used as dehydrating agent and a base, such as pyridine or Et3N. Most suitable solvents are hydrocarbons, preferably benzene, toluene or acetonitrile. Alternatively halogenated solvents can be used, for example dichloromethane, chloroform or chlorobenzene.
Depending on the nature of starting materials, the reaction is performed at temperature from −40° c. to 200° C., in particular from −10° C. to 120° C., more specifically from 0° C. to 100° C., even more specifically from room temperature to 100° C.
Amides of type XI can accessed by reacting a carbonyl of type XII, preferably a carboxylic acid (X═OH) or an acid chloride (X═Cl), with an amines of type XIII in an organic solvent, preferably THF or dichloromethane. Typically the reaction is performed in a range between 0° C. and room temperature in the presence of an organic base, preferably N(C2H5)3 or pyridine (see e.g. WO 8303968). If X═OH, the addition of an activating agent, preferably a carbodiimide or acid chloride, may be preferred (see e.g Bioorganic & Medicinal Chemistry, 2010, 18, 3088-3115).
Amides of type XI′ can accessed following the same procedure as for compounds of formula XIII (see above).
If required, compounds of type XIII can be synthesized from the correspond nitriles. As described Synlett. 2007, 4 652-654 or Tetrahedron 2012, 68, 2696-2703, nitriles will react with organometallic agents M-R4 and of type X. Preferably Grignard or Lithium reagent, in ethereal solvents, preferably THF at low temperature and under inert conditions to furnish compounds of type XIII. The synthesis of compounds of type XIII can take place in two steps or one pot.
Alternatively, amines of type XIII can synthesized via formation of the correspond carboxylic azide and quench with water (Journal of the American Chemical Society, 1949, 71, 2233-7; Journal of the American Chemical Society, 1990, 112, 297-304) or via Grignard addition to enamines (Tetrahedron Letters, 1992, 33, 1689-92; US20030216325; J. Am.
Chem. Soc. 0217, 139, 12398-12401; Compounds of formula XIII′ can be synthesized from the correspond nitriles XIIb via halogenation, followed by reaction with the correspond organometallic agents M-R3 and M-R4 (see reference, Synthesis 2006, 24, 4143-4150; Organometallics 2017, 36, 911-919; WO2012/074067; J. Org. Chem. 2013, 78, 1216-1221). Preferable organometallic species are based on Li, Mg, B or Zn. The reaction takes places in organic solvents such as ether, hexane, THF or CH2Cl2.
In a range of temperature from −20° C. to rt. In addition, the reaction can also be promoted by addition of metal species, such as Ti(OiPr)4, CeCl3 or BF3.
Compounds of formula XIIIa (where Hal=F) can be prepared from nitrile XIIIb via metalation and reaction with a fluorinated agent. Prefer metalation agent are tBuLi, BuLi, LDA or Et3N; preferable fluorinated agents are NFSI or HF (see Organic Reactions 2007, 69, 347-672; Org. Chem. 1998, 63, 8052-8057: Tetrahedron Lett. 1987, 28, 2359-2362).
Alternatively, compounds of compounds of formula XIIa (Hal=F) can be obtained via chlorination of compounds XIIb, followed by Cl,F— exchange using a fluorinating agens such as Et3N*3HF (see reference, e-EROS Encyclopedia of Reagents for Organic Synthesis, 2001). Preferable chlorinated agents are SOCl2 or Olah's reagent; preferable fluorinated agents are Et3N*3HF.
Compound of type III-3 can be also synthesized via Suzuki coupling of halides of type XIV with a boronic acid XV (see for example, Journal of Fluorine Chemistry, 2010, 131, 856-860); wherein R31 and R41 together with the groups they are attached to form a tetramethyl-1,3,2-dioxaborolane-ring or independently from one another mean hydrogen or C1-C6-alkyl to yield compounds III-3
Compounds of type XIV, wherein Hal is halogen, preferably chloro and bromo, can be obtained by transformation of an amide of type XVI with a halogenating reagent, such as phosphorus oxachloride, phosphorus pentachloride, phosphoric trichloride, phosphorus oxybromide, thionyl chloride or Vilsmeier reagent. The reaction takes place in the presence of an organic solvent, preferably THF, benzene, CCl4, or dichloromethane. Typically the reaction is performed in a range between 0° C. to 180° C. (see as reference, Journal of Medicinal Chemistry, 2004, 47, 663-672; Journal of Organic Chemistry, 1980, 45, 80-89; Bulletin des Societes Chimiques Belges, 1991, 100, 169-174).
Amides of type XVI can be prepared from compounds of type XVII, wherein Rx is a substituted or unsubstituted C1-C6-alkyl, C1-C6-halogenalkyl, phenyl, benzyl, 5- and 6-membered heteroaryl. The reaction takes places in the presence of acid, preferably acetic acid, HCl, triflic acid or a mixture of sodium acetate and acetic acid. Typically the reaction in performed net or in polar solvents, preferably in water, methanol or acetonitrile (see WO2016/156085; Pharmaceutical Chemistry Journal, 2005, 39, 405-408).
Alternatively, compounds of type XIV can be direct synthesized from compounds of type XVII in the presence of a halogenating reagent, such as sulfonyl chloride. The reaction takes places neat or in organic solvents, such as chloroform, dichloromethane or acetonitrile, in a range of temperature from 0° C. to room temperature (see, Tetrahedrons Letters, 2010, 51, 4609; Tetrahedron Letters, 1986, 27(24), 2743-6).
Compounds of type XVII can also be obtained by the reaction of alcohol III or alkene IIIa and a thiocyanate under acidic conditions, see for example Bioorganic & Medicinal Chemistry Letters, 2013, 23(7), 2181-2186; Pharmaceutical Chemistry Journal, 2005, 39, 405-408; wherein wherein Rx is most preferably substituted or unsubstituted C1-C6-alkyl, C1-C6-halogenalkyl, phenyl, benzyl, 5- and 6-membered heteroaryl. Preferably acids are sulfuric acid, HCl or trific acid. The reaction takes place most preferably in water, dichloromethane, toluene or a mixture of solvents, in a range of temperatures from 0° C. to 110° C.
Amides type XVI can be synthesized via ring expansion of oxime XVIII in the presence of an acid. Most suitable acids are for example, sulfuric acid, polyphosphoric acid or POCl3.
Typically the reaction in performed net or in a polar solvents, preferably in water, methanol or acetonitrile (see Bioorganic & Medicinal Chemistry Letters, 2002, 12(3), 387-390; Medicinal Chemistry Research, 2015, 24(2), 523-532).
Oxime of type XVIII can be easily prepared from ketone of type XIX in the presence of hydroxylamine or hydroxylamine hydrochloride in polar solvents such as water, pyridine, ethanol or methanol. The reaction can take place in the presence of absence of a base, such as sodium acetate or sodium hydroxide, in a range of temperatures from room temperature to 120° C. (Journal of Organic Chemistry, 2016, 81(1), 336-342).
Ketone of type XIX are either commercial available or readily prepared by a skilled person.
Alternatively compounds II-3 can be synthesized from compounds XX, which are commercially available or can be synthesized according to procedures known in literature, in which X2 denotes for hydrogen or halogen (Cl, Br, I).
Compounds XXI (and X1 denotes for halogen (Cl, Br, I) or C1-C6-alkoxycarbonyl) can be metalated with Grignard-reagents (X3 denotes for Cl, Br or I), for example methyl magnesium-X3, ethyl magnesium-X3, isopropyl-magnesium-X3 and phenyl magnesium X3 among others, or lithium organic reagents like methyl-lithium, ethyl-lithium, butyl-lithium and phenyl-lithium among others, and reacted with compounds XXII to yield derivatives XX, whereas R31 and R41 independently from each other denote for C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five- or six-membered heteroaryl and aryl.
Subsequently compounds XX (X2═Cl, Br, I) can be reacted with carbon monoxide yielding esters XXIII following published literature (Science of Synthesis (2014), 2, 67-93; Comprehensive Inorganic Chemistry 11 (2013), 6, 1-24; RSC Catalysis Series (2015), 21 (New Trends in Cross-Coupling), 479-520; Metal-catalyzed Cross-Coupling Reactions and More (Editor: A. De Meijere) (2014), 1, 133-278; Domino Reactions (Editor L. Tietze) (2014), 7-30; Synthesis 2014, 46 (13), 1689-1708; RSC Advances (2014), 4 (20), 10367-10389), for example using Pd-catalyst (i.e. Pd(dppf)C2 ([1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) and sodium methanolate in methanol under elevated pressure (10-200 bar) of carbon monoxide.
Compounds XXIII can be hydrolyzed using acidic or basic conditions, for example hydrochloric or sulfuric acid, or sodium or potassium carbonate, hydrogen carbonate or hydroxide in water or solvent mixtures with water and alcoholic solvents (preferably methanol, ethanol, isopropanol), or acetonitrile, acetone, dimethylformamide or N-methyl pyrrolidine, at temperatures from 0° C. to 100° C. yielding intermediates XXIV.
Intermediates XXIV can be activated with reagents like HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), CDI (1,1′-Carbonyldiimidazole), DCC (N,N-Methanetetraylbis[cyclohexanamine]) and others known in literature (Eur. JOC 2013, 4325; Tetrahedron 2004, 60, 2447; Tetrahedron 2005, 61, 10827; Chem. Soc. Rev. 2009, 38, 606; Chem. Rev. 2011, 111, 6557) to further react and yield compounds XXV.
Furthermore compounds XXV are oxidized with MnO2, hypochlorite, activated DMSO, Cr(VI)-containing reagents or employing other oxidizing conditions known in literature (Korean Chemical Society (2015), 36(12), 2799; Hudlicky, Oxidations in Organic Chemistry, American Chemical Society, Washington D.C., 1990; Acc. Chem. Res. 2002, 35, 774; JACS 1984, 106, 3374; Tetrahedron Letters 56 (2015) 6878; Backvall, Modern Oxidation Methods, Wiley, Weinheim 2004; Tojo, Oxidation of Alcohols to Aldehydes and Ketones, Springer 2006) to provide carbonyl compounds XXVI.
Subsequently the amides XXVI can be transferred into the triflate XXVII by reaction with trifluoromethyl sulfonic anhydride in an inert solvent, like dichloromethane, chloroform, carbon tetrachloride, benzene, toluene or chlorobenzene in the presence of a base, for example an organic base like pyridine, triethylamine or diisopropyl ethylamine or an aqueous base like solutions of sodium or potassium hydroxide, carbonate or hydrogen carbonate in water at temperatures preferably between 0° C. and 100° C.
These compounds XXVII are reacted with fluorination reagents (Kirsch, Modern Fluoroorganic Chemistry, Wiley 2013)) like deoxo-fluor (BAST, bis(2-methoxyethyl)aminosulfur trifluoride, Journal of Fluorine Chemistry (2016), 182, 41; Singh, et al. Synthesis 17, 2561, (2002)), DAST (Diethylaminoschwefeltrifluorid, Hudlicky Org. React. 35, 513, (1988)), Fluolead (4-tert-Butyl-2,6-dimethylphenylsulfur trifluoride, WO 2013118915; US 20080039660), Diethylaminodifiuorosulfinium tetrafluoroborate (XtalFluor-E) or morpholinodifluorosulfinium tetrafluoroborate (XtalFluor-M) (Journal of organic chemistry (2010), 75(10), 3401) to yield difluoro compounds XXVIIIa
Subsequently these triflates XXVIIIa can be reacted under Suzuki conditions (European Journal of Organic Chemistry (2008), (12), 2013) with boronic acids XV, in which R311 and R411 together with the groups they are attached to form a tetramethyl-1,3,2-dioxaborolane-ring or independently from one another mean hydrogen or C1-C6-alkyl to yield compounds III-3.
Alternatively, compounds of type II-3 can also be obtained intramolecular cyclization of amines of type XXIX in the presence of an acid. Most preferably acids are HCl, trifluoroacetic acid, acetic acid or sulfuric acid. The reaction is preform in dichloromethane, water, ethanol, THF or chloroform, at temperature from room temperature to 120° C. (see, Synthesis, 1995, (5), 592-604; Heterocycles, 1988, 27(10), 2403-12).
Amines of type XXIX are either commercial available or easily prepared by a skilled person or following the procedures described before.
Alternatively compounds II-3 can be synthesized from the compounds of type XVII as described above, wherein Rx is substituted or unsubstituted C1-C6-alkyl C1-C6-halogenalkyl, phenyl, benzyl and 5- and 6-membered heteroaryl via a coupling reaction of compound XXX (wherein X=halogen, proton or the correspond activated metal species) via metal catalysis. Prefer metal catalylist are palladium, cupper, niquel, or a mixture of them, such as Pd(PPh3)4, Pd(dppf)Cl2, NiCl2(PPh3)2 or CuTC. The reaction takes place most preferably in organic solvent, such toluene, DMF THF or a mixtures of solvents, in a range of temperatures from 0° C. to 150° C. (see references Synlett 2014, 25, 2574-2578; Org. Lett. 2014, 16, 1120-1123; Heterocycle 2009, 77, 233-239; WO2013/152063). The reaction can also be performed with the corresponded oxidized version of compounds of formula XVII (see reference, WO2013/152063).
The synthesis of compounds XVII is described above.
For the activation of the compounds of the formula XXX; when X is halogen, the metal insertion can be done using organometallic species from magnesium, lithium, zinc, or mixtures. Prefer reagents are Mg, iPrMgCl, iPrMgBr, BuLi, iPrMgCl*LiCl, Zn, Mg/LiCl, Bu3MgLi or Bu3ZnLi. The reaction is performed in an inert solvent, such as THF, MTBA, ether, THF/dioxane, or hexane, in the presence of absence from salts, such as LiCl, and/or additive, such as PivOH, AlCl3, LnCl3 or TfOH, in a range of temperatures from −78° C. to 100° C. (see for examples, Chem. Rev. 2014, 114, 1207-1257).
Alternatively, the compounds of the formula XXX (when X is B, Zn or Sn) can be activated in the presence or absence from metal catalyst (such as Pd or Zn). Most preferably X is a boronic acid, a boronic ester or an stannate. Prefer metal catalyst are Pd(OAc)2, Pd(dba)3, PdCl2(PPh3)2 or Et3Zn. The reaction is performed in an inert solvent, such as THF, MTBA, ether, THF/dioxane, or hexane, in the presence or absence from ligands, such as SPhos, XPhos or PPh3, in a range of temperatures from −78° C. to 100° C. (Organometallic Chemistry, 2000, 595(1), 31-35; Journal of Organometallic Chemistry, 2006, 691(12), 2821-2826).
On the other hand, the compounds of the formula XXX (when X is proton) can be activated via H-activation in the presence of a metal catalyst, such as rhodium, palladium, niquel, iridum or palladium, in the presence of an appropriate ligand, with or without an activating agent and/or base and/or in an inert solvent. Prefer combination are [(Ind)Ir(COD)]/dmpe, [Ir(OMe)(COD)]2/dttbpy, Pd(OAc)2/phenanthroline, or Pd(OAc)2/N-acetyl valine. Most prefer inert solvents are hexane. Suitable base are sodium carbonate, silver carbonate or pyridine (see for examples, Org. Lett 2013, 15, 670-673; J. Am. Chem. Soc. 2003, 125, 7792-7793)
In the similar matter the compounds of the formula II-2 can be synthesized from the reaction of compounds of the formula XXX and XXVI using the same conditions as for the reaction of compound of formula XXX and XVII (see above).
Compounds of formula XXXI can be obtained from XVII using a halide source in an organic solvent preferably a hydrocarbon such as toluene or benzene, in the presence or in the absence of an initiator at elevated temperature, preferably azo-bis-isobutyronitrile. When Hal are both bromo, prefer halide sources are N-bromosuccinimide or 1,3-dibromohydantoin (see for example WO 2008/035379). When Hal are both fluor, prefer halide sources are hydrogen fluoride triethyl amine (3HF*Et3N) (see for example WO 2013/047749). Alternatively, XXXI (Hal=F) can also be obtained through XXXI (Hal=Br) using preferably hydrogen fluoride triethyl amine (see for example WO 2017016915).
Compounds of formula II-2 and II-3 can also be obtained from compounds XXXI′ (y=1, 2 or 3; where R5 and R6 can be halogen or proton) using the same conditions as above (see reference, WO2013/172063; Applied Org. Chem. 2016, 30, 767-771; Synthesis 1987, 4, 409-411; e-Ros Encyclopedia of Reagents for Org. Synthesis 2001; Heterocycles 1986, 24, 3337-3340). Compounds XXXI′ can be easily synthesized for skilled person using XXXVI or XVII via oxidation
Alternatively, compounds XXXI′ can be easily synthesized for skilled person from XVI′ via oxidation, for example via HCl/Cl2; followed by reaction with Rx—OH (see Synthesis 1987, 4, 409-411)
On the other hand, compounds of formula II-2 and II-3 can also be obtained from compounds XXXI″ (where R5 and R6 can be halogen or proton) using the same conditions as above (see reference, Synthesis 2015, 47, 3286-3291; J. Am. Chem. Soc. 1997, 119, 12376-12377). Compounds XXXI′ can be easily synthesized for skilled person starting from compounds of formula XVI′ by alkylation.
Alternatively compounds II-3 can be synthesized from the compounds of type XXXII and pyridines XXX (where X=halogen) via a Goossen reaction in the presence of a Pd catalyst, a copper catalyst or in a mixture of Pd and Cu catalyst. Preferably compounds XXXII are salts or acids, more prefer salts are when Y═K, Li or Na. Preferably, Pd catalyst are Pd(ddpf)Cl2, Pd(PPh3)4, Pd(PPh3)2Cl2, Pd(P(t-Bu)3)2, Pd(acac)2, Pd(iPr)2Ph2, Pd(P(t-Bu)2Ph)2Cl2, Pd(dba)2, Pdl2, Pd(OAc)2, PdBr2, PdC2, or Pd(TFA)2. Preferably Cu catalysts are CuCl, CuBr, Cul, CuCO3, Cu, Cu2O or CuOAc. Additionally special ligands such as phenantroline, PPh3, BINAP, P(Cy)3, bipyridine, dppm, P(tBu)3, P(p-Tol)3, P(o-Tol)3, P(t-Bu)2Ph, 1,2-bis(diphenylphosphino)ethane (dppe), 1,3-bis(diphenylphosphino)propane (dppp), 1,4-bis(diphenylphosphinobutane) (dppb), 1,3-bis(diphenylphosphino)-2,2-dimethylpropane, 1,3-bis(diphenylphosphino)-2-methyl-2-butyl-propane, P(1-naph)3, XPhos, SPhos, XantPhos or RuPhos can optionally be used. Preferable bases are pyridine, Cs2CO3, CuCO3, K2CO3 or Ag2CO3. If Y is Li, Na, K or Cs the reaction may proceed without use of an additional base. Preferable optional additives are molecular sieves, KBr, NaF, KF, Bu4NOAc, Bu4NI, Bu4NCl, Bu4NBr or Bu4NF. The reaction takes place in the presence or absence of organic solvents such as NMP, toluene, DMF, DMSO, DMA, DMPU, diglyme, xylene, mesitylene, methyl acetate, ethyl acetate, propyl acetate, butyl acetate or a mixture of organic solvents; in a range of temperatures from −40° C. to 200° C. (see references, J. Am. Chem. Soc. 2006, 128, 11350-11351; J. Am. Chem. Soc. 2007, 129, 4824-4833; Org. Lett. 2014, 16, 2664-2667; Sciences 2006, 313, 662-664; Tetrahedron Lett. 2017, 58, 2723-2726).
The compounds of the formula XXXII are obtained by the reaction of alcohol III or alkene IIIa and a cyano compound under acidic conditions, wherein Y is most preferably an ester (Y═C1-C6-alkyl). Preferably acids are sulfuric acid, HCl or trific acid. The reaction takes place most preferably in water, dichloromethane, trichloromethane, tetrachloromethane, cyclohexane, pentane, hexane, heptane, toluene, xylene, mesitylene, chlorobenzene or a mixture of solvents, in a range of temperatures from 0° C. to 110° C. Compounds XXXII (where Y is a salt, i.e. Li, Na, K, Cs) can be easily obtained by a skilled person via hydrolysis of compounds XXXII (where Y is for example C1-C6-alkyl).
In the similar matter the compounds of the formula II-2 can be synthesized from compounds of the formula XXXII using the same conditions as for compounds of formula II-3 by Goossen-type reaction (see above).
Compounds of formula XXXII (where Y is an esther) can be obtained from compounds of the formula XXXIII by halogenation in an organic solvent preferably a hydrocarbon such as toluene or benzene, in the presence or in the absence of an initiator at elevated temperature, preferably azo-bis-isobutyronitrile or dibenzoyl peroxide. When Hal are both bromo, prefer halide sources are N-bromosuccinimide or 1,3-dibromohydantoin (see for example WO 2008/035379). When Hal are both fluor, prefer halide sources are hydrogen fluoride triethyl amine (3HF*Et3N) (see for example WO 2013/047749). Alternatively, XXXII (Hal=F) can also be obtained through XXXI (Hal=Br) using preferably hydrogen fluoride triethyl amine (see for example WO 2017016915).
Alternatively, compounds of the formula I-1 (is the compound of the formula I wherein R12═H) can be synthesized from compounds of type XXXIV in the reaction with the compound XXXV. When X is halogen, the metal insertion can be done using organometallic species from magnesium, lithium, zinc, or mixtures. Prefer reagents are Mg, iPrMgCl, iPrMgBr, BuLi, iPrMgCl*LiCl, Zn, Mg/LiCl, Bu3MgLi or Bu3ZnLi. The reaction is performed in an inert solvent, such as THF, MTBA, ether, THF/dioxane, or hexane, in the presence of absence from salts, such as LiCl, and/or additive, such as PivOH, AlCl3, LnCl3, BF3×OEt2 or TfOH, in a range of temperatures from −78° C. to 100° C. In addition, the reaction can also facilitated by the presence of second metal or catalyst, such as palladium, zinc, niquel or cupper, such as CuCN, Pd(OAc)2, ZnCl2, CuCl, ZnBr2, Pd(dba)3, PdCl2(PPh3)2, Ni(dppd)Cl2, or CuBr2*Me2S, in the presence or absence from appropriate ligands, such as SPhos, XPhos or PPh3 (see for examples, Chem. Rev. 2014, 114, 1207-1257).
Additionally, compounds I-1 can also be obtained via addition of XXXV (where X is B, Zn or Sn) to XXXIV in the presence or absence from metal catalyst (such as Pd or Zn). Most preferably X is a boronic acid, a boronic ester or an stannate. Prefer metal catalyst are Pd(OAc)2, Pd(dba)3, PdCl2(PPh3)2 or Et3Zn. The reaction is performed in an inert solvent, such as THF, MTBA, ether, THF/dioxane, or hexane, in the presence or absence from ligands, such as SPhos, XPhos or PPh3, in a range of temperatures from −78° C. to 100° C. (Organometallic Chemistry, 2000, 595(1), 31-35; Journal of Organometallic Chemistry, 2006, 691(12), 2821-2826).
Compound of formula I-1 can also be synthesized from compounds of type XXXIV in the reaction with the compound XXXVa (X═H) via H-activation in the presence of a metal catalyst, such as rhodium, palladium, niquel, iridum. or palladium, in the presence of an appropriate ligand, with or without an activating agent and/or base and/or in an inert solvent. Prefer combination are [(Ind)Ir(COD)]/dmpe, [Ir(OMe)(COD)]2/dttbpy, Pd(OAc)2/phenanthroline, or Pd(OAc)2/N-acetyl valine. Most prefer inert solvents are hexane. Suitable base are sodium carbonate, silver carbonate or pyridine (see for examples, Org. Lett 2013, 15, 670-673; J. Am. Chem. Soc. 2003, 125, 7792-7793)
Compounds XXXIV can be obtained from compounds XXXIVa by reaction with a halide source in an organic solvent preferably a hydrocarbon such as toluene or benzene, in the presence or in the absence of an initiator at elevated temperature, preferably azo-bis-isobutyronitrile. When R5 and R6 are both bromo, prefer halide sources are N-bromosuccinimide or 1,3-dibromohydantoin (see for example WO 2008/035379). When R5 and R6 are both fluor, prefer halide sources are hydrogen fluoride triethyl amine (3HF*Et3N) from compounds XXXIVa or XXXIVb (where R5 and R6 are both bromo).
Alternatively, compounds XXXIV could also be obtained via ketone XXXIVc via XXXX as follows based on a literature precedent (US 2008/0275242). A skilled person will realize that compounds XXXIV can be formed using a suitable halogenation agent, preferably diethyl aminosulfur trifluoride, HF/SF4 or phosphorus trihalides in or without an organic solvent, preferably a chlorinated hydrocarbon such as dichloromethane at, e.g., room temperature. If appropriate, the reaction can be performed from −10° C. to elevated temperatures.
In the other way around, compounds XXXIVc can be accessed by reacting compounds of type XXXIV (where R5 and R6 are in particular bromo) under aqueous or mildly acid conditions in an organic solvent.
Compounds XXXV are either commercially available or can be easily prepared by a skilled person, for examples from the correspond pyridine following literature procedure (see for examples US 2014/0194386).
Alternatively, compounds II could also be obtained from compounds I-1 (R12═H). The reaction can take place by reaction with an oxidating reagent such as NBS, NCS, KMnO4, oxygen or PhIO, in an organic solvent, preferably hydrocarbon such as dichlromethane, THF or toluene, at temperature in the range from 0° C. to 100° C. Sometime followed by the addition of a base, like NaOH or tBuOK (see for example, Chem. Rev. 1963, 63, 489-510; Tetrahedron, 1988, 44, 4431-4446).
In the similar way, compounds of the formula I-3 having OH as R12 can be synthesized from compounds of type XXXVI in the reaction with the compound XXXV. When X is halogen, the metal insertion can be done using organometallic species from magnesium, lithium, zinc, or mixtures. Preferred reagents are Mg, iPrMgCl, iPrMgBr, BuLi, iPrMgCl*LiCl, Zn, Zn(CH3)2, Zn(Et)2, Mg/LiCl, Bu3MgLi or Bu3ZnLi. The reaction is performed in an inert solvent, such as THF, MTBA, diethyl ether, THF/dioxane, or hexane, in the presence of absence from salts, such as LiCl, and/or additive, such as PivOH, AlCl3, LnCl3 or TfOH, in a range of temperatures from −78° C. to 100° C. In addition, the reaction can also be facilitated by the presence of second metal or catalyst, such as palladium, zinc, nickel or copper, such as CuCN, Pd(OAc)2, ZnCl2, CuCl, ZnBr2, Pd(dba)3, PdCl2(PPh3)2, Ni(dppd)C2, or CuBr2*Me2S, in the presence or absence from appropriate ligands, such as SPhos, XPhos or PPh3 (see for examples, Chem. Rev. 2014, 114, 1207-1257; J. Org. Chem. 2012, 77, 7901-70912).
Additionally, compounds I-3 can also be obtained via addition of XXXV (where X is B, Zn or Sn-containing substitutent) to XXXVI in the presence or absence from metal catalyst (such as Pd, Ni, Fe or Zn). Most preferably X is a boronic acid, a boronic ester or a stannate. Preferred metal catalyst are Pd(OAc)2, Pd(dba)3, PdCl2(PPh3)2, Et2Zn, Ni(acac)2, NiCl2(dppf), or Fe(acac)3. The reaction is performed in an inert solvent, such as THF, MTBA, diethyl ether, THF/dioxane, or hexane, in the presence or absence from ligands, such as SPhos, XPhos or PPh3, in a range of temperatures from −78° C. to 100° C. (see for example, Org. Lett. 2010, 12, 2690-2693).
Compound of formula I-3 can also be synthesized from compounds of type XXXVI in the reaction with the compound XXXVa (X═H) via CH-activation in the presence of a metal catalyst, such as rhodium, palladium, nickel, iridium, iron or palladium, in the presence of an appropriate ligand, with or without an activating agent and/or base and/or in an inert solvent. Preferred combinations are [(Ind)Ir(COD)]/dmpe, [Ir(OMe)(COD)]2/dttbpy, Pd(OAc)2/phenanthroline, Pd(OAc)2/N-acetyl valine, Pd(OAc)2/(bisSO)/BQ, [Rh(coe)2Cl]2/p-(Et2N)PhPCy2, Ni(COD)2/SIPr or Fe(PDP)(SbF6)2. Most preferred inert solvents are ethereal solvents like diethyl ether, THF, MTBE, or hydrocarbon solvents like hexane, heptane or toulene. Suitable base are sodium carbonate, silver carbonate, silver acetate, or pyridine (see for examples, Org. Lett 2013, 15, 670-673; J. Am. Chem. Soc. 2003, 125, 7792-7793; Org. Lett. 2016, 18(4), 744-747; Nature 2016, 531, -224; Nature 2016, 533, 230-234; Science 2016, 351, 1421-1424;)
The compounds of the formula XXXVI can be directly synthesized from the compounds XXXIV by oxidation reaction. Typically the reaction is performed in a range between 0° C. to room temperature. Suitable oxidant reagents are MCPBA, H2O2, P2O5, P2O5/Na2WO4, ozone, oxygen, sodium perborate, urea hydrogen peroxide, etc. Most preferable solvents are MeOH, EtOH, CH2Cl2, water, toluene etc. (see for example, Synthetic Communications, 2011, 41(10), 1520-1528; U.S., 5292746, 8 Mar. 1994). The reaction can also takes place in the presence of an acid, such as TFA, methylsulfonic acid, HCl, AcOH, etc. Moreover, it can also takes place in the presence of a catalyst based on Rheneium, ruthenium, etc as metal
Alternative, compounds XXXVI can be synthesized from compounds XXXIV via reduction to amine and followed by oxidation to N-oxide. The reduction can be performed in a range between 0° C. to room temperature. Suitable reduction reagents are NaBH4 or NaBH3(CN). Most preferable solvents are MeOH, EtOH, CH2Cl2, or water. The reaction can also be performed using hydrogen, trichhlorosilanes, etc in the presence of a metal catalyst.
Compounds II can also obtained from compounds II-3 by reaction with a halide source in an organic solvent preferably a hydrocarbon such as toluene or benzene, in the presence or in the absence of an initiator at elevated temperature, preferably azo-bis-isobutyronitrile. When R5 and R6 are both bromo, prefer halide sources are N-bromosuccinimide or 1,3-dibromohydantoin (see for example WO 2008/035379). When R5 and R6 are both fluor, prefer halide sources are hydrogen fluoride triethyl amine (3HF*Et3N) from compounds II-3 or II-4 (where R5 and R6 are both bromo) (see for example WO 2013/047749).
Alternatively, compounds II could also be obtained from compounds I-3. The reaction can take place by reaction with an organic reagent such as CDI or thionyl chloride, in an organic solvent, preferably hydrocarbon such as THF or toluene, at temperature in the range from 0° C. to 100° C.
The N-oxides may be prepared from the inventive compounds according to conventional oxidation methods, e. g. by treating compounds I with an organic peracid such as metachloroperbenzoic acid (cf. WO 03/64572 or J. Med. Chem. 38(11), 1892-903, 1995); or with inorganic oxidizing agents such as hydrogen peroxide (cf. J. Heterocyc. Chem. 18(7), 1305-8, 1981) or oxone (cf. J. Am. Chem. Soc. 123(25), 5962-5973, 2001). The oxidation may lead to pure mono-N-oxides or to a mixture of different N-oxides, which can be separated by conventional methods such as chromatography.
In the following, the intermediate compounds are further described. A skilled person will readily understand that the preferences for the substituents, also in particular the ones given in the tables below for the respective substituents, given herein in connection with compounds I apply for the intermediates accordingly. Thereby, the substituents in each case have independently of each other or more preferably in combination the meanings as defined herein.
If the synthesis yields mixtures of isomers, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (e. g. under the action of light, acids or bases). Such conversions may also take place after use, e. g. in the treatment of plants in the treated plant, or in the harmful fungus to be controlled.
In the definitions of the variables given above, collective terms are used which are generally representative for the substituents in question. The term “Cn-Cm” indicates the number of carbon atoms possible in each case in the substituent or substituent moiety in question.
The term “halogen” refers to fluorine, chlorine, bromine and iodine.
The term “C1-C6-alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, e.g. methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl. Likewise, the term “C2-C4-alkyl” refers to a straight-chained or branched alkyl group having 2 to 4 carbon atoms, such as ethyl, propyl (n-propyl), 1-methylethyl (iso-propoyl), butyl, 1-methylpropyl (sec.-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert.-butyl).
The term “C1-C6-halogenalkyl” refers to an alkyl group having 1 or 6 carbon atoms as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above. Examples are “C1-C2-halogenalkyl” groups such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl or pentafluoroethyl.
The term “C1-C6-hydroxyalkyl” refers to an alkyl group having 1 or 6 carbon atoms as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by OH groups.
The term “C1-C4-alkoxy-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), where According to one hydrogen atom of the alkyl radical is replaced by a C1-C4-alkoxy group (as defined above). Likewise, the term “C1-C6-alkoxy-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), where According to one hydrogen atom of the alkyl radical is replaced by a C1-C6-alkoxy group (as defined above).
The term “C2-C6-alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and a double bond in any position. Examples are “C2-C4-alkenyl” groups, such as ethenyl, 1-propenyl, 2-propenyl (allyl), 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl.
The term “C2-C6-alkynyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and containing at least one triple bond. Examples are “C2-C4-alkynyl” groups, such as ethynyl, prop-1-ynyl, prop-2-ynyl (propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl.
The term “C1-C6-alkoxy” refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkyl group. Examples are “C1-C4-alkoxy” groups, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methyl-propoxy, 2-methylpropoxy or 1,1-dimethylethoxy.
The term “C1-C6-halogenalkoxy” refers to a C1-C6-alkoxy radical as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above. Examples are “C1-C4-halogenalkoxy” groups, such as OCH2F, OCHF2, OCF3, OCH2Cl, OCHCl2, OCCl3, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chlorothoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, OC2F5, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoro-propoxy, 2 chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromopropoxy, 3 bromopropoxy, 3,3,3-trifluoropropoxy, 3,3,3-trichloropropoxy, OCH2—C2F5, OCF2—C2F5, 1-fluoromethyl-2-fluoroethoxy, 1-chloromethyl-2-chloroethoxy, 1-bromomethyl-2-bromoethoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy.
The term “C2-C6-alkenyloxy” refers to a straight-chain or branched alkenyl group having 2 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkenyl group. Examples are “C2-C4-alkenyloxy” groups.
The term “C2-C6-alkynyloxy” refers to a straight-chain or branched alkynyl group having 2 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkynyl group. Examples are “C2-C4-alkynyloxy” groups.
The term “C3-C6-cycloalkyl” refers to monocyclic saturated hydrocarbon radicals having 3 to 6 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. Accordingly, a saturated three-, four-, five-, six-, seven-, eight-, nine or ten-membered carbocyclyl or carbocycle is a “C3-C10-cycloalkyl”.
The term “C3-C6-cycloalkenyl” refers to a monocyclic partially unsaturated 3-, 4-5- or 6-membered carbocycle having 3 to 6 carbon ring members and at least one double bond, such as cyclopentenyl, cyclopentadienyl, cyclohexadienyl. Accordingly, a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine or ten-membered carbocyclyl or carbocycle is a “C3-C10-cycloalkenyl”.
The term “C3-C8-cycloalkyl-C1-C4-alkyl” refers to alkyl having 1 to 4 carbon atoms (as defined above), where According to one hydrogen atom of the alkyl radical is replaced by a cycloalkyl radical having 3 to 8 carbon atoms (as defined above).
The term “C1-C6-alkylthio” as used herein refers to straight-chain or branched alkyl groups having 1 to 6 carbon atoms (as defined above) bonded via a sulfur atom. Accordingly, the term “C1-C6-halogenalkylthio” as used herein refers to straight-chain or branched halogenalkyl group having 1 to 6 carbon atoms (as defined above) bonded through a sulfur atom, at any position in the halogenalkyl group.
The term “C(═O)—C1-C6-alkyl” refers to a radical which is attached through the carbon atom of the group C(═O) as indicated by the number valence of the carbon atom. The number of valence of carbon is 4, that of nitrogen is 3. Likewise the following terms are to be construed: NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH (C3-C6-cycloalkyl), N (C3-C6-cycloalkyl)2, C(═O)—NH(C1-C6-alkyl), C(═O)—N(C1-C6-alkyl)2.
The term “saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine or ten-membered heterocyclyl or heterocycle, wherein the heterocyclyl or heterocycle contains 1, 2, 3 or 4 heteroatoms selected from N, O and S” is to be understood as meaning both saturated and partially unsaturated heterocycles, wherein the ring member atoms of the heterocycle include besides carbon atoms 1, 2, 3 or 4 heteroatoms independently selected from the group of O, N and S. For example:
The term “substituted” refers to substituted with 1, 2, 3 or up to the maximum possible number of substituents.
The term “5- or 6-membered heteroaryl” or “5- or 6-membered heteroaromatic” refers to aromatic ring systems including besides carbon atoms, 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S, for example,
Agriculturally acceptable salts of the inventive compounds encompass especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, have no adverse effect on the fungicidal action of said compounds. Suitable cations are thus in particular the ions of the alkali metals, preferably sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, of the transition metals, preferably manganese, copper, zinc and iron, and also the ammonium ion which, if desired, may carry one to four C1-C4-alkyl substituents and/or one phenyl or benzyl substituent, preferably diisopropylammonium, tetramethylammonium, tetrabutylammonium, trimethylbenzylammonium, furthermore phosphonium ions, sulfonium ions, preferably tri(C1-C4-alkyl)sulfonium, and sulfoxonium ions, preferably tri(C1-C4-alkyl)sulfoxonium. Anions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of C1-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting such inventive compound with an acid of the corresponding anion, preferably of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.
The inventive compounds can be present in atropisomers arising from restricted rotation about a single bond of asymmetric groups. They also form part of the subject matter of the present invention.
Depending on the substitution pattern, the compounds of formula I and their N-oxides may have one or more centers of chirality, in which case they are present as pure enantiomers or pure diastereomers or as enantiomer or diastereomer mixtures. Both, the pure enantiomers or diastereomers and their mixtures are subject matter of the present invention.
In the following, particular embodiments of the inventive compounds are described. Therein, specific meanings of the respective substituents are further detailed, wherein the meanings are in each case on their own but also in any combination with one another, particular embodiments of the present invention.
Furthermore, in respect of the variables, generally, the embodiments of the compounds I also apply to the intermediates.
For every R1 that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of any other R1 that may be present in the ring.
According to one embodiment of formula I, R1 is H, halogen or C1-C6-alkyl, in particular H, CH3, Et, F, Cl, more specifically H, CH3, F or Cl most preferred H, F or Cl.
According to another embodiment of formula I, R1 is hydrogen.
According to still another embodiment of formula I, R1 is halogen, in particular Br, F or Cl, more specifically F or Cl.
According to another embodiment of formula I, R1 is F
According to another embodiment of formula I, R1 is Cl
According to another embodiment of formula I, R1 is Br.
According to still another embodiment of formula I, R1 is OH.
According to still another embodiment of formula I, R1 is CN.
According to still another embodiment of formula I, R1 is NO2.
According to still another embodiment of formula I, R1 is SH.
According to still another embodiment of formula I R1 is NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2 or NH—SO2—Rx, wherein Rx is C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted with one, two, three, four or five substituents Rx1 independently selected from C1-C4-alkyl, halogen, OH, CN, C1-C4-halogenalkyl, C1-C4-alkoxy, or C1-C4-halogenalkoxy. In particular C1-C4-alkyl, such as NHCH3 and N(CH3)2. In particular Rx is C1-C4-alkyl, and phenyl that is substituted with one CH3, more specifically SO2—Rx is CH3 and tosyl group (“Ts”).
According to still another embodiment of formula I, R1 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3 or CH2CH3.
According to still another embodiment of formula I, R1 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CHF2, CH2F, CCl3, CHCl2, CH2Cl, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula I, R1 is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C2-C4-alkenyl or C2-C4-halogenalkenyl, such as CH═CH2, C(CH3)═CH2, CH═CCl2, CH═CF2, CCl═CCl2, CF═CF2, CH═CH2, CH2CH═CCl2, CH2CH═CF2, CH2CCl═CCl2, CH2CF═CF2, CCl2CH═CCl2, CF2CH═CF2, CCl2CCl═CCl2, or CF2CF═CF2.
According to still another embodiment of formula I, R1 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, C≡CCl, C≡CF. CH2C≡CH, CH2C≡CCl, or CH2C≡CF.
According to still another embodiment of formula I, R1 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3 or OCH2CH3.
According to still another embodiment of formula I, R1 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to still another embodiment of formula I R1 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R1 is C3-C6-cycloalkyl, for example cyclopropyl, substituted with one, two, three or up to the maximum possible number of identical or different groups R1b as defined and preferably herein.
According to still another embodiment of formula I, R1 is C3-C6-halogencycloalkyl. In a special embodiment R1 is fully or partially halogenated cyclopropyl.
According to still another embodiment of formula I, R1 is unsubstituted aryl or aryl that is substituted with one, two, three or four R1b, as defined herein. In particular, R1 is unsubstituted phenyl or phenyl that is substituted with one, two, three or four R1b, as defined herein.
According to still another embodiment of formula I, R1 is unsubstituted 5- or 6-membered heteroaryl. According to still a further embodiment, R1 is 5- or 6-membered heteroaryl that is substituted with one, two or three R1b, as defined herein.
According to still another embodiment of formula I, R1 is in each case independently selected from hydrogen, halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy and C3-C6-cycloalkyl; wherein the acyclic moieties of R1 are not further substituted or carry one, two, three, four or five identical or different groups R1a as defined below and wherein the carbocyclic, heteroaryl and aryl moieties of R1 are not further substituted or carry one, two, three, four or five identical or different groups R1b as defined below.
According to still another embodiment of formula I, R1 is independently selected from hydrogen, halogen, OH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy and C1-C6-halogenalkoxy, in particular independently selected from H, F, Cl, Br, CN, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
R1a are the possible substituents for the acyclic moieties of R1.
R1a according to the invention is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenoxy group is unsubstituted or unsubstituted or substituted with R11a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular selected from halogen, C1-C2-alkyl, C1-C2-halogenalkyl, C1-C2-alkoxy and C1-C2-halogenalkoxy, more specifically selected from halogen, such as F, Cl and Br.
In to one embodiment R1a is independently selected from halogen, OH, CN, C1-C2-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R1a is independently selected from F, Cl, OH, CN, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl and C1-C2-halogenalkoxy.
According to one embodiment R1a is independently selected from halogen, such as F, Cl, Br and I, more specifically F, Cl and Br.
According to still another embodiment of formula I, R1a is independently selected from OH, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R1a is independently selected from OH, cyclopropyl and C1-C2-halogenalkoxy.
According to still another embodiment of formula I, R1a is independently selected from aryl and phenoxy, wherein the aryl and phenoxy group is unsubstituted or substituted with R11a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular selected from halogen, C1-C2-alkyl, C1-C2-halogenalkyl, C1-C2-alkoxy and C1-C2-halogenalkoxy, more specifically selected from halogen, such as F, Cl and Br.
R1b are the possible substituents for the carbocyclic, heteroaryl and aryl moieties of R1. R1b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy.
According to one embodiment thereof R1b is independently selected from halogen, CN, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R1b is independently selected from F, Cl, Br, OH, CN, CH3, OCH3, CHF2, OCHF2, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl, OCF3, and OCHF2.
According to still another embodiment thereof R1b is independently selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R1b is independently selected from halogen, CN, OH, CH3, CHF2, OCHF2, OCF3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and halogenmethoxy, more specifically independently selected from F, Cl, OH, CH3, OCH3,CHF2, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl, OCHF2 and OCF3.
Rx in the substituent NH—SO2—Rx is in each case independently selected from C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl and aryl that is substituted with one, two, three, four or five substituents Rx1 independently selected from C1-C4-alkyl, halogen, OH, CN, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy. In particular, Rx is in each case independently selected from C1-C4-alkyl, halogen, OH, CN and phenyl that is substituted with one, two or three Rx1 independently selected from C1-C2-alkyl, more specifically Rx is in each case independently selected from C1-C4-alkyl and phenyl that is substituted with one CH3, more specifically SO2—Rx is the tosyl group (“Ts”).
Particularly preferred embodiments of R1 according to the invention are in Table P1 below, wherein each line of lines P1-1 to P1-16 corresponds to one particular embodiment of the invention. Thereby, for every R1 that is present in the inventive compounds, these specific embodiments and preferences apply independently of the meaning of any other R1 that may be present in the ring:
For every R2 that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of the other R2 that may be present in the ring.
According to one embodiment of formula I, R2 is H, halogen or C1-C6-alkyl, in particular H, CH3, Et, F, Cl, more specifically H, CH3, F or Cl most preferred H, F or Cl.
According to another of formula I, R2 is halogen, in particular Br, F or Cl, more specifically F or Cl.
According to another embodiment of formula I, R2 is F
According to another embodiment of formula I, R2 is Cl
According to another embodiment of formula I, R2 is Br.
According to still another embodiment of formula I, R2 is hydrogen.
According to still another embodiment of formula I, R2 is OH.
According to still another embodiment of formula I, R2 is CN.
According to still another embodiment of formula I, R2 is NO2.
According to still another embodiment of formula I, R2 is SH.
In a further specific embodiment R2 is NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2 or NH—SO2—Rx, wherein Rx is C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted with one, two, three, four or five substituents Rx2 independently selected from C1-C4-alkyl, halogen, OH, CN, C1-C4-halogenalkyl, C1-C4-alkoxy, or C1-C4-halogenalkoxy. In particular C1-C4-alkyl, such as NHCH3 and N(CH3)2. In particular Rx is C1-C4-alkyl, and phenyl that is substituted with one CH3, more specifically SO2—Rx is CH3 and tosyl group (“Ts”).
According to still another embodiment of formula I, R2 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3 or CH2CH3.
According to still another embodiment of formula I, R2 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CHF2, CH2F, CCl3, CHCl2, CH2Cl, CF3CH2, CCl3CH2 or CF2CHF2.
According to still a further embodiment, R2 is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C2-C4-alkenyl or C2-C4-halogenalkenyl, such as CH═CH2, CH═CCl2, CH═CF2, CCl═CCl2, CF═CF2, CH═CH2, CH2CH═CCl2, CH2CH═CF2, CH2CCl═CCl2, CH2CF═CF2, CCl2CH═CCl2, CF2CH═CF2, CCl2CCl═CCl2, or CF2CF═CF2.
According to still a further embodiment, R2 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, C≡CCl, C≡CF. CH2C≡CH, CH2C≡CCl, or CH2C≡CF.
According to still another embodiment of formula I, R2 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3 or OCH2CH3.
According to still another embodiment of formula I, R2 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
In a further specific embodiment R2 is C3-C6-cycloalkyl, in particular cyclopropyl.
In a further specific embodiment, R2 is C3-C6-cycloalkyl, for example cyclopropyl, substituted with one, two, three or up to the maximum possible number of identical or different groups R2b as defined and preferably herein.
According to still another embodiment of formula I, R2 is C3-C6-halogencycloalkyl. In a special embodiment R2 is fully or partially halogenated cyclopropyl.
According to still another embodiment of formula I, R2 is unsubstituted aryl or aryl that is substituted with one, two, three or four R2b, as defined herein. In particular, R2 is unsubstituted phenyl or phenyl that is substituted with one, two, three or four R2b, as defined herein.
According to still another embodiment of formula I, R2 is unsubstituted 5- or 6-membered heteroaryl. According to still a further embodiment, R2 is 5- or 6-membered heteroaryl that is substituted with one, two or three R2b, as defined herein.
According to still another embodiment of formula I, R2 is in each case independently selected from hydrogen, halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy and C3-C6-cycloalkyl; wherein the acyclic moieties of R2 are not further substituted or carry one, two, three, four or five identical or different groups R2a as defined below and wherein the cycloalkyl moieties of R2 are not further substituted or carry one, two, three, four or five identical or different groups R2b as defined below.
According to still another embodiment of formula I, R2 is independently selected from hydrogen, halogen, OH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy and C1-C6-halogenalkoxy, in particular independently selected from H, F, Cl, Br, CN, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
R2a are the possible substituents for the acyclic moieties of R2.
R2a according to the invention is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalky, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenoxy group is unsubstituted or substituted with R22a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular selected from halogen, C1-C2-alkyl, C1-C2-halogenalkyl, C1-C2-alkoxy and C1-C2-halogenalkoxy, more specifically selected from halogen, such as F, Cl and Br.
According to one embodiment R2a is independently selected from halogen, OH, CN, C1-C2-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalky and C1-C2-halogenalkoxy. Specifically, R2a is independently selected from F, Cl, OH, CN, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl and C1-C2-halogenalkoxy.
According to one embodiment R2a is independently selected from halogen, such as F, Cl, Br and I, more specifically F, Cl and Br.
According to still another embodiment of formula I, R2a is independently selected from OH, C3-C6-cycloalkyl, C3-C6-halogencycloalky and C1-C2-halogenalkoxy. Specifically, R2a is independently selected from OH, cyclopropyl and C1-C2-halogenalkoxy.
According to still another embodiment of formula I, R2a is independently selected from aryl and phenoxy, wherein the aryl and phenoxy group is unsubstituted or substituted with R22a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular selected from halogen, C1-C2-alkyl, C1-C2-halogenalkyl, C1-C2-alkoxy and C1-C2-halogenalkoxy, more specifically selected from halogen, such as F, Cl and Br.
R2b are the possible substituents for the carbocyclic, heteroaryl and aryl moieties of R2.
R2b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalky and C1-C4-halogenalkoxy.
According to one embodiment thereof R2b is independently selected from halogen, CN, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R2b is independently selected from F, Cl, Br, OH, CN, CH3, OCH3, CHF2, OCHF2, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl, OCF3, and OCHF2.
According to still another embodiment thereof R2b is independently selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R2b is independently selected from halogen, OH, CH3, OCH3, CN, CHF2, OCHF2, OCF3, OCH3 cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl and halogenmethoxy, more specifically independently selected from F, Cl, OH, CH3, OCH3, CHF2, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl, OCHF2 and OCF3.
Particularly preferred embodiments of R2 according to the invention are in Table P2 below, wherein each line of lines P2-1 to P2-16 corresponds to one particular embodiment of the invention. Thereby, for every R2 that is present in the inventive compounds, these specific embodiments and preferences apply independently of the meaning of any other R2 that may be present in the ring:
According to one embodiment of formula I, R3 is independently selected from CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkynyl, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), CR′═NOR″, C3-C6-halogencycloalkyl, a saturated three-, four-, five-, six-, membered carbo- or heterocycle, a five- or six-membered heteroaryl, aryl and C1-C6-alkyl substituted with CN, C1-C6-alkoxy, C1-C4-halogenalkoxy, C1-C6-alkylthio, S(O)n—C1-C6-alkyl, S(O)n—C1-C6-halogenalkyl, NH—SO2—Rx, N(C1-C6-alkyl)2, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), a saturated three-, four-, five-, six-, membered carbo- or heterocycle, aryl; wherein Rx, R′ and R″ are defined below; and wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbo-, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R3b as defined below.
According to one embodiment of formula I, R3 is selected from C1-C6-alkyl, C2-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkynyl, CH(═O), C(═O)C2-C6-alkyl, C(═O)O(C2-C6-alkyl), CR′═NOR″, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkyl-five- and six-membered heteroaryl or aryl; wherein the aryl is unsubstituted or substituted by halogen or C1-C6-halogenalkyl; wherein R′ and R″ are defined below; and wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R3b as defined below.
According to one embodiment of formula I, R3 is selected from C1-C6-alkyl substituted with CN, C1-C6-alkoxy, C1-C4-halogenalkoxy, C1-C6-alkylthio, S(O)n—C1-C6-alkyl, NH—SO2—Rx, N(C1-C6-alkyl)2, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), a saturated three-, four-, five-, six-, membered carbo- or heterocycle, aryl; wherein Rx is defined below; and wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R3b as defined below.
According to still another embodiment of formula I, R3 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, CN, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkylaryl, C1-C6-alkylheteroaryl, phenyl, pyridine, pyrimidine, thiophene, imidazole, triazol, oxadiazol wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbocycle, heterocycle, heteroaryl and aryl moieties are unsubstituted or substituted by substituents R3b as defined below.
According to another embodiment of formula I, R3 is F
According to another embodiment of formula I, R3 is Cl
According to another embodiment of formula I, R3 is Br.
According to still another embodiment of formula I, R3 is OH.
According to still another embodiment of formula I, R3 is CN.
According to still another embodiment of formula I, R3 is NO2.
According to still another embodiment of formula I, R3 is SH.
According to still another embodiment of formula I, R3 is C1-C6-alkylthio, such as SCH3, SC2H5, Sn-propyl, Si-propyl, Sn-butyl, Si-butyl, Stert-butyl, Sn-pentyl, Si-pentyl, CH2SCH3 or CH2SCH2CH3.
According to still another embodiment of formula I, R3 is C1-C6-halogenalkylthio, such as SCF3, SCCl3, CH2SCF3 or CH2SCF3.
According to still another embodiment of formula I, R3 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or is substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted. In a particular embodiment, R3 is selected from C1-C6-halogenalkyl, phenyl-CH2, halogenphenyl-CH2, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or is substituted with substituents R3b as defined below.
According to still another embodiment of formula I, R3 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or substituted by substituents R3b as defined below. According to one embodiment thereof, the carbo- and heterocycle is unsubstituted. In a particular embodiment, R3 is selected from substituted C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or substituted by substituents R3b as defined below.
According to another embodiment of formula I, R3 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkylaryl, six-membered heteroaryl or aryl which is unsubstituted or substituted with halogen or C1-C6-halogenalkyl, and wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R3b as defined below.
According to still another embodiment of formula I, R3 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, CN, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkylaryl, phenyl, pyridine, pyrimidine, thiophene, imidazole, triazol, oxadiazol wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R3a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R3b as defined below.
According to still another embodiment of formula I, R3 is C1-C6-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R3 is C1-C6-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R3 is C1-C6-alkyl such as CH3.
According to still another embodiment of formula I, R3 is C1-C6-alkyl such as C2H5.
According to still another embodiment of formula I, R3 is C1-C6-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl which is substituted with at least one group R3a, which independently of one another are selected from:
According to still another embodiment of formula I, R3 is CH3 is substituted with at least one group R3a, which independently of one another are selected from:
According to still another embodiment of formula I, R3 is O2H5 is substituted with at least one group R3a, which independently of one another are selected from:
According to still another embodiment of formula I, R3 is CH2CN.
According to still another embodiment of formula I, R3 is CH2OH.
According to still another embodiment of formula I, R3 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula I, R3 is CH2F.
According to still another embodiment of formula I, R3 is CHF2.
According to still another embodiment of formula I, R3 is CF3.
According to still a further embodiment of formula I, R3 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2, CH2CH═CH2 or C(CH3)C═CH2.
According to a further specific embodiment of formula I, R3 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CF═CF2, CCl═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CH2CF═CF2, CH2CCl═CCl2, CF2CF═CF2 or CCl2CCl═CCl2.
According to still a further embodiment of formula I, R3 is C2-C6-cycloalkenyl, in particular C2-C4-cycloalkenyl, such as CH═CH2-cPr.
According to still a further embodiment of formula I, R3 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, C≡C—Cl, C≡C—CH3, CH2—C≡CH, CH2—C≡CCl or CH2—C≡C—CH3.
According to still a further embodiment of formula I, R3 is C2-C6-cycloalkynyl in particular C2-C4-cycloalkynyl, such as C≡C-cPr.
According to a further specific embodiment of formula I, R3 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3, CH2CH3 or CH2OCH3.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-C1-C6-alkoxy, in particular C1-C4-alkyl-C1-C4-alkoxy, more specifically C1-C2-alkyl-C1-C2-alkoxy, such as CH2OCH3 or CH2OCH2CH3.
According to a further specific embodiment of formula I, R3 is C2-C6-alkenyloxy, in particular C2-C4-alkenyloxy, more specifically C1-C2-alkenyloxy such as OCH═CH2, OCH2CH═CH2OC(CH3)CH═CH2, CH2OCH═CH2, or CH2OCH2CH═CH2.
According to a further specific embodiment of formula I, R3 is C2-C6-alkynyloxy, in particular C2-C4-alkynyloxy, more specifically C1-C2-alkynyloxy such as OC≡CH, OCH2C≡CH or CH2OC≡CH
According to a further specific embodiment of formula I, R3 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-C1-C6-halogenalkoxy, in particular C1-C4-alkyl-C1-C4-halogenalkoxy, more specifically C1-C2-alkyl-C1-C2-halogenalkoxy such as CH2OCF3, CH2OCHF2, CH2OCH2F, CH2OCCl3, CH2OCHCl2 or CH2OCH2Cl, in particular CH2OCF3, CH2OCHF2, CH2OCCl3 or CH2OCHCl2.
According to a further specific embodiment of formula I, R3 is CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl) or C(═O)N(C1-C6-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R3 is C1-C4-alkyl-CH(═O), C1-C4-alkyl-C(═O)C1-C6-alkyl, C1-C4-alkyl-C(═O)O(C1-C6-alkyl), C1-C4-alkyl-C(═O)NH(C1-C6-alkyl) or C1-C4-alkyl-C(═O)N(C1-C6-alkyl)2, especially CH2CH(═O), CH2C(═O)C1-C6-alkyl, CH2C(═O)O(C1-C6-alkyl), CH2C(═O)NH(C1-C6-alkyl) or CH2C(═O)N(C1-C6-alkyl)2 wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R3 is CR′═NOR″ such as C(CH3)═NOCH3, C(CH3)═NOCH2CH3 or C(CH3)═NOCF3.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-NH(C1-C4-alkyl) or C1-C6-alkyl-N(C1-C4-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-S(O)n—C1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and n is 1, 2 or 3.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-S(O)n—C1-C6-halogenalkyl, wherein halogenalkyl is CF3 or CHF2 and n is 1, 2 or 3.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-S(O)n-aryl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R3b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3. According to one embodiment, R3 is unsubstituted phenyl. According to another embodiment, R3 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl-NH—SO2—Rx wherein Rx is C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted with one, two, three, four or five substituents Rx2 independently selected from C1-C4-alkyl, halogen, OH, CN, C1-C4-halogenalkyl, C1-C4-alkoxy, or C1-C4-halogenalkoxy, such as CH2NHSO2CF3 or CH2NHSO2CH3.
According to still another embodiment of formula I, R3 is selected from C1-C6-alkyl which is substituted, a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to one embodiment, R3 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is selected from C1-C6-alkyl, especially with CH2 optionally substituted CH2 which is substituted with a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl, especially CH2 substituted with a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl, especially CH2 substituted with a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl, especially CH2 substituted by a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to a further specific embodiment of formula I, R3 is C1-C6-alkyl, especially CH2 substituted with a 5-membered saturated heterocycle which contains one N as ring member and optionally one or two groups CH2 are replaced by C(═O).
According to still another embodiment of formula I, R3 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to still another embodiment of formula I, R3 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.
According to still a further embodiment, R3 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.
According to still another embodiment of formula I, R3 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to one embodiment, R3 is a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is a 3-membered saturated carbocycle, which is unsubstituted such as cyclopropyl According to one embodiment, R3 is a 3-membered saturated carbocycle, which is substituted with halogen, more specifically by F, such as C3H3F2.
According to one embodiment, R3 is a 3-membered saturated carbocycle, which is substituted with halogen. More specifically by Cl, such as C3H3Cl2.
According to one embodiment, R3 is a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to one embodiment, R3 is a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to still another embodiment of formula I, R3 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, R3 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted with substituents R3b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, in the embodiments of R3 described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one 0.
According to one embodiment, R3 is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to still another embodiment of formula I, R3 is a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to still another embodiment of formula I, R3 is a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R3b. According to still another embodiment of formula I, it is substituted with R3b.
According to still another embodiment of formula I, R3 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted with one, two or three identical or different groups R3b which independently of one another are selected from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular from CN, F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3 and S(O)2CH3.
According to still another embodiment of formula I, R3 is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R3b which independently of one another are selected from from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular from CN, F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3. According to one embodiment, R3 is unsubstituted phenyl. According to another embodiment, R3 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to still another embodiment of formula I, R3 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R3 is a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
Particularly preferred embodiments of R3 according to the invention are in Table P3 below, wherein each line of lines P3-1 to P3-33 corresponds to one particular embodiment of the invention, wherein P3-1 to P3-33 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R3 is bound is marked with “#” in the drawings.
According to one embodiment of formula I, R4 is selected from CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C06-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkynyl, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), CR′═NOR″, C3-C6-halogencycloalkyl, a saturated three-, four-, five-, six-, membered carbo- or heterocycle, a five- or six-membered heteroaryl, aryl and phenoxy; and C1-C6-alkyl substituted with CN, C1-C6-alkoxy, C1-C4-halogenalkoxy, C1-C6-alkylthio, S(O)n—C1-C6-alkyl, S(O)n—C1-C6-halogenalkyl, NH—SO2—Rx, N(C1-C6-alkyl)2, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), a saturated three-, four-, five-, six-, membered carbo- or heterocycle, aryl; wherein Rx, R′ and R″ are defined below; and wherein the acyclic moieties of R4 are unsubstituted or substituted with identical or different groups R4a as defined below and wherein wherein the carbo-, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R4b as defined below.
According to one embodiment of formula I, R4 is selected from C1-C6-alkyl, C2-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C06-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkynyl, CH(═O), C(═O)C2-C6-alkyl, C(═O)O(C2-C6-alkyl), CR′═NOR″, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkyl-five- and six-membered heteroaryl, a five- or six-membered heteroaryl, aryl aryl and phenoxy, which is unsubstituted or substituted by halogen or C1-C6-halogenalkyl; wherein R′ and R″ are defined below; and wherein the acyclic moieties of R3 are unsubstituted or substituted with identical or different groups R4a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R4b as defined below.
According to one embodiment of formula I, R4 is selected from C1-C6-alkyl substituted with CN, C1-C6-alkoxy, C1-C4-halogenalkoxy, C1-C6-alkylthio, S(O)n—C1-C6-alkyl, NH—SO2—Rx, N(C1-C6-alkyl)2, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), a saturated three-, four-, five-, six-, membered carbo- or heterocycle, aryl; wherein Rx is defined below; and wherein the acyclic moieties of R4 are unsubstituted or substituted with identical or different groups R4a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R4b as defined below.
According to another embodiment of formula I, R4 is F
According to another embodiment of formula I, R4 is Cl
According to another embodiment of formula I, R4 is Br.
According to still another embodiment of formula I, R4 is OH.
According to still another embodiment of formula I, R4 is CN.
According to still another embodiment of formula I, R4 is NO2.
According to still another embodiment of formula I, R4 is SH.
According to still another embodiment of formula I, R4 is C1-C6-alkylthio, such as SCH3, SC2H5, Sn-propyl, Si-propyl, Sn-butyl, Si-butyl, Stert-butyl, Sn-pentyl, Si-pentyl, CH2SCH3 or CH2SCH2CH3.
According to still another embodiment of formula I, R4 is C1-C6-halogenalkylthio, such as SCF3, SCCl3, CH2SCF3 or CH2SCF3.
According to still another embodiment of formula I, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl or C1-C6-alkyl which is substituted, C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or is substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted. In a particular embodiment, R4 is selected from C1-C6-halogenalkyl, phenyl-CH2, halogenphenyl-CH2, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or is substituted with substituents R4b as defined below.
According to still another embodiment of formula I, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl or C1-C6-alkyl which is substituted, C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or substituted by substituents R4b as defined below. According to one embodiment thereof, the carbo- and heterocycle is unsubstituted.
In a particular embodiment, R4 is selected from substituted C1-C6-halogenalkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbo- and heterocycle, wherein the carbo- and heterocycle is unsubstituted or substituted by substituents R4b as defined below.
According to another embodiment of formula I, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkylaryl, six-membered heteroaryl or aryl which is unsubstituted or substituted with halogen or C1-C6-halogenalkyl, and wherein the acyclic moieties of R4 are unsubstituted or substituted with identical or different groups R4a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R4b as defined below.
According to still another embodiment of formula I, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, CN, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkylaryl, phenyl, pyridine, pyrimidine, thiophene, imidazole, triazol, oxadiazol wherein the acyclic moieties of R4 are unsubstituted or substituted with identical or different groups R4a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted with substituents R4b as defined below.
According to still another embodiment of formula I, R4 is C1-C6-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R4 is C1-C6-alkyl such as CH3.
According to still another embodiment of formula I, R4 is C1-C6-alkyl such as C2H5.
According to still another embodiment of formula I, R4 is C1-C6-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl which is substituted with at least one group R4a, which independently of one another are selected from:
According to still another embodiment of formula I, R4 is CH3 is substituted with at least one group R4a, which independently of one another are selected from:
According to still another embodiment of formula I, R4 is O2H5 is substituted with at least one group R4a, which independently of one another are selected from:
According to still another embodiment of formula I, R4 is CH2CN.
According to still another embodiment of formula I, R4 is CH2OH.
According to still another embodiment of formula I, R4 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula I, R4 is CH2F.
According to still another embodiment of formula I, R4 is CHF2.
According to still another embodiment of formula I, R4 is CF3.
According to still a further embodiment of formula I, R4 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2, CH2CH═CH2 or C(CH3)C═CH2.
According to a further specific embodiment of formula I, R4 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CF═CF2, CCl═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CH2CF═CF2, CH2CCl═CCl2, CF2CF═CF2 or CCl2CCl═CCl2.
According to still a further embodiment of formula I, R4 is C2-C6-cycloalkenyl, in particular C2-C4-cycloalkenyl, such as CH═CH2-cPr.
According to still a further embodiment of formula I, R4 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, C≡C—Cl, C≡C—CH3, CH2—C≡CH, CH2—C≡CCl or CH2—C≡C—CH3.
According to still a further embodiment of formula I, R4 is C2-C6-cycloalkynyl in particular C2-C4-cycloalkynyl, such as C≡C-cPr.
According to a further specific embodiment of formula I, R4 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3, CH2CH3 or CH2OCH3.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-C1-C6-alkoxy, in particular C1-C4-alkyl-C1-C4-alkoxy, more specifically C1-C2-alkyl-C1-C2-alkoxy, such as CH2OCH3 or CH2OCH2CH3.
According to a further specific embodiment of formula I, R4 is C2-C6-alkenyloxy, in particular C2-C4-alkenyloxy, more specifically C1-C2-alkenyloxy such as OCH═CH2, OCH2CH═CH2OC(CH3)CH═CH2, CH2OCH═CH2, or CH2OCH2CH═CH2.
According to a further specific embodiment of formula I, R4 is C2-C6-alkynyloxy, in particular C2-C4-alkynyloxy, more specifically C1-C2-alkynyloxy such as OC≡CH, OCH2C≡CH or CH2OC≡CH
According to a further specific embodiment of formula I, R4 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-C1-C6-halogenalkoxy, in particular C1-C4-alkyl-C1-C4-halogenalkoxy, more specifically C1-C2-alkyl-C1-C2-halogenalkoxy such as CH2OCF3, CH2OCHF2, CH2OCH2F, CH2OCCl3, CH2OCHCl2 or CH2OCH2Cl, in particular CH2OCF3, CH2OCHF2, CH2OCCl3 or CH2OCHCl2.
According to a further specific embodiment of formula I, R4 is CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl) or C(═O)N(C1-C6-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R4 is C1-C4-alkyl-CH(═O), C1-C4-alkyl-C(═O)C1-C6-alkyl, C1-C4-alkyl-C(═O)O(C1-C6-alkyl), C1-C4-alkyl-C(═O)NH(C1-C6-alkyl) or C1-C4-alkyl-C(═O)N(C1-C6-alkyl)2, especially CH2CH(═O), CH2C(═O)C1-C6-alkyl, CH2C(═O)O(C1-C6-alkyl), CH2C(═O)NH(C1-C6-alkyl) or CH2C(═O)N(C1-C6-alkyl)2 wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R4 is CR′═NOR″ such as C(CH3)═NOCH3, C(CH3)═NOCH2CH3 or C(CH3)═NOCF3.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-NH(C1-C4-alkyl) or C1-C6-alkyl-N(C1-C4-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R4 is C1-C6-alkylthio, in particular C1-C4-alkoxy, more specifically C1-C3-alkylthio such as CH2SCH3 or CH2SCH2CH3.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-S(O)n—C1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and n is 1, 2 or 3.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-S(O)n—C1-C6-halogenalkyl, wherein halogenalkyl is CF3 or CHF2 and n is 1, 2 or 3.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-S(O)n-aryl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R4b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3. According to one embodiment, R4 is unsubstituted phenyl. According to another embodiment, R4 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl-NH—SO2—Rx wherein Rx is C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted with one, two, three, four or five substituents Rx2 independently selected from C1-C4-alkyl, halogen, OH, CN, C1-C4-halogenalkyl, C1-C4-alkoxy, or C1-C4-halogenalkoxy, such as CH2NHSO2CF3 or CH2NHSO2CH3.
According to still another embodiment of formula I, R4 is selected from C1-C6-alkyl which is substituted, a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to one embodiment, R4 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is selected from C1-C6-alkyl, especially CH2 which is substituted with a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkylheterocycle, especially CH2 substituted with a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkylheterocycle, especially CH2 substituted with a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkylheterocycle, especially CH2 substituted by a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkylheterocycle, especially CH2 substituted with a 5-membered saturated heterocycle which contains one N as ring member and optionally one or two groups CH2 are replaced by C(═O).
According to still another embodiment of formula I, R4 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to still another embodiment of formula I, R4 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.
According to still a further embodiment, R4 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.
According to still another embodiment of formula I, R4 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.
According to one embodiment, R4 is a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is a 3-membered saturated carbocycle, which is unsubstituted such as cyclopropyl.
According to one embodiment, R4 is a 3-membered saturated carbocycle, which is substituted with halogen, more specifically by F, such as C3H3F2.
According to one embodiment, R4 is a 3-membered saturated carbocycle, which is substituted with halogen. More specifically by Cl, such as C3H3Cl2.
According to one embodiment, R4 is a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R4 is a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to still another embodiment of formula I, R4 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, R4 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted with substituents R4b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, in the embodiments of R4 described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one O.
According to one embodiment, R4 is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to still another embodiment of formula I, R4 is a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to still another embodiment of formula I, R4 is a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to still another embodiment of formula I, R4 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted with one, two or three identical or different groups R4b which independently of one another are selected from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular from CN, F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3 and S(O)2CH3.
According to still another embodiment of formula I, R4 is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R4b which independently of one another are selected from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C1-C2-halogenalkoxy and S(O)n—C1-C6-alkyl, in particular from CN, F, Cl, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3. According to one embodiment, R4 is unsubstituted phenyl. According to another embodiment, R4 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to still another embodiment of formula I, R4 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R4 is a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one N as ring member. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains three N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b. According to one specific embodiment thereof, said 5-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) 0.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one S as ring member. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one S and one N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one S and two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one oxygen and one N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 5-membered saturated heteroaryl which contains one oxygen and two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 6-membered saturated heteroaryl which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 6-membered saturated heteroaryl which one N as ring member. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 6-membered saturated heteroaryl which two N as ring members.
According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 10-membered saturated heteroaryl which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to one specific embodiment thereof, said 10-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) N.
According to a further specific embodiment of formula I, R4 is C1-C6-alkyl, especially CH2 substituted by a 10-membered saturated heteroaryl which one N as ring members.
According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted by R4b.
According to still another embodiment of formula I, R4 is CH2 substituted by a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R4 is CH2 substituted by a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to a further particular embodiment, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, CN, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C06-alkynyl, C2-C6-halogenalkynyl, aryl, heteroaryl, three-, four-, five- or six-membered carbocycle and heterocycle, phenoxy, and C1-C6-alkyl substituted by CN, three-, four-, five- or six-membered carbocycle and heterocycle, aryl and heteroaryl; wherein the carbocycle and heterocycle is unsubstituted or carries one, two, three or four substituents R4b as defined below. According to one embodiment thereof, the carbocycle, heterocycle, heteroaryl and aryl are unsubstituted. In a particular embodiment, R4 is selected from C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, aryl, heteroaryl, cypropropyl and C1-C6-alkyl substituted by aryl and heteroaryl; wherein the aryl and heteroaryl are unsubstituted or carries one, two, three or four substituents R4b as defined below. Particularly preferred embodiments of R4 according to the invention are in Table P4 below, wherein each line of lines P4-1 to P4-190 corresponds to one particular embodiment of the invention, wherein P4-1 to P4-190 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R4 is bound is marked with “#” in the drawings.
According to still another embodiment of formula I, R3, R4 together with the carbon atom to which they are bound form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, wherein the heteroatom N may carry one substituent RN selected from C1-C4-alkyl, C1-C4-halogenalkyl and SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted with one, two or three substituents selected from CN, C1-C4-alkyl, halogen, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy; and wherein the heteroatom S may be in the form of its oxide SO or SO2, and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R34 independently selected from halogen, OH, CN, NO2, SH, NH2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, C1-C4-alkoxy-C1-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R34a selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy; and wherein in each case one or two CH2 groups of the carbo- or heterocycle may be replaced by a group independently selected from C(═O) and C(═S).
According to one embodiment, R3 and R4 form a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R3 and R4 form a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R3 and R4 form a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R3 and R4 form a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R3 and R4 form a 7-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R4b. According to still another embodiment of formula I, it is substituted with R4b.
According to one embodiment, R3 and R4 together with the carbon atom to which they are bound form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle that is unsubstituted or substituted. According to a further embodiment, the heterocycle formed by R3 and R4 is saturated.
According to a further embodiment, the heterocycle formed by R3 and R4 is a saturated unsubstituted or substituted heterocycle, wherein the heterocycle contains one, two or three, more particularly one or two, specifically one, heteroatom(s) selected from NH, NRN, O, S, S(═O) and S(═O)2, wherein RN is defined and preferably defined above. According to one embodiment, this saturated heterocycle is unsubstituted. According to a further embodiment, the saturated heterocycle carries one, two, three or four substituents R34. In one further particular embodiment, said heterocycle is four- or six-membered.
According to a further embodiment, the unsubstituted or substituted and saturated or partially unsaturated heterocycle is three-, four-, five- or six-membered and contains one, two or three, more particularly one or two, heteroatoms selected from NH, NRN, O, S, S(═O) and S(═O)2, wherein RN is as defined above or preferably selected from C1-C2-alkyl, C1-C2-halogenalkyl and SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one C1-C2-alkyl. In one further particular embodiment, said heterocycle is four- or six-membered.
According to a further embodiment, the heterocycle formed by R3 and R4 contains one, two or three, more specifically one or two, heteroatoms selected from NH and NRN, wherein RN is as defined and preferably defined below, more particularly selected from C1-C2-alkyl, C1-C2-halogenalkyl and SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl. In one embodiment thereof, it contains one or two heteroatoms NH, in particular one NH. In another embodiment, it contains one or two heteroatoms NRN, in particular one NRN, wherein RN in each case is as defined and preferably defined above.
According to a further embodiment, the heterocycle formed by R3 and R4 contains one, two or three, more specifically one or two, in particular one, heteroatom(s) selected from S, S(═O) and S(═O)2. In one embodiment thereof, it contains one or two heteroatoms S, in particular one S. In another embodiment, it contains one or two heteroatoms S(═O), in particular one S(═O). In still another embodiment, it contains one or two heteroatoms S(═O)2, in particular one S(═O)2.
According to a further embodiment, the heterocycle formed by R3 and R4 contains one or two heteroatoms O. In one embodiment thereof, it contains one heteroatom O. In another embodiment, it contains two heteroatoms O.
According to a further embodiment, the heterocycle formed by R3 and R4 is unsubstituted, i.e. it does not carry any substituent R34. According to a further embodiment, it carries one, two, three or four R34.
According to one particular embodiment, R3 and R4 together form a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of NH, NRN, O, S, S(═O) and S(═O)2, as ring members, wherein RN is defined and preferably defined above. In one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R34. According to a further embodiment, it carries one, two, three or four R34.
According to a further particular embodiment, R3 and R4 together form a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of NH, NRN, O, S, S(═O) and S(═O)2, as ring members, wherein RN is as defined and preferably defined above. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R34. According to a further embodiment, it carries one, two, three or four R34.
According to a further particular embodiment, R3 and R4 together form a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of NH, NRN, O, S, S(═O) and S(═O)2, as ring members, wherein RN is as defined and preferably defined below. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R34. According to a further embodiment, it carries one, two, three or four R34. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms selected from NH and NRN. According to a further specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms O. According to a further specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms selected from S, S(═O) and S(═O)2. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R34. According to a further embodiment, it carries one, two, three or four R34.
According to one further embodiment R3 together with R4 and with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered carbocycle, more specifically five- or six-membered carbocycle, that is unsubstituted or carries one, two, three or four substituents R34 as defined below. According to one embodiment thereof, R3 and R4 form a cyclopropyl, that is unsubstituted or carries one, two, three or four substituents R34 as defined below. According to a further embodiment thereof, R3 and R4 form a cyclobutyl, that is unsubstituted or carries one, two, three or four substituents R34 as defined below. According to still a further embodiment thereof, R3 and R4 form a cyclopentyl, that is unsubstituted or carries one, two, three or four substituents R34 as defined below. According to still a further embodiment thereof, R3 and R4 form a cyclohexyl, that is unsubstituted or carries one, two, three or four substituents R34 as defined below. According to still a further embodiment thereof, R3 and R4 form a cycloheptyl, that is unsubstituted or carries one, two, three or four substituents R34 as defined below.
R34 are the possible substituents for the carbo- or heterocycle formed by R3 and R4 and are independently selected from halogen, OH, CN, NO2, SH, NH2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, C1-C4-alkoxy-C1-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R34a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy; and wherein in each case one or two CH2 groups of the carbo- or heterocycle may be replaced by a group independently selected from C(═O) and C(═S).
In one preferred embodiment, R34 is in each case independently selected from halogen, OH, CN, SH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy and C1-C6-alkylthio. In one further preferred embodiment, R34 is in each case independently selected from halogen, C1-C6-alkyl and C1-C6-halogenalkyl. In one further particular embodiment, R34 is in each case independently selected from C1-C6-alkyl, such as methyl and ethyl.
RN is the substituent of the heteroatom NRN that is contained in the heterocycle formed by R3 and R4 in some of the inventive compounds. RN is selected from C1-C4-alkyl, C1-C4-halogenalk and SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from C1-C4-alkyl. In one preferred embodiment, RN is in each case independently selected from C1-C2-alkyl, C1-C2-halogenalkyl and SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl substituents. In one particular embodiment, RN is in each case independently selected from C1-C2-alkyl, more particularly methyl. In one particular embodiment, RN is in each case independently selected from SO2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl.
According to still another embodiment of formula I, R3, R4 together with the carbon atom to which they are bound form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocycle; wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R34 independently selected from halogen, OH, CN, NO2, SH, NH2, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, C1-C4-alkoxy-C1-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R34a selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy.
According to still another embodiment of formula I, R3, R4 together with the carbon atom to which they are bound form a saturated or partially unsaturated four-, five-, six-membered carbo- or heterocycle; wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R34 independently selected from halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy.
Particularly preferred embodiments of combinations of R3 and R4 according to the invention are in Table P34 below, wherein each line of lines P34-1 to P34-171 corresponds to one particular embodiment of the invention, wherein P34-1 to P34-171 are also in any combination with one another a preferred embodiment of the present invention. The carbon atom, to which R3 and R4 are bound is marked with * in the drawings. “Ts” in the drawings stands for the tosylgroup SO2-(p-CH3)phenyl.
Rx in the substituent NH—SO2—Rx is in each case independently selected from C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl and aryl that is substituted by one, two, three, four or five substituents Rx1 independently selected from C1-C4-alkyl. In particular, Rx is in each case independently selected from C1-C4-alkyl and phenyl that is substituted by one, two or three Rx1 independently selected from C1-C2-alkyl, more specifically Rx is in each case independently selected from C1-C4-alkyl and phenyl that is substituted by one CH3., more specifically SO2—Rx is the tosyl group (“Ts”).
R3a are the possible substituents for the the acyclic moieties of R3 and the R3a are in each case independently selected from halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH (C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, S(O)n—C1-C6-alkyl, S(O)n—C1-C6-halogenalkyl, S(O)n-aryl, CH(═O), C(═O)C1-C6-alkyl, C(═O)OC1-C6-alkyl, C(═O)NHC1-C6-alkyl, C(═O)N(C1-C6-alkyl)2, CR′═NOR″, a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, aryl and phenoxy; wherein in each case one or two CH2 groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(═O) and C(═S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkylthio, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy and S(O)n—C1-C6-alkyl; wherein n is 0, 1 and 2;
In one preferred embodiment, R3a is in each case independently selected from halogen, OH, CN, C1-C6-alkoxy, C1-C6-halogenalkoxy, heteroaryl, phenyl and halogenphenyl, wherein the halogenphenyl is substituted by halogen selected from the group consisting of F, Cl and Br. In one further preferred embodiment, R3a is in each case independently selected from halogen, heteroaryl, phenyl and halogenphenyl, wherein the halogenphenyl is substituted by halogen selected from the group consisting of F, Cl and Br, in particular selected from F and Cl.
In one further preferred embodiment, R3a is in each case independently selected from halogen, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, phenyl, and heteroaryl; wherein the heteroaryl and phenyl is substituted by halogen selected from the group consisting of F, Cl and Br or by C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy. In one further preferred embodiment, R3a is in each case independently selected from halogen heteroaryl and phenyl wherein the heteroaryl and phenyl is substituted by halogen selected from the group consisting of F, Cl and Br, in particular selected from F and Cl.
R3b are the possible substituents for the carbocycle, heterocycle, heteroaryl and aryl moieties are independently selected from halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, S(O)n—C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or substituted with substituents selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
In one preferred embodiment, R3b is in each case independently selected from halogen, OH, CN, SH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy and C1-C6-alkylthio. In one further preferred embodiment, R3b is in each case independently selected from halogen, C1-C6-alkoxy, C1-C6-halogenalkoxy and C1-C6-halogenalkyl. In one further particular embodiment, R3b is in each case independently selected from C1-C6-alkyl, such as methyl and ethyl. In one further particular embodiment, R3b is in each case independently selected from halogen, such as F, Cl and Br.
R4a are the possible substituents for the the acyclic moieties of R4 and the R4a are in each case independently selected from halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, S(O)n—C1-C6-alkyl, S(O)n-aryl, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl), CR′═NOR″, a saturated or partially unsaturated three-, four, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, aryl, phenoxy; wherein in each case one or two CH2 groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(═O) and C(═S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkylthio, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy and S(O)n—C1-C6-alkyl; wherein n is 0, 1 and 2; According to one preferred embodiment, R4a is in each case independently selected from halogen, OH, CN, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH—SO2—Rx, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl) and CR′═NOR″.
According to one preferred embodiment, R4a is in each case independently selected from OH, CN, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl) such as CN, CHO, C(O)O(CH3),CO2NH(CH3), CO2N(CH3)2 or NHSO2CF3.
According to one preferred embodiment, R4a is in each case independently selected from C1-C6-alkylthio, C1-C6-halogenalkylthio, S(O)n—C1-C6-alkyl, S(O)n-aryl, such as SCH3, SO2CH3, SO2Ph.
According to one preferred embodiment, R4a is in each case independently selected from NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH—SO2—Rx, such as NH(CH3), N(CH3)2 or NHSO2CH3, NHSO2CF3.
According to one preferred embodiment, R4a is in each case independently selected from C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, such as cyclopropyl or fully or partially halogenated cyclopropyl.
According to one preferred embodiment, R4a is in each case independently selected from C1-C6-alkoxy, C1-C6-halogenalkoxy, such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to one preferred embodiment, R4a is in each case independently selected from heterocarbocycle, wherein the heretocyclocycle is a saturated, two CH2 groups are replaced by C(═O) and contains one N as a ring member.
According to one preferred embodiment, R4a is in each case independently selected from aryl, wherein the aryl is substituted with halogen selected from the group consisting of F, Cl, Br, CH3, CHF2, OCH3, OCHF3, CN or SO2CH3.
According to one prefer embodiment, R4 is unsubstituted 5- or 6-membered heteroaryl.
According to still a further embodiment, R4 is 5- or 6-membered heteroaryl substituted by halogen selected from the group consisting of F, Cl, Br, CH3, CHF2, OCH3, OCHF3, CN or SO2CH3.
According to one preferred embodiment, R4a is in each case independently selected from halogen, OH, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and heterocycle, wherein the heretocyclocycle is a saturated and contains one N as a ring member.
According to one preferred embodiment, R4a is in each case independently selected from halogen, OH, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and heterocycle, wherein the heretocyclocycle is a saturated, one CH2 group is replaced by C(═O) and contains one N as a ring member.
According to one preferred embodiment, R4a is in each case independently selected from halogen, OH, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and heterocycle, wherein the heretocyclocycle is a saturated, two CH2 groups are replaced by C(═O) and contains one N as a ring member.
According to one preferred embodiment, R4a is in each case independently selected from halogen, OH, CN, C1-C6-alkoxy, C1-C6-halogenalkoxy, phenyl, aryl, and heteroaryl, wherein the aryl and heteroaryl are substituted from the group consisting of F, Cl, Br, CH3, CHF2, OCH3, OCHF3, CN or SO2CH3. According to one further preferred embodiment, R4a is in each case independently selected from halogen, phenyl, halogenphenyl and heteroaryl, wherein the halogenphenyl is substituted with halogen selected from the group consisting of F, Cl and Br, in particular selected from F and Cl.
According to one further preferred embodiment, R4a is in each case independently selected from halogen, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6-alkoxy, C1-C4-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, phenyl, wherein the phenyl is substituted with halogen selected from the group consisting of F, Cl and Br or by C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy. According to one further preferred embodiment, R4a is in each case independently selected from halogen and phenyl wherein the phenyl is substituted with halogen selected from the group consisting of F, Cl and Br, in particular selected from F and Cl.
R4b are the possible substituents for the carbocycle, heterocycle, heteroaryl and aryl moieties and are independently selected from halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)C1-C4-alkyl), N(C(═O)C1-C4-alkyl)2, NH—SO2—Rx, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, S(O)n—C1-C6-alkyl, C1-C4-alkoxy-C1-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or substituted with substituents selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to one preferred embodiment, R4b is in each case independently selected from halogen, OH, CN, SH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio and S(O)n—C1-C6-alkyl. According to one further preferred embodiment, R4b is in each case independently selected from halogen, C1-C6-alkoxy, C1-C6-halogenalkyl, C1-C6-halogenalkoxy and S(O)n—C1-C6-alkyl. According to one further particular embodiment, R4b is in each case independently selected from C1-C6-alkyl, such as methyl and ethyl. According to one further particular embodiment, R4b is in each case independently selected from halogen, such as F, Cl and Br. According to one further particular embodiment, R4b is in each case independently selected from C1-C6-alkoxy, such as OCH3. According to one further particular embodiment, R4b is in each case independently selected from C1-C4-halogenalkoxy, such as OCHF2 and OCF3. According to one further particular embodiment, R4b is in each case independently selected from S(O)n—C1-C6-alkyl. such as SO2CH3.
R5 is halogen.
According to one preferred embodiment, R5 is F.
According to one preferred embodiment, R5 is Cl.
According to one preferred embodiment, R5 is Br.
According to one preferred embodiment, R5 is I.
R6 is halogen.
According to one preferred embodiment, R6 is F.
According to one preferred embodiment, R6 is Cl.
According to one preferred embodiment, R6 is Br.
According to one preferred embodiment, R6 is I.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from S and O, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one heteroatom S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one heteroatom O, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from O and S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one heteroatom S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2.
According to one embodiment, R7 and R8 together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one heteroatom O, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to a further embodiment, R7 and R8 together with the carbon atoms to which they are bound form a six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R78)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.
According to the invention, there can be zero, one, two or three R78 present, namely for o is 0, 1, 2 or 3.
According to one embodiment, o is 0.
According to a further embodiment, o is 1.
According to a further embodiment, o is 2 or 3. According to one specific embodiment thereof, o is 2, according to a further specific embodiment, o is 3.
For every R78 that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of any other R78 that may be present in the ring. Furthermore, the particular embodiments and preferences given herein for R78 apply independently for each of o=1, o=2 and o=3.
According to one specific embodiment, R78 is halogen, in particular F, Cl, Br or I, more specifically F, Cl or Br, in particular F or Cl.
According to still another embodiment of formula I, R78 is F.
According to still another embodiment of formula I, R78 is Cl.
According to still another embodiment of formula I, R78 is Br.
According to a further specific embodiment, R78 is OH.
According to a further specific embodiment, R78 is CN.
According to a further specific embodiment, R78 is NO2.
According to still another embodiment of formula I, R78 is SH.
According to still another embodiment of formula I, R78 is NH2.
According to still another embodiment of formula I, R78 is, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH(C(═O)(C1-C4-alkyl), N(C(═O)(C1-C4-alkyl)2, wherein C1-C4-alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R78 is NH—SO2—Rx such as NHSO2—CH3, NH—SO2—CH2—CH3, NH—SO2—CF3 or NH—SO2-Ts.
According to a further specific embodiment of formula I, R78 is CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl) or C(═O)NH(C1-C6-alkyl), wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R78 is CR′═NOR″ such as C(CH3)═NOCH3, C(CH3)═NOCH2CH3 or C(CH3)═NOCF3.
According to a further specific embodiment, R78 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl., in particular CH3.
According to a further specific embodiment, R78 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still a further embodiment, R78 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2 or CH2CH═CH2.
According to still another embodiment of formula I R78 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R78 is C3-C6-halogencycloalkyl. In a special embodiment R1 is fully or partially halogenated cyclopropyl.
According to still a further embodiment, R78 is C3-C6-cycloalkyl-C2-C6-alkenyl, in particular C3-C6-cycloalkyl-C2-C4-alkenyl, more specifically C3-C6-cycloalkyl-C2-C3-alkenyl, such as C3H5—CH═CH2.
According to a further specific embodiment, R78 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2. CH2CF═CF2, CH2CCl═CCl2. CF2CF═CF2 or CCl2CCl═CCl2.
According to still a further embodiment, R78 is C2-C6-alkynyl, in particular C2-C4-alkynyl, more specifically C2-C3-alkynyl, such as C≡CH.
According to still a further embodiment, R78 is C2-C6-halogenalkynyl, in particular C2-C4-halogenalkynyl, more specifically C2-C3-halogenalkynyl.
According to a further specific embodiment, R78 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3 or OCH2CH3.
According to a further specific embodiment, R78 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2, OCH2Cl and OCF2CHF2, in particular OCF3, OCHF2 and OCF2CHF2.
According to a further specific embodiment of formula I, R78 is C2-C6-alkenyloxy, in particular C2-C4-alkenyloxy, more specifically C1-C2-alkenyloxy such as OCH═CH2, OCH2CH═CH2.
According to a further specific embodiment of formula I, R78 is C2-C6-alkynyloxy, in particular C2-C4-alkynyloxy, more specifically C1-C2-alkynyloxy such as OC≡CH According to a further specific embodiment of formula I, R78 is S(O)n—C1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and n is 1, 2 or 3.
According to a further specific embodiment of formula I, R78 is S(O)n—C1-C6-halogenalkyl, wherein halogenalkyl is CF3 or CHF2 and n is 1, 2 or 3.
According to still another embodiment of formula I, R78 is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R78b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, R78 is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R78b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.
According to still another embodiment of formula I, in the embodiments of R78 described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one O.
According to one embodiment, R78 is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R78b. According to still another embodiment of formula I, it is substituted by R78b.
According to still another embodiment of formula I, R78 is a 5-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R78b. According to still another embodiment of formula I, it is substituted by R78b.
According to still another embodiment of formula I, R78 is a 6-membered saturated heterocycle which contains 1, 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R78b. According to still another embodiment of formula I, it is substituted by R78b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1, heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R78b. According to still another embodiment of formula I, it is substituted by R78b.
According to still another embodiment of formula I, R78 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R78b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular CN, F, Cl, Br, CH3, OCH3, CHF2, CF3OCHF2, and OCF3.
According to still a further specific embodiment, R78 is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R78b, as defined and preferably herein. In particular, R78 is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R78b, as defined herein. In one embodiment R78 is unsubstituted phenyl.
According to still another embodiment of formula I, R78 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R78 is a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to one further embodiment, R78 is in each case independently selected from halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl, S(O)n—C1-C6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a as defined and preferably defined herein, and wherein the heterocyclic, alicyclic, phenyl and heteroaryl moieties of R78 are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R78b as defined and preferably defined herein.
According to one further embodiment, R78 is in each case independently selected from halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl, S(O)n—C1-C6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a as defined and preferably defined herein, and wherein the heterocyclic, alicyclic, phenyl and heteroaryl moieties of R78 are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R78b as defined and preferably defined herein. According to one specific embodiment, the acyclic and cyclic moieties of R78 are not further substituted, according to another embodiment, the acyclic moieties of R78 carry one, two, three or four identical or different groups R78a as defined and preferably defined herein.
According to a further embodiment, R78 is in each case independently selected from halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C06-alkynyl, C1-C6-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and S(O)n—C1-C6-alkyl, wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R78 are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R78b as defined and preferably defined herein.
According to a further embodiment, R78 is in each case independently selected from halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C06-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and S(O)n—C1-C6-alkyl, wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R78 are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R78b as defined and preferably defined herein. According to one specific embodiment, the acyclic and cyclic moieties of R78 are not further substituted, according to another embodiment, the acyclic moieties of R78 carry one, two, three or four identical or different groups R78a as defined and preferably defined herein.
According to still a further embodiment, R78 is in each case independently selected from halogen, C1-C6-alkyl and C1-C6-alkoxy, wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a defined and preferably defined herein.
According to still a further embodiment, R78 is in each case independently selected from CN, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy and C1-C6-halogenalkoxy, wherein the acyclic moieties of R78 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R78a defined and preferably defined herein. According to one specific embodiment, the acyclic and cyclic moieties of R78 are not further substituted, according to another embodiment, the acyclic moieties of R78 carry one, two, three or four identical or different groups R78a as defined and preferably defined herein.
R78a are the possible substituents for the acyclic moieties of R78. R78a is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C3-C6-halogencycloalkyl, C3-C6-halogencycloalkenyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heteroaryl and phenyl group is unsubstituted or carries one, two, three, four or five substituents R78a′ selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to one embodiment R78a is independently selected from halogen, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy. Specifically, R78a is independently selected from F, Cl, Br, I, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and C1-C2-halogenalkoxy.
According to a further embodiment, R78a is independently halogen, in particular selected from F, Cl, Br and I, more specifically F, Cl and Br.
R78b are the possible substituents for the cycloalkyl, heterocyclyl, heteroaryl and phenyl moieties of R78. R78b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy and C1-C6-alkylthio.
According to one embodiment thereof R78b is independently selected from halogen, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl and C1-C4-halogenalkoxy, in particular halogen, C1-C4-alkyl and C1-C4-alkoxy. Specifically, R78b is independently selected from F, Cl, CN, CH3, OCH3 and halogenmethoxy.
Particularly preferred embodiments of R7 and R8, optionally substituted by (R78)o, according to the invention are in Table P78 below, wherein each line of lines P78-1 to P78-82 corresponds to one particular embodiment of the invention, wherein P78-1 to P78-82 are also in any combination with one another a preferred embodiment of the present invention. Thereby, the positions of the heteroaryls marked with “#” represents the connection points (carbon atoms 5′ and 6′ in formula I) with the remaining skeleton of the compounds of formula I:
According to one embodiment of formula I, R9 is selected from the group consisting of H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, and ORY.
According to one embodiment of formula I, R9 is H.
According to still another embodiment of formula I, R9 is halogen, in particular F, Cl, Br or I, more specifically F, Cl or Br, in particular F or Cl.
According to still another embodiment of formula I, R9 is F.
According to still another embodiment of formula I, R9 is Cl.
According to still another embodiment of formula I, R9 is Br.
According to still another embodiment of formula I, R9 is OH.
According to still another embodiment of formula I, R9 is CN.
According to still another embodiment of formula I, R9 is NO2.
According to still another embodiment of formula I, R9 is SH.
According to still another embodiment of formula I, R9 is NH2.
According to still another embodiment of formula I, R9 is, NH(C1-C4-alkyl), in particular NH(CH3), NH(C2H5).
According to still another embodiment of formula I, R9 is, N(C1-C4-alkyl)2, in particular NH(CH3)2, NH(C2H5)2.
According to still another embodiment of formula I, R9 is, NH(C2-C4-alkenyl), in particular NH(CH═CH2), NH(CH2CH═CH2).
According to still another embodiment of formula I, R9 is, N(C2-C4_-alkenyl)2, in particular N(CH═CH2)2, N(CH2CH═CH2)2.
According to still another embodiment of formula I, R9 is, NH(C2-C4-alkynyl), in particular NH(C≡CH), NH(CH2C≡CH).
According to still another embodiment of formula I, R9 is, N(C2-C4-alkynyl)2, in particular N(C≡CH)2, N(CH2C≡CH)2.
According to still another embodiment of formula I, R9 is, NH(C3-C6-cycloalkyl), in particular NH(C3H7), NH(C4H9).
According to still another embodiment of formula I, R9 is, N(C3-C6-cycloalkyl)2, in particular N(C3H7)2, N(C4H9)2.
According to still another embodiment of formula I, R9 is N(C1-C4-alkyl)(C2-C4-alkenyl), in particular N(CH3)(CH═CH2), N(CH3)(CH2CH═CH2), N(C2H5)(CH═CH2), N(C2H5)(CH2CH═CH2).
According to still another embodiment of formula I, R9 is N(C1-C4-alkyl)(C2-C4-alkynyl), in particular N(CH3)(C≡CH), N(CH3)(CH2C≡CH), N(C2H5)(C≡CH), N(C2H5)(CH2C≡CH).
According to still another embodiment of formula I, R9 is N(C1-C4-alkyl)(C3-C6-cycloalkyl), in particular N(CH3)(C3H7), N(CH3)(C4H9), N(C2H5)(C3H7), N(CH3)(C4H9).
According to still another embodiment of formula I, R9 is N(C2-C4-alkenyl)(C2-C4-alkynyl), in particular N(CH═CH2)(C≡CH), N(CH2CH═CH2)(CH2C≡CH), N(CH═CH2)(C≡CH), N(CH2CH═CH2)(CH2C≡CH).
According to still another embodiment of formula I, R9 is N(C2-C4-alkenyl)(C3-C6-cycloalkyl), in particular N(CH═CH2)(C3H7), N(CH2CH═CH2)(C4H9), N(CH═CH2)(C3H7), N(CH2CH═CH2)(C4H9).
According to still another embodiment of formula I, R9 is N(C2-C4-alkynyl)(C3-C6-cycloalkyl), in particular N(C≡CH)(C3H7), N(CH2C≡CH)(C4H9), N(C≡CH)(C3H7), N(CH2C≡CH)(C4H9).
According to still another embodiment of formula I, R9 is, NH(C(═O)(C1-C4-alkyl), in particular NH(C(═O)(CH3), NH(C(═O)(C2H5).
According to still another embodiment of formula I, R9 is N(C(═O)(C1-C4-alkyl)2, in particular N(C(═O)(CH3)2, N(C(═O)(C2H5)2.
According to a further specific embodiment of formula I, R9 is NH—SO2—Rx such as NHSO2—CH3, NH—SO2—CH2—CH3, NH—SO2—CF3, NH—SO2-Ts.
According to still another embodiment of formula I, R9 is S(O)n—C1-C6-alkyl such as SCH3, S(═O) CH3, S(O)2CH3.
According to still another embodiment of formula I, R9 is S(O)n-aryl such as S-phenyl, S(═O) phenyl, S(O)2phenyl.
According to still another embodiment of formula I, R9 is S(O)n—C2-C6-alkenyl such as SCH═CH2, S(═O)CH═CH2, S(O)2CH═CH2, SCH2CH═CH2, S(═O)CH2CH═CH2, S(O)2CH2CH═CH2.
According to still another embodiment of formula I, R9 is S(O)n—C2-C6-alkynyl such as SC≡CH, S(═O)C≡CH, S(O)2C≡CH, SCH2C≡CH, S(═O)CH2C≡CH, S(O)2CH2C≡CH.
According to a further specific embodiment of formula I, R9 is CH(═O).
According to a further specific embodiment of formula I, R9 is C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl) or C(═O)NH(C1-C6-alkyl), wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R9 is C(═O)C2-C6-alkenyl, C(═O)O(C2-C6-alkenyl) or C(═O)NH(C2-C6-alkenyl), wherein alkenyl is CH═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R9 is C(═O)C2-C6-alkynyl, C(═O)O(C2-C6-alkynyl) or C(═O)NH(C2-C6-alkynyl), wherein alkynyl is C≡CH, CH2C≡CH.
According to a further specific embodiment of formula I, R9 is C(═O)C3-C6-cycloalkyl, C(═O)O(C3-C6-cycloalkyl) or C(═O)NH(C3-C6-cycloalkyl), wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to a further specific embodiment of formula I, R9 is CH(═S).
According to a further specific embodiment of formula I, R9 is C(═S)C1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R9 is C(═S)C2-C6-alkenyl, wherein alkenyl is CH═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R9 is C(═S)C2-C6-alkynyl, wherein alkynyl is C≡CH, CH2C≡CH.
According to a further specific embodiment of formula I, R9 is C(═S)C3-C6-cycloalkyl, wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to a further specific embodiment of formula I, R9 is C(═S)NHC1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R9 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3. or C2H5, in particular CH3 or CH2CH3.
According to still another embodiment of formula I, R9 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CH3—CHF, CF3CH2, CCl3CH2 or CF2CHF2, in particular FCH2 or F2CH.
According to still a further embodiment of formula I, R9 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2, C(CH3)═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R9 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CF2CH═CF2, CCl2CH═CCl2, CF2CF═CF2, CCl2CCl═CCl2.
According to still a further embodiment of formula I, R9 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, CH2C≡CH, C≡CCl, CH2C≡CCl, or CCl2C≡CCl.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY is C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY is C1-C6-alkyl, in particular C1-C4-alkyl, more specifically C1-C2-alkoxy. R9 is such as OCH3 or OCH2CH3.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl. R9 is such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY C2-C6-alkenyl, in particular C2-C4-alkenyl, more specifically C1-C2-alkenyl. R9 is such as OCH═CH2, OCH2CH═CH2.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C1-C2-halogenalkenyl.
According to a further specific embodiment of formula I, R9 is ORY, wherein RY C2-C6-alkynyl, in particular C2-C6-alkynyl, in particular C2-C4-alkynyl, more specifically C1-C2-alkynyl. R9 is such as OC≡CH, According to a further specific embodiment of formula I, R9 is ORY, wherein RY C2-C6-halogenalkynyl, in particular C2-C6-halogenalkynyl, in particular C2-C4-halogenalkynyl, more specifically C1-C2-halogenalkynyl. R9 is such as OC≡CCl, OCH2C≡CCl, or OCCl2C≡CCl.
According to still another embodiment of formula I, R9 is is ORY, wherein RY C3-C6-cycloalkenyl, in particular cyclopropenyl.
According to still another embodiment of formula I, R9 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R9 is C3-C6-halogencycloalkyl. In a special embodiment R9b is fully or partially halogenated cyclopropyl, such as 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl.
According to still another embodiment of formula I, R9 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R9b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular F, Cl, Br, CH3, OCH3, CF3 and OCF3.
According to still another embodiment of formula I, R9 is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R9b which independently of one another are selected from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular CN, F, Cl, Br, CH3, OCH3, CHF2, OCHF2, CF3 and OCF3. According to one embodiment, R9 is unsubstituted phenyl. According to another embodiment, R9 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to still another embodiment of formula I, R9 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R9 is a 6-membered heteroaryl such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to still another embodiment of formula I, R9 is in each case independently selected from H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C06-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and C3-C6-halogencycloalkyl, wherein the acyclic moieties of R9 are unsubstituted or substituted with identical or different groups R9a as defined and preferably defined herein, and wherein the carbocyclic, phenyl and heteroaryl moieties of R9 are unsubstituted or substituted with identical or different groups R9b as defined and preferably defined herein.
According to still another embodiment of formula I, R9 is in each case independently selected from H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C06-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and C3-C6-halogencycloalkyl, wherein the acyclic moieties of R9 are unsubstituted or substituted with identical or different groups R9a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R9 are unsubstituted or substituted with identical or different groups R9b as defined and preferably defined herein.
R9a are the possible substituents for the acyclic moieties of R9.
According to one embodiment R9a is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenyl group is unsubstituted or substituted with substituents R91a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to one embodiment R9a is independently selected from halogen, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy. Specifically, R9a is independently selected from F, Cl, Br, I, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and C1-C2-halogenalkoxy.
According to still another embodiment of formula I, R9a is independently halogen, in particular selected from F, Cl, Br and I, more specifically F, Cl and Br.
R9b are the possible substituents for the carbocyclic, heteroaryl and phenyl moieties of R9. R9b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy and C1-C6-alkylthio.
According to one embodiment thereof R9b is independently selected from halogen, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl and C1-C4-halogenalkoxy, in particular halogen, C1-C4-alkyl and C1-C4-alkoxy. Specifically, R9b is independently selected from F, Cl, CN, CH3, OCH3 and halogenmethoxy.
Particularly preferred embodiments of R9 according to the invention are in Table P9 below, wherein each line of lines P9-1 to P9-43 corresponds to one particular embodiment of the invention, wherein P9-1 to P9-43 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R9 is bound is marked with “#” in the drawings.
According to one embodiment of formula I, R10 is selected from the group consisting of H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy and ORY.
According to one embodiment of formula I, R10 is H.
R10 is selected from the group consisting of halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy and ORY.
According to still another embodiment of formula I, R10 is halogen, in particular F, Cl, Br or I, more specifically F, Cl or Br, in particular F or Cl.
According to still another embodiment of formula I, R10 is F.
According to still another embodiment of formula I, R10 is Cl.
According to still another embodiment of formula I, R10 is Br.
According to still another embodiment of formula I, R10 is OH.
According to still another embodiment of formula I, R10 is CN.
According to still another embodiment of formula I, R10 is NO2.
According to still another embodiment of formula I, R10 is SH.
According to still another embodiment of formula I, R10 is NH2.
According to still another embodiment of formula I, R10 is NH(C1-C4-alkyl), in particular NH(CH3), NH(C2H5).
According to still another embodiment of formula I, R10 is, N(C1-C4-alkyl)2, in particular NH(CH3)2, NH(C2H5)2.
According to still another embodiment of formula I, R10 is NH(C2-C4-alkenyl), in particular NH(CH═CH2), NH(CH2CH═CH2).
According to still another embodiment of formula I, R10 is, N(C2-C4_-alkenyl)2, in particular N(CH═CH2)2, N(CH2CH═CH2)2.
According to still another embodiment of formula I, R10 is NH(C2-C4-alkynyl), in particular NH(C≡CH), NH(CH2C≡CH).
According to still another embodiment of formula I, R10 is N(C2-C4-alkynyl)2, in particular N(C≡CH)2, N(CH2C≡CH)2.
According to still another embodiment of formula I, R10 is NH(C3-C6-cycloalkyl), in particular NH(C3H7), NH(C4H9).
According to still another embodiment of formula I, R10 is N(C3-C6-cycloalkyl)2, in particular N(C3H7)2, N(C4H9)2.
According to still another embodiment of formula I, R10 is N(C1-C4-alkyl)(C2-C4-alkenyl), in particular N(CH3)(CH═CH2), N(CH3)(CH2CH═CH2), N(C2H5)(CH═CH2), N(C2H5)(CH2CH═CH2).
According to still another embodiment of formula I, R10 is N(C1-C4-alkyl)(C2-C4-alkynyl), in particular N(CH3)(C≡CH), N(CH3)(CH2C≡CH), N(C2H5)(C≡CH), N(C2H5)(CH2C≡CH).
According to still another embodiment of formula I, R10 is N(C1-C4-alkyl)(C3-C6-cycloalkyl), in particular N(CH3)(C3H7), N(CH3)(C4H9), N(C2H5)(C3H7), N(CH3)(C4H9).
According to still another embodiment of formula I, R10 is N(C2-C4-alkenyl)(C2-C4-alkynyl), in particular N(CH═CH2)(C≡CH), N(CH2CH═CH2)(CH2C≡CH), N(CH═CH2)(C≡CH), N(CH2CH═CH2)(CH2C≡CH).
According to still another embodiment of formula I, R10 is N(C2-C4-alkenyl)(C3-C6-cycloalkyl), in particular N(CH═CH2)(C3H7), N(CH2CH═CH2)(C4H9), N(CH═CH2)(C3H7), N(CH2CH═CH2)(C4H9).
According to still another embodiment of formula I, R10 is N(C2-C4-alkynyl)(C3-C6-cycloalkyl), in particular N(C≡CH)(C3H7), N(CH2C≡CH)(C4H9), N(C≡CH)(C3H7), N(CH2C≡CH)(C4H9).
According to still another embodiment of formula I, R10 is, NH(C(═O)(C1-C4-alkyl), in particular NH(C(═O)(CH3), NH(C(═O)(C2H5).
According to still another embodiment of formula I, R10 is N(C(═O)(C1-C4-alkyl)2, in particular N(C(═O)(CH3)2, N(C(═O)(C2H5)2.
According to a further specific embodiment of formula I, R10 is NH—SO2—Rx such as NHSO2—CH3, NH—SO2—CH2—CH3, NH—SO2—CF3, NH—SO2-Ts.
According to still another embodiment of formula I, R10 is S(O)n—C1-C6-alkyl such as SCH3, S(═O) CH3, S(O)2CH3.
According to still another embodiment of formula I, R10 is S(O)n-aryl such as S-phenyl, S(═O) phenyl, S(O)2phenyl.
According to still another embodiment of formula I, R10 is S(O)n—C2-C6-alkenyl such as SCH═CH2, S(═O)CH═CH2, S(O)2CH═CH2, SCH2CH═CH2, S(═O)CH2CH═CH2, S(O)2CH2CH═CH2.
According to still another embodiment of formula I, R10 is S(O)n—C2-C6-alkynyl such as SC≡CH, S(═O)C≡CH, S(O)2C≡CH, SCH2C≡CH, S(═O)CH2C≡CH, S(O)2CH2C≡CH.
According to a further specific embodiment of formula I, R10 is CH(═O).
According to a further specific embodiment of formula I, R10 is C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl) or C(═O)NH(C1-C6-alkyl), wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R10 is C(═O)C2-C6-alkenyl, C(═O)O(C2-C6-alkenyl) or C(═O)NH(C2-C6-alkenyl), wherein alkenyl is CH═CH2, C(CH3)═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R10 is C(═O)C2-C6-alkynyl, C(═O)O(C2-C6-alkynyl) or C(═O)NH(C2-C6-alkynyl), wherein alkynyl is C≡CH, CH2C≡CH, According to a further specific embodiment of formula I, R10 is C(═O)C3-C6-cycloalkyl, C(═O)O(C3-C6-cycloalkyl) or C(═O)NH(C3-C6-cycloalkyl), wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to a further specific embodiment of formula I, R10 is CH(═S).
According to a further specific embodiment of formula I, R10 is C(═S)C1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R10 is C(═S)C2-C6-alkenyl, wherein alkenyl is CH═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R10 is C(═S)C2-C6-alkynyl, wherein alkynyl is C≡CH, CH2C≡CH.
According to a further specific embodiment of formula I, R10 is C(═S)C3-C6-cycloalkyl, wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to a further specific embodiment of formula I, R10 is C(═S)NHC1-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R10 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3. or C2H5, in particular CH3 or CH2CH3.
According to still another embodiment of formula I, R10 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CH3—CHF, CF3CH2, CCl3CH2 or CF2CHF2, in particular FCH2 or F2CH.
According to still a further embodiment of formula I, R10 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2.
According to a further specific embodiment of formula I, R10 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CF2CH═CF2, CCl2CH═CCl2, CF2CF═CF2, CCl2CCl═CCl2.
According to still a further embodiment of formula I, R10 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, CH2C≡CH, C≡CCl, CH2C≡CCl, or CCl2C≡CCl.
According to a further specific embodiment of formula I, R10 is ORY, wherein RY is C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl.
According to a further specific embodiment of formula I, R10 is ORY, wherein RY is C1-C6-alkyl, in particular C1-C4-alkyl, more specifically C1-C2-alkoxy. R10 is such as OCH3 or OCH2CH3.
According to a further specific embodiment of formula I, R10 is ORY, wherein RY is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl. R10 is such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to a further specific embodiment of formula I, R10 is ORY, wherein RY C2-C6-alkenyl, in particular C2-C4-alkenyl, more specifically C1-C2-alkenyl. R10 is such as OCH═CH2, OCH2CH═CH2.
According to a further specific embodiment of formula I, R10 is ORY, wherein RY C2-C6-alkynyl, in particular C2-C6-alkynyl, in particular C2-C4-alkynyl, more specifically C1-C2-alkynyl. R10 is such as OC≡CH, OC≡CCl, OCH2C≡CCl, or OCCl2C≡CCl According to still another embodiment of formula I R10 is ORY, wherein RY is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R10 is ORY, wherein RY is C3-C6-halogencycloalkyl. In a special embodiment R1 is fully or partially halogenated cyclopropyl.
According to still another embodiment of formula I, R10 is is ORY, wherein RY C3-C6-cycloalkenyl, in particular cyclopropenyl.
According to still another embodiment of formula I, R10 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R10 is C3-C6-halogencycloalkyl. In a special embodiment R10b is fully or partially halogenated cyclopropyl, such as 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl
According to still another embodiment of formula I, R10 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R10b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular F, Cl, Br, CH3, OCH3, CF3 and OCF3.
According to still another embodiment of formula I, R10 is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted with identical or different groups R10b which independently of one another are selected from CN, halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular CN, F, Cl, Br, CH3, OCH3, CHF2, OCHF2, CF3 and OCF3. According to one embodiment, R10 is unsubstituted phenyl. According to another embodiment, R10 is phenyl, that is substituted with one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to still another embodiment of formula I, R10 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R9 is a 6-membered heteroaryl such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to still another embodiment of formula I, R10 is in each case independently selected from H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C6-alkenyloxy, C3-C06-alkynyloxy, C3-C6-cycloalkyl and C3-C6-halogencycloalkyl, wherein the acyclic moieties of R10 are unsubstituted or substituted with identical or different groups R10a as defined and preferably defined herein, and wherein the carbocyclic, phenyl and heteroaryl moieties of R10 are unsubstituted or substituted with identical or different groups R10b as defined and preferably defined herein.
According to still another embodiment of formula I, R10 is in each case independently selected from H, halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C06-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and C3-C6-halogencycloalkyl, wherein the acyclic moieties of R10 are unsubstituted or substituted with identical or different groups R10a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R10 are unsubstituted or substituted with identical or different groups R10b as defined and preferably defined herein.
R10a are the possible substituents for the acyclic moieties of R9.
According to one embodiment R10a is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenyl group is unsubstituted or substituted with substituents R10a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to one embodiment R10a is independently selected from halogen, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy. Specifically, R10a is independently selected from F, Cl, Br, I, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and C1-C2-halogenalkoxy.
According to still another embodiment of formula I, R10a is independently halogen, in particular selected from F, Cl, Br and I, more specifically F, Cl and Br.
R10b are the possible substituents for the carbocyclic, heteroaryl and phenyl moieties of R10. R10b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy and C1-C6-alkylthio.
According to one embodiment thereof R10b is independently selected from halogen, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl and C1-C4-halogenalkoxy, in particular halogen, C1-C4-alkyl and C1-C4-alkoxy. Specifically, R10b is independently selected from F, Cl, CN, CH3, OCH3 and halogenmethoxy.
Particularly preferred embodiments of R10 according to the invention are in Table P10 below, wherein each line of lines P10-1 to P10-43 corresponds to one particular embodiment of the invention, wherein P10-1 to P10-43 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R10 is bound is marked with “#” in the drawings.
According to still another embodiment of formula I, R9, R10 together with the carbon atoms to which they are bound form a five-, six-, or seven-membered carbo-, heterocyclic or heteroaromatic ring; wherein the heterocyclic or heteroaromatic ring contains 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein N may carry one substituent RN selected from C1-C4-alkyl, C1-C4-halogenalkyl and SO2Ph, wherein Ph is unsubstituted or substituted with substituents selected from C1-C4-alkyl, halogen, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, and CN; and wherein S may be in the form of its oxide SO or SO2; and wherein in each case one or two CH2 groups of the carbo- or heterocycle may be replaced by a group independently selected from C(═O) and C(═S); and wherein the carbo-, heterocyclic or heteroaromatic ring is substituent by (R11)m wherein m is 0, 1, 2, 3 or 4;
According to still another embodiment of formula I, R9 and R10 together with the carbon atoms to which they are bound form a saturated or partially unsaturated five-, six- or seven-membered carbo- and heterocycle that is unsubstituted or substituted.
According to one embodiment, R9 and R10 form a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 7-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 3-membered saturated heterocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 4-membered saturated heterocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 5-membered saturated heterocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 6-membered saturated heterocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 7-membered saturated heterocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 5-membered saturated heteroaryl. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
According to one embodiment, R9 and R10 form a 6-membered heteroaryl. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R11. According to still another embodiment of formula I, it is substituted with R11.
For every R11 that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of any other R11 that may be present in the ring.
According to one embodiment of formula I, wherein m is 0, 1, 2, 3 or 4.
According to still another embodiment of formula I, m is 0.
According to still another embodiment of formula I, m is 1.
According to still another embodiment of formula I, m is 2 or 3. According to one specific embodiment thereof, m is 2. According to still another embodiment of formula I, m is 3.
According to one embodiment of formula I, R11 is halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy or, C1-C6-halogenalkoxy, in particular CH3, Et, CHF2, OCH3, OCHF2, OCF3, F, Cl, more specifically H, CH3, F or Cl most preferred F or Cl.
According to still another embodiment of formula I, R11 is halogen, in particular Br, F or Cl, more specifically F or Cl.
According to still another embodiment of formula I, R11 is OH.
According to still another embodiment of formula I, R11 is CN.
According to still another embodiment of formula I R11 is NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2 or NH—SO2—Rx, wherein Rx is C1-C4-alkyl, C1-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted with one, two, three, four or five substituents Rx1 independently selected from C1-C4-alkyl.
According to still another embodiment of formula I, R11 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3.
According to still another embodiment of formula I, R11 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CHF2, CH2F, CCl3, CHCl2 or CH2Cl.
According to still another embodiment of formula I, R11 is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C2-C4-alkenyl or C2-C4-halogenalkenyl, such as CH═CH2, C(CH3)═CH2, CH2CH═CH2, CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CF═CF2, CCl═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CH2CF═CF2, CH2CCl═CCl2, CF2CF═CF2 or CCl2CCl═CCl2.
According to still another embodiment of formula I, R11 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, CH2C≡CH, C≡C—Cl, C≡C—CH3, CH2C≡CH, CH2C≡CCl or CH2C≡C—CH3.
According to still another embodiment of formula I, R11 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3 or OCH2CH3.
According to still another embodiment of formula I, R11 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to still another embodiment of formula I R11 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R11 is C3-C6-cycloalkyl, for example cyclopropyl, substituted with one, two, three or up to the maximum possible number of identical or different groups R11b as defined and preferably herein.
According to still another embodiment of formula I, R11 is C3-C6-halogencycloalkyl. In a special embodiment R11 is fully or partially halogenated cyclopropyl.
According to still another embodiment of formula I, R11 is unsubstituted aryl or aryl that is substituted with one, two, three or four R11b, as defined herein. In particular, R11 is unsubstituted phenyl or phenyl that is substituted with one, two, three or four R11b, as defined herein.
According to still another embodiment of formula I, R11 is unsubstituted 5- or 6-membered heteroaryl. According to still a further embodiment, R11 is 5- or 6-membered heteroaryl that is substituted with one, two or three R11b, as defined herein.
According to still another embodiment of formula I, R11 is in each case independently selected from halogen, OH, CN, NO2, SH, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, NH—SO2—Rx, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy and C3-C6-cycloalkyl; wherein the acyclic moieties of R11 are not further substituted or carry one, two, three, four or five identical or different groups R11a as defined below and wherein the carbocyclic, heterocyclic and heteroaryl moieties of R11 are not further substituted or carry one, two, three, four or five identical or different groups R11b as defined below.
According to still another embodiment of formula I, R11 is independently selected from halogen, OH, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy and C1-C6-halogenalkoxy, in particular independently selected from F, Cl, Br, CN, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
R11a are the possible substituents for the acyclic moieties of R1.
R11a according to the invention is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenyl group is unsubstituted or unsubstituted or substituted with R111a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-alkylthio.
R11a according to the invention is independently selected from halogen, OH, CN, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy, C1-C6-alkylthio, aryl and phenoxy, wherein the aryl and phenyl group is unsubstituted or unsubstituted or substituted with R111a selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular selected from halogen, C1-C2-alkyl, C1-C2-halogenalkyl, C1-C2-alkoxy, C1-C2-halogenalkoxy, more specifically selected from halogen, such as F, Cl and Br.
In to one embodiment R11a is independently selected from halogen, OH, CN, C1-C2-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R11a is independently selected from F, Cl, OH, CN, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl and C1-C2-halogenalkoxy.
According to one embodiment R11a is independently selected from halogen, such as F, Cl, Br and I, more specifically F, Cl and Br.
According to still another embodiment of formula I, R11a is independently selected from OH, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R11a is independently selected from OH, cyclopropyl and C1-C2-halogenalkoxy.
R11b are the possible substituents for the carbocyclic, heterocyclic and heteroaryl moieties of R11.
R11b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy.
According to one embodiment thereof R11b is independently selected from halogen, CN, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalky and C1-C2-halogenalkoxy. Specifically, R11b is independently selected from F, Cl, OH, CN, CH3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and halogenmethoxy.
According to still another embodiment thereof R11b is independently selected from C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2-halogenalkoxy. Specifically, R11b is independently selected from OH, CH3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl and halogenmethoxy, more specifically independently selected from OH, CH3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl cyclopropyl and OCHF2.
Particularly preferred embodiments of combinations of R9 and R10 according to the invention are in Table P35 below, wherein each line of lines P35-1 to P35-305 corresponds to one particular embodiment of the invention, wherein P35-1 to P35-305 are also in any combination with one another a preferred embodiment of the present invention. The carbon atom, to which R9 bound is marked with * in the drawings and the carbon atom, to which R10 is bound is marked with # in the drawings. cPr stands for cyclopropyl.
According to one embodiment of formula I, R12 is H.
According to still another embodiment of formula I, R12 is OH.
According to a further specific embodiment of formula I, R12 is CH(═O).
According to a further specific embodiment of formula I, R12 is C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl) or C(═O)N(C1-C6-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R12 is C(═O)C2-C6-alkenyl, C(═O)O(C2-C6-alkenyl), C(═O)NH (C2-C6-alkenyl) or C(═O)N(C2-C6-alkenyl)2), wherein alkenyl is CH═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R12 is C(═O)C2-C6-alkynyl, C(═O)O(C2-C6-alkynyl), C(═O)NH(C2-C6-alkynyl) or C(═O)N(C2-C6-alkynyl)2, wherein alkynyl is C≡CH, CH2C≡CH.
According to a further specific embodiment of formula I, R12 is C(═O)C3-C6-cycloalkyl, C(═O)O(C3-C6-cycloalkyl), C(═O)NH (C3-C6-cycloalkyl) or C(═O)N(C3-C6-cycloalkyl)2, wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to a further specific embodiment of formula I, R12 is CH(═S).
According to a further specific embodiment of formula I, R12 is C(═S)C1-C6-alkyl, C(═S)O(C1-C6-alkyl), C(═S)NH(C1-C6-alkyl) or C(═S)N(C1-C6-alkyl)2, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to a further specific embodiment of formula I, R12 is C(═S)C2-C6-alkenyl, C(═S)O(C2-C6-alkenyl), C(═S)NH(C2-C6-alkenyl) or C(═S)N(C2-C6-alkenyl)2, wherein alkenyl is CH═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R12 is C(═S)O(C2-C6-alkynyl), C(═S)NH(C2-C6-alkynyl) or C(═S)N(C2-C6-alkynyl)2, wherein alkynyl is C≡CH, CH2C≡CH.
According to a further specific embodiment of formula I, R12 is C(═S)C3-C6-cycloalkyl, C(═S)O(C3-C6-cycloalkyl) or C(═S)N(C3-C6-cycloalkyl)2, wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).
According to still another embodiment of formula I, R12 is C1-C6-alkyl, such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.
According to still another embodiment of formula I, R12 is C1-C6-alkyl, in particular C1-C4-alkyl, such as CH3, C2H5, n-propyl, i-propyl.
According to still another embodiment of formula I, R12 is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula I R12 is C3-C6-cycloalkyl, in particular cyclopropyl.
According to still another embodiment of formula I, R12 is C3-C6-halogencycloalkyl. In a special embodiment R12b is fully or partially halogenated cyclopropyl, such as 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-C2-cyclopropyl.
According to still another embodiment of formula I, R12 is C1-C4-alkoxy and C1-C4-halogenalkoxy, in particular C1-C3-alkoxy, C1-C3-halogenalkoxy, such as CH2OCH3, CH2OCF3 or CH2OCHF2.
According to a further specific embodiment of formula I, R12 is ORY, wherein RY is C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, phenyl and phenyl-C1-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy;
According to a further specific embodiment of formula I, R12 is ORY, wherein RY is C1-C6-alkyl, in particular C1-C4-alkyl, more specifically C1-C2-alkyl. R12 is such as OCH3 or OCH2CH3.
According to a further specific embodiment of formula I, R12 is ORY, wherein RY is C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl. R12 is such as OCF3, OCHF2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to a further specific embodiment of formula I, R12 is ORY, wherein RY C2-C6-alkenyl, in particular C2-C4-alkenyl, more specifically C1-C2-alkenyl. R12 is such as OCH═CH2, OCH2CH═CH2.
According to a further specific embodiment of formula I, R12 is ORY, wherein RY C2-C6-alkynyl, in particular C2-C6-alkynyl, in particular C2-C4-alkynyl, more specifically C1-C2-alkynyl. R12 is such as OC≡CH
According to still another embodiment of formula I, R12 is ORY, wherein RY is C3-C6-halogencycloalkyl. In a special embodiment R1 is fully or partially halogenated cyclopropyl.
According to still another embodiment of formula I, R12 is is ORY, wherein RY and phenyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to still another embodiment of formula I, R12 is is ORY, wherein RY phenyl-C1-C6-alkyl, such as phenyl-CH2, herein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy. R12 is such as OCH2Ph.
According to still a further embodiment of formula I, R12 is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH═CH2, C(CH3)═CH2, CH2CH═CH2.
According to a further specific embodiment of formula I, R12 is C2-C6-halogenalkenyl, in particular C2-C4-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH═CHF, CH═CHCl, CH═CF2, CH═CCl2, CH2CH═CHF, CH2CH═CHCl, CH2CH═CF2, CH2CH═CCl2, CF2CH═CF2, CCl2CH═CCl2, CF2CF═CF2, CCl2CCl═CCl2.
According to still a further embodiment of formula I, R12 is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C≡CH, CH2C≡CH.
According to still another embodiment of formula I, R12 is S(O)n—C1-C6-alkyl such as SCH3, S(═O) CH3, S(O)2CH3.
According to still another embodiment of formula I, R12 is S(O)n—C1-C6-halogenalkyl such as SCF3, S(═O)CF3, S(O)2CF3, SCHF2, S(═O)CHF2, S(O)2CHF2.
According to still another embodiment of formula I, R12 is S(O)n-aryl such as S-phenyl, S(═O) phenyl, S(O)2phenyl, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R78a′ selected from the group consisting of halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy; According to still another embodiment of formula I, R12 is S(O)n—C2-C6-alkenyl such as SCH═CH2, S(═O)CH═CH2, S(O)2CH═CH2, SCH2CH═CH2, S(═O)CH2CH═CH2, S(O)2CH2CH═CH2.
According to still another embodiment of formula I, R12 is S(O)n—C2-C6-alkynyl such as SC≡CH, S(═O)C≡CH, S(O)2C≡CH, SCH2C≡CH, S(═O)CH2C≡CH, S(O)2CH2C≡CH.
According to still another embodiment of formula I, R12 is SO2—NH(C1-C6-alkyl), is C1-C6-alkyl, in particular C1-C4-alkyl, more specifically C1-C2-alkyl. R12 is such as SO2NHCH3 or SO2NHCH2CH3.
According to still another embodiment of formula I, R12 is SO2—NH(C1-C6-halogenalkyl), wherein C1-C6-halogenalkyl, in particular C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl. R12 is such as SO2NHCF3, SO2NHCHF2, SO2NHCH2F, SO2NHCCl3, SO2NHCHCl2 or SO2NHCH2Cl, in particular SO2NHCF3, SO2NHCHF2, SO2NHCCl3 or SO2NHCHCl2.
According to still another embodiment of formula I, R12 is SO2—NHaryl, wherein the aryl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy. R12 is such as SO2NHPh.
According to still another embodiment of formula I, R12 is tri-(C1-C6 alkyl)silyl, in particular C1-C4-alkyl, such as CH3. or C2H5. R12 is such as OSi(CH3)3
According to still another embodiment of formula I, R12 is di-(C1-C6 alkoxy)phosphoryl), in particular C1-C4-alkoxy, such as OCH3. or OC2H5. R12 is such as OPO(OCH3)2.
According to still another embodiment of formula I, R12 is phenyl-C1-C6-alkyl, such as phenyl-CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R12b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular F, Cl, Br, CH3, OCH3, CF3 and OCF3.
According to still another embodiment of formula I, R12 is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R12b which independently of one another are selected from halogen, C1-C2-alkyl, C1-C2-alkoxy, C1-C2-halogenalkyl and C1-C2-halogenalkoxy, in particular F, Cl, Br, CH3, OCH3, CF3 and OCF3. According to one embodiment, R12 is unsubstituted phenyl. According to another embodiment, R12 is phenyl, that is substituted by one, two or three, in particular one, halogen, in particular selected from F, Cl and Br, more specifically selected from F and Cl.
According to still another embodiment of formula I, R12 is a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-triazolyl-1-yl, 1,2,4-triazol-3-yl 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl.
According to still another embodiment of formula I, R12 is a 6-membered heteroaryl such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1,3,5-triazin-2-yl and 1,2,4-triazin-3-yl.
According to still another embodiment of formula I, R12 is in each case independently selected from H, halogen, OH, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy and C3-C6-cycloalkyl wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the carbocyclic, phenyl and heteroaryl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H, halogen, OH, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy and C3-C6-cycloalkyl, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H and ORY, wherein RY is most preferably C1-C6-alkyl, C1-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, phenyl and phenyl-C1-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to still another embodiment of formula I, R12 is in each case independently selected from H and ORY, wherein RY is most preferably C2-C6-alkenyl, C2-C6-alkynyl, phenyl and phenyl-C1-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, C1-C4-alkyl, C1-C4-halogenalkyl, C1-C4-alkoxy and C1-C4-halogenalkoxy.
According to still another embodiment of formula I, R12 is in each case independently selected from H, CH(═O), C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl) and C(═O)NH(C1-C6-alkyl), C(═O)N(C1-C6-alkyl)2, C(═O)C2-C6-alkenyl, C(═O)O(C2-C6-alkenyl), C(═O)NH(C2-C6-alkenyl), C(═O)N(C2-C6-alkenyl)2, C(═O)C2-C6-alkynyl, C(═O)O(C2-C6-alkynyl), C(═O)NH(C2-C6-alkynyl), C(═O)N(C2-C6-alkynyl)2C(═O)C3-C6-cycloalkyl, C(═O)O(C3-C6-cycloalkyl), C(═O)NH(C3-C6-cycloalkyl) and C(═O)N(C3-C6-cycloalkyl)2, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H, C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), C(═O)NH(C1-C6-alkyl), C(═O)N(C1-C6-alkyl)2, C(═O)C2-C6-alkenyl, C(═O)O(C2-C6-alkenyl), C(═O)NH(C2-C6-alkenyl), C(═O)N(C2-C6-alkenyl)2, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H, S(O)n—C1-C6-alkyl, S(O)n—C1-C6-halogenalkyl, S(O)n—C1-C6-alkoxy, S(O)n—C2-C6-alkenyl, S(O)n—C2-C6-alkynyl, S(O)naryl, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the aryl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H, SO2—NH(C1-C6-alkyl), SO2—NH(C1-C6-halogenalkyl), SO2—NH-phenyl, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the aryl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to still another embodiment of formula I, R12 is in each case independently selected from H, C1-C6-alkyl, C(═O)C1-C6-alkyl, C(═O)O(C1-C6-alkyl), S(O)n—C1-C6-alkyl, S(O)naryl, wherein the acyclic moieties of R12 are unsubstituted or substituted with identical or different groups R12a as defined and preferably defined herein, and wherein the aryl moieties of R12 are unsubstituted or substituted with identical or different groups R12b as defined and preferably defined herein.
According to one embodiment R12a is independently selected from halogen, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4-halogenalkoxy. Specifically, R12a is independently selected from F, Cl, Br, I, C1-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1-Cl-cyclopropyl, 1,1-F2-cyclopropyl, 1,1-Cl2-cyclopropyl and C1-C2-halogenalkoxy.
According to still another embodiment of formula I, R12a is independently halogen, in particular selected from F, Cl, Br and I, more specifically F, Cl and Br.
R12b are the possible substituents for the cycloalkyl, heteroaryl and phenyl moieties of R12. R12b according to the invention is independently selected from halogen, OH, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4-halogenalkoxy and C1-C6-alkylthio.
According to one embodiment thereof R12b is independently selected from halogen, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-halogenalkyl and C1-C4-halogenalkoxy, in particular halogen, C1-C4-alkyl and C1-C4-alkoxy. Specifically, R12b is independently selected from F, Cl, CN, CH3, CHF2, CF3OCH3 and halogenmethoxy.
Particularly preferred embodiments of R12 according to the invention are in Table P12 below, wherein each line of lines P12-1 to P12-50 corresponds to one particular embodiment of the invention, wherein P12-1 to P12-50 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R12 is bound is marked with “#” in the drawings.
Particular embodiments of the compounds I are the following compounds: I-A, I-B, I-C, I-D, I-E, I-F, I-G. In these formulae, the substituents R4, R9, R10 and R12 are independently as defined in claim 1 or preferably defined below:
Table 1-1 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is H and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-1.A-1 to I-A.1-1.A-540, I-B.1-1.A-1 to I-B.1-1.A-540, I-C.1-1.A-1 to I-C.1-1.A-540, I-D.1-1.A-1 to I-D.1-1.A-540, I-E.1-1.A-1 to I-E.1-1.A-540, I-F.1-1.A-1 to I-F.1-1.A-540, I-G.1-1.A-1 to I-G.1-1.A-540).
Table 1-2 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is CH3 and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-2.A-1 to I-A.1-2.A-540, I-B.1-2.A-1 to I-B.1-2.A-540, I-C.1-2.A-1 to I-C.1-2.A-540, I-D.1-2.A-1 to I-D.1-2.A-540, I-E.1-2.A-1 to I-E.1-2.A-540, I-F.1-2.A-1 to I-F.1-2.A-540, I-G.1-2.A-1 to I-G.1-2.A-540).
Table 1-3 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is CH2CH═CH2 and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-3.A-1 to I-A.1-3.A-540, I-B.1-3.A-1 to I-B.1-3.A-540, I-C.1-3.A-1 to I-C.1-3.A-540, I-D.1-3.A-1 to I-D.1-3.A-540, I-E.1-3.A-1 to I-E.1-3.A-540, I-F.1-3.A-1 to I-F.1-3.A-540, I-G.1-3.A-1 to I-G.1-3.A-540).
Table 1-4 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is C(═O)OCH3 and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-4.A-1 to I-A.1-4.A-540, I-B.1-4.A-1 to I-B.1-4.A-540, I-C.1-4.A-1 to I-C.1-4.A-540, I-D.1-4.A-1 to I-D.1-4.A-540, I-E.1-4.A-1 to I-E.1-4.A-540, I-F.1-4.A-1 to I-F.1-4.A-540, I-G.1-4.A-1 to I-G.1-4.A-540).
Table 1-5 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is SO2NHCH3 and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-5.A-1 to I-A.1-5.A-540, I-B.1-5.A-1 to I-B.1-5.A-540, I-C.1-5.A-1 to I-C.1-5.A-540, I-D.1-5.A-1 to I-D.1-5.A-540, I-E.1-5.A-1 to I-E.1-5.A-540, I-F.1-5.A-1 to I-F.1-5.A-540, I-G.1-5.A-1 to I-G.1-5.A-540).
Table 1-6 Compounds of the formula I-A, I-B, I-C, I-D, I-E, I-F, I-G in which R12 is OH and the meaning for the combination of R4, R9 and R10 for each individual compound corresponds in each case to one line of Table A (compounds I-A.1-6.A-1 to I-A.1-6.A-540, I-B.1-6.A-1 to I-B.1-6.A-540, I-C.1-6.A-1 to I-C.1-6.A-540, I-D.1-6.A-1 to I-D.1-6.A-540, I-E.1-6.A-1 to I-E.1-6.A-540, I-F.1-6.A-1 to I-F.1-6.A-540, I-G.1-6.A-1 to I-G.1-6.A-540).
Accordingly, the present invention relates further to the process for the synthesis of compounds of the formula I of claim 1, comprising the a) step of reacting a compound B
wherein R1, R2, R3, R4, R7, R8, R9 and R10 are as defined in claim 1 and R5, R6 are H or halogen.
Accordingly, the present invention relates further to the the intermediate compounds B
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one further embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment the invention relates to the intermediate compounds B, wherein
According to one embodiment of formula B, R3 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula B, R3 is CH3.
According to still another embodiment of formula B, R3 is C2H5.
According to still another embodiment of formula B, R3 is C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula B, R3 is CH2F.
According to still another embodiment of formula B, R3 is CHF2.
According to still another embodiment of formula B, R3 is CF3.
According to still another embodiment of formula B, R3 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula B, R4 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula B, R4 is CH3.
According to still another embodiment of formula B, R4 is C2H5.
According to still another embodiment of formula B, R4 is C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula B, R4 is CH2F.
According to still another embodiment of formula B, R4 is CHF2.
According to still another embodiment of formula B, R4 is CF3.
According to still another embodiment of formula B, R4 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula I B, R5 is Cl.
According to still another embodiment of formula B, R5 is Br.
According to still another embodiment of formula B, R5 is F.
According to still another embodiment of formula B, R5 is H.
According to one embodiment of formula B, R6 is Cl.
According to still another embodiment of formula B, R6 is Br.
According to still another embodiment of formula B, R6 is F.
According to still another embodiment of formula B, R6 is H.
R7 and R8 together with the carbon atoms to which they are bound together form a phenyl which is unsubstituted or substituted by R78 being halogen.
According to one embodiment of formula B, R7 and R8 form phenyl.
According to still another embodiment of formula B, R7 and R8 form phenyl substituted by F.
According to still another embodiment of formula B, R7 and R8 form 1-F-phenyl.
According to still another embodiment of formula B, R7 and R8 form 2-F-phenyl.
According to still another embodiment of formula B, R7 and R8 form 3-F-phenyl.
According to still another embodiment of formula B, R7 and R8 form 4-F-phenyl.
According to still another embodiment of formula B, R7 and R8 form phenyl substituted by Br.
According to still another embodiment of formula B, R7 and R8 form 1-Br-phenyl.
According to still another embodiment of formula B, R7 and R8 form 2-Br-phenyl.
According to still another embodiment of formula B, R7 and R8 form 3-Br-phenyl.
According to still another embodiment of formula B, R7 and R8 form 4-Br-phenyl.
According to still another embodiment of formula B, R7 and R8 form phenyl substituted by Cl.
According to still another embodiment of formula B, R7 and R8 form 1-Cl-phenyl.
According to still another embodiment of formula B, R7 and R8 form 2-Cl-phenyl.
According to still another embodiment of formula B, R7 and R8 form 3-Cl-phenyl.
According to still another embodiment of formula B, R7 and R8 form 4-Cl-phenyl.
According to one embodiment of formula B, Y is H.
Y can be S(O)yY1, where Y1 is C1-C4-alkyl such as S—C2H5, S-n-C3H7, S-i-C3H7, S-n C4H9, S-i-C4H9, S-sec-C4H9, S-t-C4H9, SO—CH3, SO—C2H5, SO-n-C3H7, SO-i-C3H7, SO-n-C4H9, SO-i-C4H9, SO-sec-C4H9, SO-t-C4H9, SO2—CH3, SO2—C2H5, SO2-n-C3H7, SO2-i-C3H7, SO2-n-C4H9, SO2-i-C4H9, SO2-sec-C4H9, SO2-t-C4H9 According to still another embodiment of formula B, Y is SY1, wherein Y1 is phenyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SC6H5, S-(o-F—C6H4), S-(m-F—C6H4), S-(p-F—C6H4), S-(o-C1-C6H4), S-(m-C1-C6H4), S-(p-C1-C6H4), S(o-CH3—C6H4), S-(m-CH3—C6H4), S-(p-CH3—C6H4), S-(o-OCH3—C6H4), S-(m-OCH3—C6H4), S-(p-OCH3—C6H4), S-(o-NO2—C6H4), S-(m-NO2—C6H4), S-(p-NO2—C6H4), preferably of S—C6H5.
According to still another embodiment of formula B, Y is SOY1, wherein Y1 is phenyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SO—C6H5, SO-(o-F—C6H4), SO-(m-F—C6H4), SO-(p-F—C6H4), SO-(o-C1-C6H4), SO-(m-C1-C6H4), SO(p-C1-C6H4), SO-(o-CH3—C6H4), SO-(m-CH3—C6H4), SO-(p-CH3—C6H4), SO-(o-OCH3—C6H4), SO(m-OCH3—C6H4), SO-(p-OCH3—C6H4), SO-(o-NO2—C6H4), SO-(m-NO2—C6H4), SO-(p-NO2—C6H4), preferably of SO—C6H5.
According to still another embodiment of formula B, Y is SO2Y1, wherein Y1 is phenyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SO2—C6H5, SO2-(o-F—C6H4), SO2-(m-F—C6H4), SO2-(p-F—C6H4), SO2-(o-Cl—C6H4), SO2-(m-Cl—C6H4), SO2-(p-C1-C6H4), SO2-(o-CH3—C6H4), SO2-(m-CH3—C6H4), SO2-(p-CH3—C6H4), SO2-(o- OCH3—C6H4), SO2-(m-OCH3—C6H4), SO2-(p-OCH3—C6H4), SO2-(o-NO2—C6H4), SO2-(m-NO2—C6H4), SO2-(p-NO2—C6H4), preferably of SO2—C6H5.
According to still another embodiment of formula B, Y is SY1, wherein Y1 is benzyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SC6H5, S-(o-F-benzyl), S-(m-F-benzyl), S-(p-F-benzyl), S-(o-Cl-benzyl), S-(m-Cl-benzyl), S-(p-Cl-benzyl), S-(o-CH3-benzyl), S-(m-CH3-benzyl), S-(p-CH3-benzyl), S-(o-OCH3-benzyl), S-(m-OCH3-benzyl), S-(p-OCH3-benzyl), S-(o-NO2-benzyl), S-(m-NO2-benzyl), S-(p-NO2-benzyl), preferably of S-benzyl.
According to still another embodiment of formula B; Y is SOY1, wherein Y1 is benzyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SO-benzyl, SO-(o-F-benzyl), SO-(m-F-benzyl), SO-(p-F-benzyl), SO-(o-Cl-benzyl), SO-(m-Cl-benzyl), SO-(p-Cl-benzyl), SO-(o-CH3-benzyl), SO-(m-CH3-benzyl), SO-(p-CH3-benzyl), SO-(o-OCH3-benzyl), SO-(m-OCH3-benzyl), SO-(p-OCH3-benzyl), SO-(o-NO2-benzyl), SO-(m-NO2-benzyl), SO-(p-NO2-benzyl), preferably of SO-benzyl.
According to still another embodiment of formula B, Y is SO2Y1, wherein Y1 is benzyl which is unsubstituted or substituted by by CN, NO2, halogen, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy.
According to still another embodiment of formula B, Y is selected from the group consisting of SO2-benzyl, SO2-(o-F-benzyl), SO2-(m-F-benzyl), SO2-(p-F-benzyl), SO2-(o-Cl-benzyl), SO2-(m-Cl-benzyl), SO2-(p-Cl-benzyl), SO2-(o-CH3-benzyl), SO2-(m-CH3-benzyl), SO2-(p-CH3-benzyl), SO2-(o-OCH3-benzyl), SO2-(m-OCH3-benzyl), SO2-(p-OCH3-benzyl), SO2-(o-NO2-benzyl), SO2-(m-NO2-benzyl), SO2-(p-NO2-benzyl), preferably of SO2-benzyl.
According to another embodiment of formula B, Y is C(═O)OY2,
According to one embodiment of formula B, Y2 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula B, Y2 is CH3.
According to still another embodiment of formula B, Y2 is C2H5.
According to still another embodiment of formula B, Y2 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula B, Y2 is CH2F.
According to still another embodiment of formula B, Y2 is CHF2.
According to still another embodiment of formula B, Y2 is CF3.
According to still another embodiment of formula B, Y2 is phenyl.
According to still another embodiment of formula B, Y2 is benzyl.
According to still another embodiment of formula B, Y2 is Mg and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Ca and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Cu and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Ni and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Co and their Cl salts and hydrooxides.
According to still another embodiment of formula B; Y2 is Cs and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Fe and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is B and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Al and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Ti and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Zn and their Cl salts and hydrooxides.
According to still another embodiment of formula B, Y2 is Pd and their Cl salts and hydrooxides.
According to still another embodiment of formula B, C(═O)OY1 is selected from the group consisting of CO2CH3, CO2C2H5, CO2-(n-C3H7), CO2-(i-C3H7), CO2-(n-C4H9), CO2-(i-C4H9), CO2-(sec-C4H9), COO2-(t-C4H9), COO2-phenyl, COO2-benzyl, COOH, COOLi, COONa, COOK, (COO)2Mg, COO—MgCl, COO—MgOH, (COO)2Ca, COO—CaCl, COO—CaOH, (COO)3B, (COO)2BCl, (COO)2BOH, COO—BCl2, COO—B(OH)2, (COO)3Al, (COO)2AlCl, (COO)2AlOH, COO—AlCl2, COO—Al(OH)2, (COO)4Ti, (COO)3TiCl, (COO)3TiOH, (COO)2TiCl2, (COO)2Ti(OH)2, COO—TiCl3, COO—Ti(OH)3, (COO)2Fe, COO—FeCl, COO—FeOH, (COO)3Fe, (COO)2FeCl, (COO)2FeOH, COO—FeCl2, COO—Fe(OH)2, (COO)2Co, COO—CoCl, COO—Co(OH), (COO)3COO, (COO)2CoCl, (COO)2Co(OH), COO—CoCl2, COO—Co(OH)2, (COO)2Ni, COO—NiCl, COO—Ni(OH), COOCu, (COO)2Cu, COO—CuCl, COO—Cu(OH), (COO)2Zn, COO—ZnCl, COO—Zn(OH), (COO)2Pd, COO—PdCl, COO—Pd(OH); preferably selected from the group consisting of CO2CH3, CO2C2H5, CO2-(n-C3H7), CO2-(i-C3H7), CO2-(n-C4H9), CO2-(i-C4H9), CO2-(sec-C4H9), CO2-(t-C4H9), COOH, COOLi, COONa, COOK, COOCu, (COO)2Cu, COO—CuCl, COO—Cu(OH).
According to still another embodiment of formula B, Y is S+(Y1)(Y3) (Y4)−, wherein
According to still another embodiment of formula B, Y is selected from the group consisting of S+(CH3)2, S+(CH3)—C2H5, S+(CH3)-n-C3H7, S+(CH3)-i-C3H7, S+(CH3)-n C4H9, S+(CH3)-i-C4H9, S+(CH3)-sec-C4H9, S+(CH3)-t-C4H9.
According to still another embodiment of formula B, Y is selected from the group consisting of S+(C2H5)2, S+(C2H5)-n-C3H7, S+(C2H5)-i-C3H7, S+(C2H5)-n C4H9, S+(C2H5)-i-C4H9, S+(C2H5)-sec-C4H9, S+(C2H5)-t-C4H9.
According to still another embodiment of formula B, Y is selected from the group consisting of S+(CH3)—C6H5, S+(CH3)-(o-F—C6H4), S+(CH3)-(m-F—C6H4), S+(CH3)-(p-F—C6H4), S+(CH3)-(o-Cl—C6H4), S+(CH3)-(m-C1-C6H4), S+(CH3)-(p-C1-C6H4), S+(CH3)-(o-CH3—C6H4), S+(CH3)- (m-CH3—C6H4), S+(CH3)-(p-CH3—C6H4), S+(CH3)—(O—OCH3—C6H4), S+(CH3)-(m-OCH3—C6H4), S+(CH3)-(p-OCH3—C6H4), S+(CH3)-(o-NO2—C6H4), S+(CH3)-(m-NO2—C6H4), S+(CH3)-(p-NO2—C6H4).
According to still another embodiment of formula B, Y is selected from the group consisting of S+(C2H5)—C6H5, S+(C2H5)-(o-F—C6H4), S+(C2H5)-(m-F—C6H4), S+(C2H5)-(p-F—C6H4), S+(C2H5)-(o-C1-C6H4), S+(C2H5)-(m-C1-C6H4), S+(C2H5)-(p-Cl—C6H4), S+(C2H5)-(o-CH3—C6H4), S+(C2H5)-(m-CH3—C6H4), S+(C2H5)-(p-CH3—C6H4), S+(C2H5)-(o-OCH3—C6H4), S+(C2H5)-(m-OCH3—C6H4), S+(C2H5)-(p-OCH3—C6H4), S+(C2H5)-(o-NO2—C6H4), S+(C2H5)-(m-NO2—C6H4), S+(C2H5)-(p-NO2—C6H4).
According to still another embodiment of formula B, Y is selected from the group consisting of S+(CH3)-benzyl, S+(CH3)-(o-F-benzyl), S+(CH3)-(m-F-benzyl), S+(CH3)-(p-F-benzyl), S+(CH3)-(o-Cl-benzyl), S+(CH3)-(m-Cl-benzyl), S+(CH3)-(p-Cl-benzyl), S+(CH3)-(o-CH3-benzyl), S+(CH3)-(m-CH3-benzyl), S+(CH3)-(p-CH3-benzyl), S+(CH3)-(o-OCH3-benzyl), S+(CH3)-(m-OCH3-benzyl), S+(CH3)-(p-OCH3-benzyl), S+(CH3)-(o-NO2-benzyl), S+(CH3)-(m-NO2-benzyl), S+(CH3)-(p-NO2-benzyl).
According to still another embodiment of formula B, Y is selected from the group consisting of S+(C2H5)-benzyl, S+(C2H5)-(o-F-benzyl), S+(C2H5)-(m-F-benzyl), S+(C2H5)-(p-F-benzyl), S+(C2H5)(o-Cl-benzyl), S(C2H5)-(m-Cl-benzyl), S+(C2H)-(p-Cl-benzyl), S+(C2H5)-(o-CH3-benzyl), S+(C2H5)-(m-CH3-benzyl), S+(C2H5)-(p-CH3-benzyl), S+(C2H5)-(o-OCH3-benzyl), S+(C2H5)-(m-OCH3-benzyl), S+(C2H5)-(p-OCH3-benzyl), S+(C2H5)-(o-NO2-benzyl), S+(C2H5)-(m-NO2-benzyl), S+(C2H5)-(p-NO2-benzyl).
Particular embodiments of the compounds B are the following compounds: B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8 and B-9. In these formulae, the substituents Y, R3, R4, R5 and R6 are independently as defined in claim 1 or preferably defined below:
Table 2-1 Compounds of the formula B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8 and B-9 the meaning for the combination of Y, R3, R4, R5 and R6 for each individual compound corresponds in each case to one line of Table B (compounds B-1.2-1.B-1 to B-1.2-1.B-540, compounds B-2.2-1.B-1 to B-2.2-1.B-540, compounds B-3.2-1.B-1 to B-3.2-1.B-540, compounds B-4.2-1.B-1 to B-4.2-1.B-540, compounds B-5.2-1.B-1 to B-5.2-1.B-540, compounds B-6.2-1.B-1 to B-6.2-1.B-540, compounds B-7.2-1.B-1 to B-7.2-1.B-540, compounds B-8.2-1.B-1 to B-8.2-1.B-540, compounds B-9.2-1.B-1 to B-9.2-1.B-540).
Accordingly, the present invention relates further to the process for the synthesis of compounds of the formula I, comprising the step of
Accordingly, the present invention relates further to the intermediate compounds C
According to one embodiment of formula C, R3 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula C, R3 is CH3.
According to still another embodiment of formula C; R3 is C2H5.
According to still another embodiment of formula C; R3 is C1-C4-halogenalkylmore specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula C, R3 is CH2F.
According to still another embodiment of formula C, R3 is CHF2.
According to still another embodiment of formula C, R3 is CF3.
According to still another embodiment of formula C, R3 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula C, R4 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula C, R4 is CH3.
According to still another embodiment of formula C, R4 is C2H5.
According to still another embodiment of formula C, R4 is C1-C4-halogenalkylmore specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula C, R4 is CH2F.
According to still another embodiment of formula C, R4 is CHF2.
According to still another embodiment of formula C, R4 is CF3.
According to still another embodiment of formula C, R4 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula C, R5 is Cl.
According to still another embodiment of formula C, R5 is Br.
According to still another embodiment of formula C, R5 is F.
According to one embodiment of formula C, R6 is Cl.
According to still another embodiment of formula C, R6 is Br.
According to still another embodiment of formula C, R6 is F.
R7 and R8 together with the carbon atoms to which they are bound together form a phenyl which is unsubstituted or substituted by R78 being halogen.
According to one embodiment of formula I, R7 and R8 form phenyl.
According to still another embodiment of formula C, R7 and R8 form phenyl substituted by F.
According to still another embodiment of formula C, R7 and R8 form 1-F-phenyl.
According to still another embodiment of formula C, R7 and R8 form 2-F-phenyl.
According to still another embodiment of formula C, R7 and R8 form 3-F-phenyl.
According to still another embodiment of formula C, R7 and R8 form 4-F-phenyl.
According to still another embodiment of formula C, R7 and R8 form phenyl substituted by Br.
According to still another embodiment of formula C, R7 and R8 form 1-Br-phenyl.
According to still another embodiment of formula C, R7 and R8 form 2-Br-phenyl.
According to still another embodiment of formula C; R7 and R8 form 3-Br-phenyl.
According to still another embodiment of formula C, R7 and R8 form 4-Br-phenyl.
According to still another embodiment of formula C, R7 and R8 form phenyl substituted by Cl.
According to still another embodiment of formula C, R7 and R8 form 1-Cl-phenyl.
According to still another embodiment of formula C, R7 and R8 form 2-Cl-phenyl.
According to still another embodiment of formula C, R7 and R8 form 3-Cl-phenyl.
According to still another embodiment of formula C, R7 and R8 form 4-Cl-phenyl.
Particular embodiments of the compounds C are the following compounds: C-1,C-2, C-3, C-4, C-5, C-6, C-7,C-8 and C-9. In these formulae, the substituents R3, R4, R5 and R6 are independently as defined in claim 1 or preferably defined below:
Table 3-1 Compounds of the formula C-1, C-2, C-3, C-4, C-5, C-6, C-7, C-8 and C-9 the meaning for the combination of R3, R4, R5 and R6 for each individual compound corresponds in each case to one line of Table C (compounds C-1.3-1.C-1 to C-1.3-1.C-12, compounds C-2.3-1.C-1 to C-2.3-1.C-12, compounds C-3.3-1.C-1 to C-3.3-1.C-12, compounds C-4.3-1.C-1 to C-4.3-1.C-12, compounds C-5.3-1.C-1 to C-5.3-1.C-12, compounds C-6.3-1.C-1 to C-6.3-1.C-12, compounds C-7.3-1.-1 to C-7.3-1.C-12, compounds C-8.3-1.C-1 to C-8.3-1.C-12, compounds C-9.3-1.C-1 to C-9.3-1.C-12).
Accordingly, the present invention relates further to the compounds II
According to one embodiment of formula II, R3 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula II, R3 is CH3.
According to still another embodiment of formula II, R3 is C2H5.
According to still another embodiment of formula II, R3 is C1-C4-halogenalkylmore specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula II, R3 is CH2F.
According to still another embodiment of formula II, R3 is CHF2.
According to still another embodiment of formula II, R3 is CF3.
According to still another embodiment of formula II, R3 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula II, R4 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula II, R4 is CH3.
According to still another embodiment of formula II, R4 is C2H5.
According to still another embodiment of formula II, R4 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula II, R4 is CH2F.
According to still another embodiment of formula II, R4 is CH F2.
According to still another embodiment of formula II, R4 is CF3.
According to still another embodiment of formula II, R4 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to still another embodiment of formula II, R9 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2, CH3CHF, CH3CF2 or CF2CHF2.
According to still another embodiment of formula II, R9 is CH2F.
According to still another embodiment of formula II, R9 is CHF2.
According to still another embodiment of formula II, R9 is CHCl2.
According to still another embodiment of formula II, R9 is CH2F, CHF2, CH2Cl, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl, CH3CHF, CH3CF2, CHCl2.
According to still another embodiment of formula II, R10 is CH3.
According to still another embodiment of formula II, R10 is C2H5.
According to still another embodiment of formula II, R10 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2, CH3CHF, CH3CF2 or CF2CHF2.
According to still another embodiment of formula II, R10 is CH2F.
According to still another embodiment of formula II, R10 is CHF2.
According to still another embodiment of formula II, R10 is CF3.
According to still another embodiment of formula II, R10 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl, CH3CHF, CH3CF2
According to a further specific embodiment of formula II, R10 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3, CH2CH3 or CH2OCH3.
According to a further specific embodiment of formula II, R10 is C1-C6-alkyl-C1-C6-alkoxy, in particular C1-C4-alkyl-C1-C4-alkoxy, more specifically C1-C2-alkyl-C1-C2-alkoxy, such as CH2OCH3 or CH2OCH2CH3.
According to a further specific embodiment of formula II, R10 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCH F2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
Particular embodiments of the compounds II are the following compounds: II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8 and II-9. In these formulae, the substituents R3, R4, R9 and R10 are independently as defined in claim 1 or preferably defined below:
Table 4-1 Compounds of the formula II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8 and II-9 in which the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds II-1.4-1.D-1 to II-1.4-1.D-216, compounds II-2.4-1.D-1 to II-2.4-1.D-216, compounds II-3.4-1.D-1 to II-3.4-1.D-216, compounds II-4.4-1.D-1 to II-4.4-1.D-216, compounds II-5.4-1.D-1 to II-5.4-1.D-216, compounds II-6.4-1.D-1 to II-6.4-1.D-216, compounds II-7.4-1.D-1 to II-7.4-1.D-216, compounds II-8.4-1.D-1 to II-8.4-1.D-216 compounds II-9.4-1.D-1 to II-9.4-1.D-216).
Accordingly, the present invention relates further to the process for the synthesis of compounds of the formula I of claim 1, comprising the step of reacting a compound D
Accordingly, the present invention relates further to the intermediate compounds D, wherein
According to one embodiment of formula D, R3 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula D, R3 is CH3.
According to still another embodiment of formula D, R3 is C2H5.
According to still another embodiment of formula D, R3 is C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula D, R3 is CH2F.
According to still another embodiment of formula D, R3 is CHF2.
According to still another embodiment of formula D, R3 is CF3.
According to still another embodiment of formula D, R3 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to one embodiment of formula D, R4 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula D, R4 is CH3.
According to still another embodiment of formula D, R4 is C2H5.
According to still another embodiment of formula D, R4 is C1-C4-halogenalkyl, more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula D; R4 is CH2F.
According to still another embodiment of formula D, R4 is CHF2.
According to still another embodiment of formula D, R4 is CF3.
According to still another embodiment of formula D, R4 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to still another embodiment of formula D, R5 is H.
According to still another embodiment of formula D, R5 is halogen.
According to still another embodiment of formula D, R6 is H.
According to still another embodiment of formula D, R6 is halogen.
According to one embodiment of formula D R9 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula D, R9 is CH3.
According to still another embodiment of formula D, R9 is C2H5.
According to still another embodiment of formula D, R9 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula D, R9 is CH2F.
According to still another embodiment of formula D, R9 is CHF2.
According to still another embodiment of formula D, R9 is CF3.
According to still another embodiment of formula D, R9 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl, CHCl2
According to a further specific embodiment of formula D, R9 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3, CH2CH3 or CH2OCH3.
According to a further specific embodiment of formula D, R9 is C1-C6-alkyl-C1-C6-alkoxy, in particular C1-C4-alkyl-C1-C4-alkoxy, more specifically C1-C2-alkyl-C1-C2-alkoxy, such as CH2OCH3 or CH2OCH2CH3.
According to a further specific embodiment of formula D, R9 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCH F2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
According to one embodiment of formula D, R9 is C1-C4-alkyl such as CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl or tert-butyl.
According to still another embodiment of formula D, R10 is CH3.
According to still another embodiment of formula D, R10 is C2H5.
According to still another embodiment of formula D, R10 is C1-C4-halogenalkyl more specifically C1-C2-halogenalkyl, such as CF3, CCl3, FCH2, ClCH2, F2CH, Cl2CH, CF3CH2, CCl3CH2 or CF2CHF2.
According to still another embodiment of formula D, R10 is CH2F.
According to still another embodiment of formula D, R10 is CHF2.
According to still another embodiment of formula D, R10 is CF3.
According to still another embodiment of formula D, R10 is CH3, CH2F, CHF2, CF3, CH2Cl, C2H5, CH2—CH2F, CH2—CHF2, CH2—CF3, CH2—CH2Cl, n-C3H7, (CH2)2—CH2F, (CH2)2—CHF2, (CH2)2—CF3, (CH2)2—CH2Cl, i-C3H7, n-C4H9, (CH2)3—CH2F, (CH2)3—CHF2 (CH2)3—CF3, (CH2)3—CH2Cl.
According to a further specific embodiment of formula D, R10 is C1-C6-alkoxy, in particular C1-C4-alkoxy, more specifically C1-C2-alkoxy such as OCH3 or OCH2CH3.
According to a further specific embodiment of formula D, R10 is C1-C6-halogenalkoxy, in particular C1-C4-halogenalkoxy, more specifically C1-C2-halogenalkoxy such as OCF3, OCH F2, OCH2F, OCCl3, OCHCl2 or OCH2Cl, in particular OCF3, OCHF2, OCCl3 or OCHCl2.
Particular embodiments of the compounds D are the following compounds: D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18. In these formulae, the substituents R3, R4, R5, R6, R9 and R10 are independently as defined in claim 1 or preferably defined below:
Table 5-1 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8,D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is H, R6 is H and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-1.D-1 to D-1.5-1.D-216, compounds D-2.5-1.D-1 to D-2.5-1.D-216, compounds D-3.5-1.D-1 to D-3.5-1.D-216, compounds D-4.5-1.D-1 to D-4.5-1.D-216, compounds D-5.5-1.D-1 to D-5.5-1.D-216, compounds D-6.5-1.D-1 to D-6.5-1.D-216, compounds D-7.5-1.D-1 to D-7.5-1.D-216, compounds D-8.5-1.D-1 to D-8.5-1.D-216, compounds D-9.5-1.D-1 to D-9.5-1.D-216, compounds D-10.5-1.D-1 to D-10.5-1.D-216, compounds D-11.5-1.D-1 to D-11.5-1.D-216, compounds D-12.5-1.D-1 to D-12.5-1.D-216, compounds D-13.5-1.D-1 to D-13.5-1.D-216, compounds D-14.5-1.D-1 to D-14.5-1.D-216, compounds D-15.5-1.D-1 to D-15.5-1.D-216, compounds D-16.5-1.D-1 to D-16.5-1.D-216, compounds D-17.5-1.D-1 to D-17.5-1.D-216, compounds D-18.5-1.D-1 to D-18.5-1.D-216.
Table 5-2 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8,D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is H, R6 is F and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-2.D-1 to D-1.5-2.D-216, compounds D-2.5-2.D-1 to D-2.5-2.D-216, compounds D-3.5-2.D-1 to D-3.5-2.D-216, compounds D-4.5-2.D-1 to D-4.5-2.D-216, compounds D-5.5-2.D-1 to D-5.5-2.D-216, compounds D-6.5-2.D-1 to D-6.5-2.D-216, compounds D-7.5-2.D-1 to D-7.5-2.D-216, compounds D-8.5-2.D-1 to D-8.5-2.D-216, compounds D-9.5-2.D-1 to D-9.5-2.D-216, compounds D-10.5-2.D-1 to D-10.5-2.D-216, compounds D-11.5-2.D-1 to D-11.5-2.D-216, compounds D-12.5-2.D-1 to D-12.5-2.D-216, compounds D-13.5-2.D-1 to D-13.5-2.D-216, compounds D-14.5-2.D-1 to D-14.5-2.D-216, compounds D-15.5-2.D-1 to D-15.5-2.D-216, compounds D-16.5-2.D-1 to D-16.5-2.D-216, compounds D-17.5-2.D-1 to D-17.5-2.D-216, compounds D-18.5-2.D-1 to D-18.5-2.D-216).
Table 5-3 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8,D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is H, R6 is Cl and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-3.D-1 to D-1.5-3.D-216, compounds D-2.5-3.D-1 to D-2.5-3.D-216, compounds D-3.5-3.D-1 to D-3.5-3.D-216, compounds D-4.5-3.D-1 to D-4.5-3.D-216, compounds D-5.5-3.D-1 to D-5.5-3.D-216, compounds D-6.5-3.D-1 to D-6.5-3.D-216, compounds D-7.5-3.D-1 to D-7.5-3.D-216, compounds D-8.5-3.D-1 to D-8.5-3.D-216, compounds D-9.5-3.D-1 to D-9.5-3.D-216, compounds D-10.5-3.D-1 to D-10.5-3.D-216, compounds D-11.5-3.D-1 to D-11.5-3.D-216, compounds D-12.5-3.D-1 to D-12.5-3.D-216, compounds D-13.5-3.D-1 to D-13.5-3.D-216, compounds D-14.5-3.D-1 to D-14.5-3.D-216, compounds D-15.5-3.D-1 to D-15.5-3.D-216, compounds D-16.5-3.D-1 to D-16.5-3.D-216, compounds D-17.5-3.D-1 to D-17.5-3.D-216, compounds D-18.5-3.D-1 to D-18.5-3.D-216).
Table 5-4 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8,D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is F, R6 is F and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-4.D-1 to D-1.5-4.D-216, compounds D-2.5-4.D-1 to D-2.5-4.D-216, compounds D-3.5-4.D-1 to D-3.5-4.D-216, compounds D-4.5-4.D-1 to D-4.5-4.D-216, compounds D-5.5-4.D-1 to D-5.5-4.D-216, compounds D-6.5-4.D-1 to D-6.5-4.D-216, compounds D-7.5-4.D-1 to D-7.5-4.D-216, compounds D-8.5-4.D-1 to D-8.5-4.D-216, compounds D-9.5-4.D-1 to E9.5-4.D-216, compounds D-10.5-4.D-1 to D-10.5-4.D-216, compounds D-11.5-4.D-1 to D-11.5-4.D-216, compounds D-12.5-4.D-1 to D-12.5-4.D-216, compounds D-13.5-4.D-1 to D-13.5-4.D-216, compounds D-14.5-4.D-1 to D-14.5-4.D-216, compounds D-15.5-4.D-1 to D-15.5-4.D-216, compounds D-16.5-4.D-1 to D-16.5-4.D-216, compounds D-17.5-4.D-1 to D-17.5-4.D-216, compounds D-18.5-4.D-1 to D-18.5-4.D-216).
Table 5-5 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8,D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is F, R6 is Cl and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-5.D-1 to D-1.5-5.D-216 compounds D-2.5-5.D-1 to D-2.5-5.D-216, compounds D-3.5-5.D-1 to D-3.5-5.D-216, compounds D-4.5-5.D-1 to D-4.5-5.D-216, compounds D-5.5-5.D-1 to D-5.5-5.D-216, compounds D-6.5-5.D-1 to D-6.5-5.D-192, compounds D-7.5-5.D-1 to D-7.5-5.D-192, compounds D-8.5-5.D-1 to D-8.5-5.D-216, compounds D-9.5-5.D-1 to D-9.5-5.D-216, compounds D-10.5-5.D-1 to D-10.5-5.D-216, compounds D-11.5-5.D-1 to D-11.5-5.D-216, compounds D-12.5-5.D-1 to D-12.5-5.D-216, compounds D-13.5-5.D-1 to D-13.5-5.D-216, compounds D-14.5-5.D-1 to D-14.5-5.D-216, compounds D-15.5-5.D-1 to D-15.5-5.D-216, compounds D-16.5-5.D-1 to D-16.5-5.D-216, compounds D-17.5-5.D-1 to D-17.5-5.D-216, compounds D-18.5-5.D-1 to D-18.5-5.D-216).
Table 5-6 Compounds of the formula D-1, D-2, D-3, D-4, D-5, D-6, D-7, D-8, D-9, D-10, D-11, D-12, D-13, D-14, D-15, D-16, D-17 and D-18 in which R5 is Cl, R6 is Cl and the meaning for the combination of R3, R4, R9 and R10 for each individual compound corresponds in each case to one line of Table D (compounds D-1.5-6.D-1 to D-1.5-6.D-216, compounds D-2.5-6.D-1 to D-2.5-6.D-216, compounds D-3.5-6.D-1 to D-3.5-6.D-216, compounds D-4.5-6.D-1 to D-4.5-6.D-216, compounds D-5.5-6.D-1 to D-5.5-6.D-216, compounds D-6.5-6.D-1 to D-6.5-6.D-216, compounds D-7.5-6.D-1 to D-7.5-6.D-216, compounds D-8.5-6.D-1 to D-8.5-6.D-216, compounds D-9.5-6.D-1 to D-9.5-6.D-216, compounds D-10.5-6.D-1 to D-10.5-6.D-216, compounds D-11.5-6.D-1 to D-11.5-6.D-216, compounds D-12.5-6.D-1 to D-12.5-6.D-216, compounds D-13.5-6.D-1 to D-13.5-6.D-216, compounds D-14.5-6.D-1 to D-14.5-6.D-216, compounds D-15.5-6.D-1 to D-15.5-6.D-216, compounds D-16.5-6.D-1 to D-16.5-6.D-216, compounds D-17.5-6.D-1 to D-17.5-6.D-216, compounds D-18.5-6.D-1 to D-18.5-6.D-216).
Accordingly, the present invention relates further to the compounds E
Particular embodiments of the compounds E are the following compounds: E-1, E-2, E-3, E-4, E-5, E-6, E-7, E-8, E-9 and E-10. In these formulae, the substituents X, R9 and R10 are independently as defined in claim 1 or preferably defined below:
Table 6-1 Compounds of the formula E-1, E-2, E-3, E-4, E-5, E-6, E-7, E-8, E-9 and E-10 in the meaning for the combination of R9 and R10 for each individual compound corresponds in each case to one line of Table E (compounds E-1.6-1.E-1 to E-1.6-1.E-50, compounds E-2.6-1.E-1 to E-2.6-1.E-50, compounds E-3.6-1.E-1 to E-3.6-1.E-50, compounds E-4.6-1.E-1 to E-4.6-1.E-50, compounds E-5.6-1.E-1 to E-5.6-1.E-50, compounds E-6.6-1.E-1 to E-6.6-1.E-50, compounds E-7.6-1.E-1 to E-7.6-1.E-50, compounds E-8.6-1.E-1 to E-8.6-1.E-50, compounds E-9.6-1.E-1 to E-9.6-1.E-50, compounds E-10.6-1.E-1 to E-10.6-1.E-50).
The compounds I and the compositions according to the invention, respectively, are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.
The compounds I and the compositions according to the invention are particularly important in the control of a multitude of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruits or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; energy and raw material plants, such as corn, soybean, rape, sugar cane or oil palm; corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e. g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.
Preferably, compounds I and compositions thereof, respectively are used for controlling a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamentals; or vegetables, such as cucumbers, tomatoes, beans or squashes.
The term “plant propagation material” is to be understood to denote all the generative parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g. potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil. These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.
Preferably, treatment of plant propagation materials with compounds I and compositions thereof, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton and soybeans.
The term “cultivated plants” is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech products on the market or in development (cf. http://cera-gmc.org/, see GM crop database therein). Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant. Such genetic modifications also include but are not limited to targeted post-translational modification of protein(s), oligo- or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties.
Plants that have been modified by breeding, mutagenesis or genetic engineering, e. g. have been rendered tolerant to applications of specific classes of herbicides, such as auxin herbicides such as dicamba or 2,4-D; bleacher herbicides such as hydroxylphenylpyruvate dioxygenase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors; acetolactate synthase (ALS) inhibitors such as sulfonyl ureas or imidazolinones; enolpyruvylshikimate-3-phosphate synthase (EPSPS) inhibitors, such as glyphosate; glutamine synthetase (GS) inhibitors such as glufosinate; protoporphyrinogen-IX oxidase inhibitors; lipid biosynthesis inhibitors such as acetyl CoA carboxylase (ACCase) inhibitors; or oxynil (i. e. bromoxynil or ioxynil) herbicides as a result of conventional methods of breeding or genetic engineering. Furthermore, plants have been made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as ALS inhibitors, HPPD inhibitors, auxin herbicides, or ACCase inhibitors. These herbicide resistance technologies are e. g. described in Pest Managem. Sci. 61, 2005, 246; 61, 2005, 258; 61, 2005, 277; 61, 2005, 269; 61, 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Sci. 57, 2009, 108; Austral. J. Agricult. Res. 58, 2007, 708; Science 316, 2007, 1185; and references quoted therein. Several cultivated plants have been rendered tolerant to herbicides by conventional methods of breeding (mutagenesis), e. g. Clearfield® summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun® sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron. Genetic engineering methods have been used to render cultivated plants such as soybean, cotton, corn, beets and rape, tolerant to herbicides such as glyphosate and glufosinate, some of which are commercially available under the trade names RoundupReady® (glyphosate-tolerant, Monsanto, U.S.A.), Cultivance® (imidazolinone tolerant, BASF SE, Germany) and LibertyLink® (glufosinate-tolerant, Bayer CropScience, Germany).
Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus Bacillus, particularly from Bacillus thuringiensis, such as 6-endotoxins, e. g. CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c; vegetative insecticidal proteins (VIP), e. g. VIP1, VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e. g. Photorhabdus spp. or Xenorhabdus spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins produced by fungi, such Streptomycetes toxins, plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroid oxidase, ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilbene synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. WO 02/015701). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP-A 374 753, WO 93/007278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03/18810 und WO 03/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coeloptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda). Genetically modified plants capable to synthesize one or more insecticidal proteins are, e. g., described in the publications mentioned above, and some of which are commercially available such as YieldGard® (corn cultivars producing the Cry1Ab toxin), YieldGard® Plus (corn cultivars producing Cry1Ab and Cry3Bb1 toxins), Starlink® (corn cultivars producing the Cry9c toxin), Herculex® RW (corn cultivars producing Cry34Ab1, Cry35Ab1 and the enzyme phosphinothricin-N-acetyltransferase [PAT]); NuCOTN® 33B (cotton cultivars producing the Cry1Ac toxin), Bollgard® I (cotton cultivars producing the Cry1Ac toxin), Bollgard® II (cotton cultivars producing Cry1Ac and Cry2Ab2 toxins); VIPCOT® (cotton cultivars producing a VIP-toxin); NewLeaf® (potato cultivars producing the Cry3A toxin); Bt-Xtra®, NatureGard®, KnockOut®, BiteGard®, Pro-tecta®, Bt11 (e. g. Agrisure® CB) and Bt176 from Syngenta Seeds SAS, France, (corn cultivars producing the Cry1Ab toxin and PAT enyzme), MIR604 from Syngenta Seeds SAS, France (corn cultivars producing a modified version of the Cry3A toxin, c.f. WO 03/018810), MON 863 from Monsanto Europe S.A., Belgium (corn cultivars producing the Cry3Bb1 toxin), IPC 531 from Monsanto Europe S.A., Belgium (cotton cultivars producing a modified version of the Cry1Ac toxin) and 1507 from Pioneer Overseas Corporation, Belgium (corn cultivars producing the Cry1F toxin and PAT enzyme).
Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens. Examples of such proteins are the SOX-called “pathogenesis-related proteins” (PR proteins, see, e. g. EP-A 392 225), plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the Mexican wild potato Solanum bulbocastanum) or T4-lysozym (e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as Erwinia amylvora). The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above.
Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more proteins to increase the productivity (e. g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants.
Furthermore, plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve human or animal nutrition, e. g. oil crops that produce health-promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera® rape, DOW Agro Sciences, Canada).
Furthermore, plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora® potato, BASF SE, Germany).
The compounds I and compositions thereof, respectively, are particularly suitable for controlling the following plant diseases:
Albugo spp. (white rust) on ornamentals, vegetables (e. g. A. candida) and sunflowers (e. g. A. tragopogonis); Alternaria spp. (Alternaria leaf spot) on vegetables, rape (A. brassicola or brassicae), sugar beets (A. tenuis), fruits, rice, soybeans, potatoes (e. g. A. solani or A. alternata), tomatoes (e. g. A. solani or A. alternata) and wheat; Aphanomyces spp. on sugar beets and vegetables; Ascochyta spp. on cereals and vegetables, e. g. A. tritici(anthracnose) on wheat and A. hordei on barley; Bipolaris and Drechslera spp. (teleomorph: Cochliobolus spp.), e. g. Southern leaf blight (D. maydis) or Northern leaf blight (B. zeicola) on corn, e. g. spot blotch (B. sorokiniana) on cereals and e. g. B. oryzae on rice and turfs; Blumeria (formerly Erysiphe) graminis (powdery mildew) on cereals (e. g. on wheat or barley); Botrytis cinerea (teleomorph: Botryotinia fuckeliana: grey mold) on fruits and berries (e. g. strawberries), vegetables (e. g. lettuce, carrots, celery and cabbages), rape, flowers, vines, forestry plants and wheat; Bremia lactucae (downy mildew) on lettuce; Ceratocystis (syn. Ophiostoma) spp. (rot or wilt) on broad-leaved trees and evergreens, e. g. C. ulmi (Dutch elm disease) on elms; Cercospora spp. (Cercospora leaf spots) on corn (e. g. Gray leaf spot: C. zeae-maydis), rice, sugar beets (e. g. C. beticola), sugar cane, vegetables, coffee, soybeans (e. g. C. sojina or C. kikuchii) and rice; Cladosporium spp. on tomatoes (e. g. C. fulvum: leaf mold) and cereals, e. g. C. herbarum (black ear) on wheat; Claviceps purpurea (ergot) on cereals; Cochliobolus (anamorph: Helminthosporium of Bipolaris) spp. (leaf spots) on corn (C. carbonum), cereals (e. g. C. sativus, anamorph: B. sorokiniana) and rice (e. g. C. miyabeanus, anamorph: H. oryzae); Colletotrichum (teleomorph: Glomerella) spp. (anthracnose) on cotton (e. g. C. gossypi), corn (e. g. C. graminicola: Anthracnose stalk rot), soft fruits, potatoes (e. g. C. coccodes: black dot), beans (e. g. C. lindemuthianum) and soybeans (e. g. C. truncatum or C. gloeosporioides); Corticium spp., e. g. C. sasakii (sheath blight) on rice; Corynespora cassiicola (leaf spots) on soybeans and ornamentals; Cycloconium spp., e. g. C. oleaginum on olive trees; Cylindrocarpon spp. (e. g. fruit tree canker or young vine decline, teleomorph: Nectria or Neonectria spp.) on fruit trees, vines (e. g. C. liriodendri, teleomorph: Neonectria liriodendri: Black Foot Disease) and ornamentals; Dematophora (teleomorph: Rosellinia) necatrix (root and stem rot) on soybeans; Diaporthe spp., e. g. D. phaseolorum (damping off) on soybeans; Drechslera (syn. Helminthosporium, teleomorph: Pyrenophora) spp. on corn, cereals, such as barley (e. g. D. teres, net blotch) and wheat (e. g. D. tritici-repentis: tan spot), rice and turf; Esca (dieback, apoplexy) on vines, caused by Formitiporia (syn. Phellinus) punctata, F. mediterranea, Phaeomoniella chlamydospora (earlier Phaeoacremonium chlamydosporum), Phaeoacremonium aleophilum and/or Botryosphaeria obtusa; Elsinoe spp. on pome fruits (E. pyri), soft fruits (E. veneta: anthracnose) and vines (E. ampelina: anthracnose); Entyloma oryzae (leaf smut) on rice; Epicoccum spp. (black mold) on wheat; Erysiphe spp. (powdery mildew) on sugar beets (E. betae), vegetables (e. g. E. pisi), such as cucurbits (e. g. E. cichoracearum), cabbages, rape (e. g. E. cruciferarum); Eutypa lata (Eutypa canker or dieback, anamorph: Cytosporina lata, syn. Libertella blepharis) on fruit trees, vines and ornamental woods; Exserohilum (syn. Helminthosporium) spp. on corn (e. g. E. turcicum); Fusarium (teleomorph: Gibberella) spp. (wilt, root or stem rot) on various plants, such as F. graminearum or F. culmorum (root rot, scab or head blight) on cereals (e. g. wheat or barley), F. oxysporum on tomatoes, F. solani (f. sp. glycines now syn. F. virguliforme) and F. tucumaniae and F. brasiliense each causing sudden death syndrome on soybeans, and F. verticilloides on corn; Gaeumannomyces graminis (take-all) on cereals (e. g. wheat or barley) and corn; Gibberella spp. on cereals (e. g. G. zeae) and rice (e. g. G. fujikuror Bakanae disease); Glomerella cingulata on vines, pome fruits and other plants and G. gossypii on cotton; Grainstaining complex on rice; Guignardia bidwellii (black rot) on vines; Gymnosporangium spp. on rosaceous plants and junipers, e. g. G. sabinae (rust) on pears; Helminthosporium spp. (syn. Drechslera, teleomorph: Cochliobolus) on corn, cereals and rice; Hemilela spp., e. g. H. vastatrix (coffee leaf rust) on coffee; Isariopsis clavispora (syn. Cladosporium vitis) on vines; Macrophomina phaseolina (syn. phaseol) (root and stem rot) on soybeans and cotton; Microdochium (syn. Fusarium) nivale (pink snow mold) on cereals (e. g. wheat or barley); Microsphaera diffusa (powdery mildew) on soybeans; Monilinia spp., e. g. M. laxa, M. fructicola and M. fructigena (bloom and twig blight, brown rot) on stone fruits and other rosaceous plants; Mycosphaerella spp. on cereals, bananas, soft fruits and ground nuts, such as e. g. M. graminicola (anamorph: Septoria tritici Septoria blotch) on wheat or M. fijiensis (black Sigatoka disease) on bananas; Peronospora spp. (downy mildew) on cabbage (e. g. P. brassicae), rape (e. g. P. parasitica), onions (e. g. P. destructor), tobacco (P. tabacina) and soybeans (e. g. P. manshurica); Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans; Phialophora spp. e. g. on vines (e. g. P. tracheiphila and P. tetraspora) and soybeans (e. g. P. gregata: stem rot); Phoma lingam (root and stem rot) on rape and cabbage and P. betae (root rot, leaf spot and damping-off) on sugar beets; Phomopsis spp. on sunflowers, vines (e. g. P. viticola: can and leaf spot) and soybeans (e. g. stem rot: P. phaseoli, teleomorph: Diaporthe phaseolorum); Physoderma maydis (brown spots) on corn; Phytophthora spp. (wilt, root, leaf, fruit and stem root) on various plants, such as paprika and cucurbits (e. g. P. capsici), soybeans (e. g. P. megasperma, syn. P. sojae), potatoes and tomatoes (e. g. P. infestans: late blight) and broadleaved trees (e. g. P. ramorum: sudden oak death); Plasmodiophora brassicae (club root) on cabbage, rape, radish and other plants; Plasmopara spp., e. g. P. viticola (grapevine downy mildew) on vines and P. halstedii on sunflowers; Podosphaera spp. (powdery mildew) on rosaceous plants, hop, pome and soft fruits, e. g. P. leucotricha on apples; Polymyxa spp., e. g. on cereals, such as barley and wheat (P. graminis) and sugar beets (P. betae) and thereby transmitted viral diseases; Pseudocercosporella herpotrichoides (eyespot, teleomorph: Tapesia yallundae) on cereals, e. g. wheat or barley; Pseudoperonospora (downy mildew) on various plants, e. g. P. cubensis on cucurbits or P. humili on hop; Pseudopezicula tracheiphilla (red fire disease or ‘rotbrenner’, anamorph: Phialophora) on vines; Puccinia spp. (rusts) on various plants, e. g. P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. hordei (dwarf rust), P. graminis (stem or black rust) or P. recondita (brown or leaf rust) on cereals, such as e. g. wheat, barley or rye, P. kuehnii (orange rust) on sugar cane and P. asparagi on asparagus; Pyrenophora (anamorph: Drechslera) tritici-repentis (tan spot) on wheat or P. teres (net blotch) on barley; Pyricularia spp., e. g. P. oryzae (teleomorph: Magnaporthe grisea, rice blast) on rice and P. grisea on turf and cereals; Pythium spp. (damping-off) on turf, rice, corn, wheat, cotton, rape, sunflowers, soybeans, sugar beets, vegetables and various other plants (e. g. P. ultimum or P. aphanidermatum); Ramularia spp., e. g. R. collo-cygni (Ramularia leaf spots, Physiological leaf spots) on barley and R. beticola on sugar beets; Rhizoctonia spp. on cotton, rice, potatoes, turf, corn, rape, potatoes, sugar beets, vegetables and various other plants, e. g. R. solani (root and stem rot) on soybeans, R. solani (sheath blight) on rice or R. cerealis (Rhizoctonia spring blight) on wheat or barley; Rhizopus stolonifer(black mold, soft rot) on strawberries, carrots, cabbage, vines and tomatoes; Rhynchosporium secalis (scald) on barley, rye and triticale; Sarocladium oryzae and S. attenuatum (sheath rot) on rice; Sclerotinia spp. (stem rot or white mold) on vegetables and field crops, such as rape, sunflowers (e. g. S. sclerotiorum) and soybeans (e. g. S. rolfsii or S. sclerotiorum); Septoria spp. on various plants, e. g. S. glycines (brown spot) on soybeans, S. tritici(Septoria blotch) on wheat and S. (syn. Stagonospora) nodorum (Stagonospora blotch) on cereals; Uncinula (syn. Erysiphe) necator (powdery mildew, anamorph: Oidium tuckei) on vines; Setospaeria spp. (leaf blight) on corn (e. g. S. turcicum, syn. Helminthosporium turcicum) and turf; Sphaceotheca spp. (smut) on corn, (e. g. S. reiliana: head smut), sorghum und sugar cane; Sphaerotheca fuliginea (powdery mildew) on cucurbits; Spongospora subterranea (powdery scab) on potatoes and thereby transmitted viral diseases; Stagonospora spp. on cereals, e. g. S. nodorum (Stagonospora blotch, teleomorph: Leptosphaeria [syn. Phaeosphaeria] nodorum) on wheat; Synchytrium endobioticum on potatoes (potato wart disease); Taphrina spp., e. g. T. deformans (leaf curl disease) on peaches and T. pruni (plum pocket) on plums; Thielaviopsis spp. (black root rot) on tobacco, pome fruits, vegetables, soybeans and cotton, e. g. T. basicola (syn. Chalara elegans); Tiletia spp. (common bunt or stinking smut) on cereals, such as e. g. T. tritici (syn. T. caries, wheat bunt) and T. controversa (dwarf bunt) on wheat; Typhula incarnata (grey snow mold) on barley or wheat; Urocystis spp., e. g. U. occulta (stem smut) on rye; Uromyces spp. (rust) on vegetables, such as beans (e. g. U. appendiculatus, syn. U. phaseoli) and sugar beets (e. g. U. betae); Ustilago spp. (loose smut) on cereals (e. g. U. nuda and U. avaenae), corn (e. g. U. maydis: corn smut) and sugar cane; Venturia spp. (scab) on apples (e. g. V. inaequalis) and pears; and Verticillium spp. (wilt) on various plants, such as fruits and ornamentals, vines, soft fruits, vegetables and field crops, e. g. V. dahliae on strawberries, rape, potatoes and tomatoes.
The compounds I and compositions thereof, respectively, are also suitable for controlling harmful fungi in the protection of stored products or harvest and in the protection of materials.
The term “protection of materials” is to be understood to denote the protection of technical and non-living materials, such as adhesives, glues, wood, paper and paperboard, textiles, leather, paint dispersions, plastics, cooling lubricants, fiber or fabrics, against the infestation and destruction by harmful microorganisms, such as fungi and bacteria. As to the protection of wood and other materials, the particular attention is paid to the following harmful fungi: Ascomycetes such as Ophiostoma spp., Ceratocystis spp., Aureobasidium pullulans, Sclerophoma spp., Chaetomium spp., Humicola spp., Petriella spp., Trichurus spp.; Basidiomycetes such as Coniophora spp., Coriolus spp., Gloeophyllum spp., Lentinus spp., Pleurotus spp., Poria spp., Serpula spp. and Tyromyces spp., Deuteromycetes such as Aspergillus spp., Cladosporium spp., Penicillium spp., Trichoderma spp., Alternaria spp., Paecilomyces spp. and Zygomycetes such as Mucor spp., and in addition in the protection of stored products and harvest the following yeast fungi are worthy of note: Candida spp. and Saccharomyces cerevisae.
The method of treatment according to the invention can also be used in the field of protecting stored products or harvest against attack of fungi and microorganisms. According to the present invention, the term “stored products” is understood to denote natural substances of plant or animal origin and their processed forms, which have been taken from the natural life cycle and for which long-term protection is desired. Stored products of crop plant origin, such as plants or parts thereof, for example stalks, leafs, tubers, seeds, fruits or grains, can be protected in the freshly harvested state or in processed form, such as pre-dried, moistened, comminuted, ground, pressed or roasted, which process is also known as post-harvest treatment. Also falling under the definition of stored products is timber, whether in the form of crude timber, such as construction timber, electricity pylons and barriers, or in the form of finished articles, such as furniture or objects made from wood. Stored products of animal origin are hides, leather, furs, hairs and the like. The combinations according the present invention can prevent disadvantageous effects such as decay, discoloration or mold. Preferably “stored products” is understood to denote natural substances of plant origin and their processed forms, more preferably fruits and their processed forms, such as pomes, stone fruits, soft fruits and citrus fruits and their processed forms.
The compounds I and compositions thereof, respectively, may be used for improving the health of a plant. The invention also relates to a method for improving plant health by treating a plant, its propagation material and/or the locus where the plant is growing or is to grow with an effective amount of compounds I and compositions thereof, respectively.
The term “plant health” is to be understood to denote a condition of the plant and/or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased biomass and/or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and/or greener leaves (“greening effect”)), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and/or biotic stress. The above identified indicators for the health condition of a plant may be interdependent or may result from each other.
The compounds of formula I can be present in different crystal modifications whose biological activity may differ. They are likewise subject matter of the present invention.
The compounds I are employed as such or in form of compositions by treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms by the fungi.
Plant propagation materials may be treated with compounds I as such or a composition comprising at least one compound I prophylactically either at or before planting or transplanting.
The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I according to the invention.
An agrochemical composition comprises a fungicidally effective amount of a compound I. The term “effective amount” denotes an amount of the composition or of the compounds I, which is sufficient for controlling harmful fungi on cultivated plants or in the protection of materials and which does not result in a substantial damage to the treated plants. Such an amount can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated cultivated plant or material, the climatic conditions and the specific compound I used.
The compounds I, their N-oxides and salts can be converted into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e. g. SC, OD, FS), emulsifiable concentrates (e. g. EC), emulsions (e. g. EW, EO, ES, ME), capsules (e. g. CS, ZC), pastes, pastilles, wettable powders or dusts (e. g. WP, SP, WS, DP, DS), pressings (e. g. BR, TB, DT), granules (e. g. WG, SG, GR, FG, GG, MG), insecticidal articles (e. g. LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e. g. GF). These and further compositions types are defined in the “Catalogue of pesticide formulation types and international coding system”, Technical Monograph No. 2, 6th Ed. May 2008, CropLife International.
The compositions are prepared in a known manner, such as described by Mollet and Grubemann, Formulation technology, Wiley VCH, Weinheim, 2001; or Knowles, New developments in crop protection product formulation, Agrow Reports DS243, T&F Informa, London, 2005.
Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.
Suitable solvents and liquid carriers are water and organic solvents, such as mineral oil fractions of medium to high boiling point, e. g. kerosene, diesel oil; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, e. g. toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, e. g. ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; DMSO; ketones, e. g. cyclohexanone; esters, e. g. lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, e. g. N-methyl pyrrolidone, fatty acid dimethyl amides; and mixtures thereof.
Suitable solid carriers or fillers are mineral earths, e. g. silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, e. g. cellulose, starch; fertilizers, e. g. ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; products of vegetable origin, e. g. cereal meal, tree bark meal, wood meal, nutshell meal, and mixtures thereof.
Suitable surfactants are surface-active compounds, such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Examples of surfactants are listed in McCutcheon's, Vol. 1: Emulsifiers & Detergents, McCutcheon's Directories, Glen Rock, USA, 2008 (International Ed. or North American Ed.).
Suitable anionic surfactants are alkali, alkaline earth or ammonium salts of sulfonates, sulfates, phosphates, carboxylates, and mixtures thereof. Examples of sulfonates are alkylaryl sulfonates, diphenyl sulfonates, alpha-olefin sulfonates, lignin sulfonates, sulfonates of fatty acids and oils, sulfonates of ethoxylated alkylphenols, sulfonates of alkoxylated arylphenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl- and tridecylbenzenes, sulfonates of naphthalenes and alkyl naphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of fatty acid esters. Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, and carboxylated alcohol or alkylphenol ethoxylates.
Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters which have been alkoxylated with 1 to 50 equivalents. Ethylene oxide and/or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar-based surfactants are sorbitans, ethoxylated sorbitans, sucrose and glucose esters or alkylpolyglucosides. Examples of polymeric surfactants are home- or copolymers of vinyl pyrrolidone, vinyl alcohols, or vinyl acetate.
Suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkylbetains and imidazolines. Suitable block polymers are block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide, or of the A-B—C type comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are polyacids or polybases. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinyl amines or polyethylene amines.
Suitable adjuvants are compounds, which have a negligible or even no pesticidal activity themselves, and which improve the biological performance of the compound I on the target. Examples are surfactants, mineral or vegetable oils, and other auxiliaries. Further examples are listed by Knowles, Adjuvants and additives, Agrow Reports DS256, T&F Informa UK, 2006, chapter 5.
Suitable thickeners are polysaccharides (e. g. xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates, and silicates.
Suitable bactericides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones.
Suitable anti-freezing agents are ethylene glycol, propylene glycol, urea and glycerin.
Suitable anti-foaming agents are silicones, long chain alcohols, and salts of fatty acids.
Suitable colorants (e. g. in red, blue, or green) are pigments of low water solubility and water-soluble dyes. Examples are inorganic colorants (e. g. iron oxide, titan oxide, iron hexacyanoferrate) and organic colorants (e. g. alizarin-, azo- and phthalocyanine colorants).
Suitable tackifiers or binders are polyvinyl pyrrolidones, polyvinyl acetates, polyvinyl alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers.
Examples for composition types and their preparation are:
10-60 wt % of a compound I and 5-15 wt % wetting agent (e. g. alcohol alkoxylates) are dissolved in water and/or in a water-soluble solvent (e. g. alcohols) ad 100 wt %. The active substance dissolves upon dilution with water.
5-25 wt % of a compound I and 1-10 wt % dispersant (e. g. polyvinyl pyrrolidone) are dissolved in organic solvent (e. g. cyclohexanone) ad 100 wt %. Dilution with water gives a dispersion.
15-70 wt % of a compound I and 5-10 wt % emulsifiers (e. g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in water-insoluble organic solvent (e. g. aromatic hydrocarbon) ad 100 wt %. Dilution with water gives an emulsion.
5-40 wt % of a compound I and 1-10 wt % emulsifiers (e. g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in 20-40 wt % water-insoluble organic solvent (e. g. aromatic hydrocarbon). This mixture is introduced into water ad 100 wt % by means of an emulsifying machine and made into a homogeneous emulsion. Dilution with water gives an emulsion.
In an agitated ball mill, 20-60 wt % of a compound I are comminuted with addition of 2-10 wt % dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate), 0.1-2 wt % thickener (e. g. xanthan gum) and water ad 100 wt % to give a fine active substance suspension. Dilution with water gives a stable suspension of the active substance. For FS type composition up to 40 wt % binder (e. g. polyvinyl alcohol) is added.
50-80 wt % of a compound I are ground finely with addition of dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate) ad 100 wt % and prepared as water-dispersible or water-soluble granules by means of technical appliances (e. g. extrusion, spray tower, fluidized bed). Dilution with water gives a stable dispersion or solution of the active substance.
50-80 wt % of a compound I are ground in a rotor-stator mill with addition of 1-5 wt % dispersants (e. g. sodium lignosulfonate), 1-3 wt % wetting agents (e. g. alcohol ethoxylate) and solid carrier (e. g. silica gel) ad 100 wt %. Dilution with water gives a stable dispersion or solution of the active substance.
In an agitated ball mill, 5-25 wt % of a compound I are comminuted with addition of 3-10 wt % dispersants (e. g. sodium lignosulfonate), 1-5 wt % thickener (e. g. carboxymethyl cellulose) and water ad 100 wt % to give a fine suspension of the active substance. Dilution with water gives a stable suspension of the active substance.
5-20 wt % of a compound I are added to 5-30 wt % organic solvent blend (e. g. fatty acid dimethyl amide and cyclohexanone), 10-25 wt % surfactant blend (e. g. alcohol ethoxylate and arylphenol ethoxylate), and water ad 100%. This mixture is stirred for 1 h to produce spontaneously a thermodynamically stable microemulsion.
An oil phase comprising 5-50 wt % of a compound I, 0-40 wt % water insoluble organic solvent (e. g. aromatic hydrocarbon), 2-15 wt % acrylic monomers (e. g. methylmethacrylate, methacrylic acid and a di- or triacrylate) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). Radical polymerization results in the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50 wt % of a compound I according to the invention, 0-40 wt % water insoluble organic solvent (e. g. aromatic hydrocarbon), and an isocyanate monomer (e. g. diphenylmethene-4,4′-diisocyanatae) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). The addition of a polyamine (e. g. hexamethylenediamine) results in the formation of polyurea microcapsules. The monomers amount to 1-10 wt %. The wt % relate to the total CS composition.
1-10 wt % of a compound I are ground finely and mixed intimately with solid carrier (e. g. finely divided kaolin) ad 100 wt %.
0.3-30 wt % of a compound I is ground finely and associated with solid carrier (e. g. silicate) ad 100 wt %. Granulation is achieved by extrusion, spray-drying or fluidized bed.
1-50 wt % of a compound I are dissolved in organic solvent (e. g. aromatic hydrocarbon) ad 100 wt %.
The compositions types i) to xiii) may optionally comprise further auxiliaries, such as 0.1-1 wt % bactericides, 5-15 wt % anti-freezing agents, 0.1-1 wt % anti-foaming agents, and 0.1-1 wt % colorants.
The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, more preferably between 1 and 70%, and in particular between 10 and 60%, by weight of active substance. The active substances are employed in a purity of from 90% to 100%, preferably from 95% to 100% (according to NMR spectrum).
For the purposes of treatment of plant propagation materials, particularly seeds, solutions for seed treatment (LS), Suspoemulsions (SE), flowable concentrates (FS), powders for dry treatment (DS), water-dispersible powders for slurry treatment (WS), water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC), and gels (GF) are usually employed. The compositions in question give, after two-to-tenfold dilution, active substance concentrations of from 0.01 to 60% by weight, preferably from 0.1 to 40%, in the ready-to-use preparations. Application can be carried out before or during sowing. Methods for applying compound I and compositions thereof, respectively, onto plant propagation material, especially seeds, include dressing, coating, pelleting, dusting, and soaking as well as in-furrow application methods. Preferably, compound I or the compositions thereof, respectively, are applied on to the plant propagation material by a method such that germination is not induced, e. g. by seed dressing, pelleting, coating and dusting.
When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 0.9 kg per ha, and in particular from 0.1 to 0.75 kg per ha.
In treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching seed, amounts of active substance of from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kilogram of plant propagation material (preferably seeds) are generally required.
When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are 0.001 g to 2 kg, preferably 0.005 g to 1 kg, of active substance per cubic meter of treated material.
Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and further pesticides (e. g. herbicides, insecticides, fungicides, growth regulators, safeners, biopesticides) may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1.
A pesticide is generally a chemical or biological agent (such as pestidal active ingredient, compound, composition, virus, bacterium, antimicrobial or disinfectant) that through its effect deters, incapacitates, kills or otherwise discourages pests. Target pests can include insects, plant pathogens, weeds, mollusks, birds, mammals, fish, nematodes (roundworms), and microbes that destroy property, cause nuisance, spread disease or are vectors for disease. The term “pesticide” includes also plant growth regulators that alter the expected growth, flowering, or reproduction rate of plants; defoliants that cause leaves or other foliage to drop from a plant, usually to facilitate harvest; desiccants that promote drying of living tissues, such as unwanted plant tops; plant activators that activate plant physiology for defense of against certain pests; safeners that reduce unwanted herbicidal action of pesticides on crop plants; and plant growth promoters that affect plant physiology e.g. to increase plant growth, biomass, yield or any other quality parameter of the harvestable goods of a crop plant.
The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area.
According to one embodiment, individual components of the composition according to the invention such as parts of a kit or parts of a binary or ternary mixture may be mixed by the user himself in a spray tank or any other kind of vessel used for applications (e. g. seed treater drums, seed pelleting machinery, knapsack sprayer) and further auxiliaries may be added, if appropriate.
Consequently, one embodiment of the invention is a kit for preparing a usable pesticidal composition, the kit comprising a) a composition comprising component 1) as defined herein and at least one auxiliary; and b) a composition comprising component 2) as defined herein and at least one auxiliary; and optionally c) a composition comprising at least one auxiliary and optionally a further active component 3) as defined herein.
Mixing the compounds I or the compositions comprising them in the use form as fungicides with other fungicides results in many cases in an expansion of the fungicidal spectrum of activity being obtained or in a prevention of fungicide resistance development. Furthermore, in many cases, synergistic effects are obtained.
The following list of pesticides II (e. g. pesticidally-active substances and biopesticides), in conjunction with which the compounds I can be used, is intended to illustrate the possible combinations but does not limit them:
N.11 Cellulose biosynthesis inhibitors: chlorthiamid, dichlobenil, flupoxam, indaziflam, isoxaben, triaziflam, 1-cyclohexyl-5-pentafluorphenyloxy-14-[1,2,4,6]thiatriazin-3-ylamine (CAS 175899-01-1);
The active substances referred to as component 2, their preparation and their activity e. g. against harmful fungi is known (cf.: http://www.alanwood.net/pesticides/); these substances are commercially available. The compounds described by IUPAC nomenclature, their preparation and their pesticidal activity are also known (cf. Can. J. Plant Sci. 48(6), 587-94, 1968; EP-A 141 317; EP-A 152 031; EP-A 226 917; EP-A 243 970; EP-A 256 503; EP-A 428 941; EP-A 532 022; EP-A 1 028 125; EP-A 1 035 122; EP-A 1 201 648; EP-A 1 122 244, JP 2002316902; DE 19650197; DE 10021412; DE 102005009458; U.S. Pat. Nos. 3,296,272; 3,325,503; WO 98/46608; WO 99/14187; WO 99/24413; WO 99/27783; WO 00/29404; WO 00/46148; WO 00/65913; WO 01/54501; WO 01/56358; WO 02/22583; WO 02/40431; WO 03/10149; WO 03/11853; WO 03/14103; WO 03/16286; WO 03/53145; WO 03/61388; WO 03/66609; WO 03/74491; WO 04/49804; WO 04/83193; WO 05/120234; WO 05/123689; WO 05/123690; WO 05/63721; WO 05/87772; WO 05/87773; WO 06/15866; WO 06/87325; WO 06/87343; WO 07/82098; WO 07/90624, WO 10/139271, WO 11/028657, WO 12/168188, WO 07/006670, WO 11/77514; WO 13/047749, WO 10/069882, WO 13/047441, WO 03/16303, WO 09/90181, WO 13/007767, WO 13/010862, WO 13/127704, WO 13/024009, WO 13/24010, WO 13/047441, WO 13/162072, WO 13/092224, WO 11/135833, CN 1907024, CN 1456054, CN 103387541, CN 1309897, WO 12/84812, CN 1907024, WO 09094442, WO 14/60177, WO 13/116251, WO 08/013622, WO 15/65922, WO 94/01546, EP 2865265, WO 07/129454, WO 12/165511, WO 11/081174, WO 13/47441).
The present invention furthermore relates to agrochemical compositions comprising a mixture of at least one compound I (component 1) and at least one further active substance useful for plant protection, e. g. selected from the groups A) to O) (component 2), in particular one further fungicide, e. g. one or more fungicide from the groups A) to K), as described above, and if desired one suitable solvent or solid carrier. Those mixtures are of particular interest, since many of them at the same application rate show higher efficiencies against harmful fungi. Furthermore, combating harmful fungi with a mixture of compounds I and at least one fungicide from groups A) to K), as described above, is more efficient than combating those fungi with individual compounds I or individual fungicides from groups A) to K).
By applying compounds I together with at least one active substance from groups A) to O) a synergistic effect can be obtained, i.e. more then simple addition of the individual effects is obtained (synergistic mixtures).
This can be obtained by applying the compounds I and at least one further active substance simultaneously, either jointly (e. g. as tank-mix) or seperately, or in succession, wherein the time interval between the individual applications is selected to ensure that the active substance applied first still occurs at the site of action in a sufficient amount at the time of application of the further active substance(s). The order of application is not essential for working of the present invention.
When applying compound I and a pesticide II sequentially the time between both applications may vary e. g. between 2 hours to 7 days. Also a broader range is possible ranging from 0.25 hour to 30 days, preferably from 0.5 hour to 14 days, particularly from 1 hour to 7 days or from 1.5 hours to 5 days, even more preferred from 2 hours to 1 day.
In the binary mixtures and compositions according to the invention the weight ratio of the component 1) and the component 2) generally depends from the properties of the active components used, usually it is in the range of from 1:10,000 to 10,000:1, often it is in the range of from 1:100 to 100:1, regularly in the range of from 1:50 to 50:1, preferably in the range of from 1:20 to 20:1, more preferably in the range of from 1:10 to 10:1, even more preferably in the range of from 1:4 to 4:1 and in particular in the range of from 1:2 to 2:1.
According to further embodiments of the binary mixtures and compositions, the weight ratio of the component 1) and the component 2) usually is in the range of from 1000:1 to 1:1, often in the range of from 100:1 to 1:1, regularly in the range of from 50:1 to 1:1, preferably in the range of from 20:1 to 1:1, more preferably in the range of from 10:1 to 1:1, even more preferably in the range of from 4:1 to 1:1 and in particular in the range of from 2:1 to 1:1.
According to further embodiments of the mixtures and compositions, the weight ratio of the component 1) and the component 2) usually is in the range of from 20,000:1 to 1:10, often in the range of from 10,000:1 to 1:1, regularly in the range of from 5,000:1 to 5:1, preferably in the range of from 5,000:1 to 10:1, more preferably in the range of from 2,000:1 to 30:1, even more preferably in the range of from 2,000:1 to 100:1 and in particular in the range of from 1,000:1 to 100:1.
According to a further embodiments of the binary mixtures and compositions, the weight ratio of the component 1) and the component 2) usually is in the range of from 1:1 to 1:1000, often in the range of from 1:1 to 1:100, regularly in the range of from 1:1 to 1:50, preferably in the range of from 1:1 to 1:20, more preferably in the range of from 1:1 to 1:10, even more preferably in the range of from 1:1 to 1:4 and in particular in the range of from 1:1 to 1:2.
According to further embodiments of the mixtures and compositions, the weight ratio of the component 1) and the component 2) usually is in the range of from 10:1 to 1:20,000, often in the range of from 1:1 to 1:10,000, regularly in the range of from 1:5 to 1:5,000, preferably in the range of from 1:10 to 1:5,000, more preferably in the range of from 1:30 to 1:2,000, even more preferably in the range of from 1:100 to 1:2,000 to and in particular in the range of from 1:100 to 1:1,000.
In the ternary mixtures, i.e. compositions according to the invention comprising the component 1) and component 2) and a compound III (component 3), the weight ratio of component 1) and component 2) depends from the properties of the active substances used, usually it is in the range of from 1:100 to 100:1, regularly in the range of from 1:50 to 50:1, preferably in the range of from 1:20 to 20:1, more preferably in the range of from 1:10 to 10:1 and in particular in the range of from 1:4 to 4:1, and the weight ratio of component 1) and component 3) usually it is in the range of from 1:100 to 100:1, regularly in the range of from 1:50 to 50:1, preferably in the range of from 1:20 to 20:1, more preferably in the range of from 1:10 to 10:1 and in particular in the range of from 1:4 to 4:1.
Any further active components are, if desired, added in a ratio of from 20:1 to 1:20 to the component 1).
These ratios are also suitable for inventive mixtures applied by seed treatment.
Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Qo site in group A), more preferably selected from compounds (A.1.1), (A.1.4), (A.1.8), (A.1.9), (A.1.10), (A.1.12), (A.1.13), (A.1.14), (A.1.17), (A.1.21), (A.1.24), (A.1.25), (A.1.26), (A.1.27), (A.1.30), (A.1.31), (A.1.32), (A.1.34) and (A.1.35); particularly selected from (A.1.1), (A.1.4), (A.1.8), (A.1.9), (A.1.13), (A.1.14), (A.1.17), (A.1.24), (A.1.25), (A.1.26), (A.1.27), (A.1.30), (A.1.31), (A.1.32), (A.1.34) and (A.1.35).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Qi site in group A), more preferably selected from compounds (A.2.1), (A.2.3) and (A.2.4); particularly selected from (A.2.3) and (A.2.4).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex II in group A), more preferably selected from compounds (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.11), (A.3.12), (A.3.15), (A.3.16), (A.3.17), (A.3.18), (A.3.19), (A.3.20), (A.3.21), (A.3.22), (A.3.23), (A.3.24), (A.3.25), (A.3.27), (A.3.28), (A.3.29), (A.3.31), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39); particularly selected from (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.12), (A.3.15), (A.3.17), (A.3.19), (A.3.22), (A.3.23), (A.3.24), (A.3.25), (A.3.27), (A.3.29), (A.3.31), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from other respiration inhibitors in group A), more preferably selected from compounds (A.4.5) and (A.4.11); in particular (A.4.11).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from C14 demethylase inhibitors in group B), more preferably selected from compounds (B.1.4), (B.1.5), (B.1.8), (B.1.10), (B.1.11), (B.1.12), (B.1.13), (B.1.17), (B.1.18), (B.1.21), (B.1.22), (B.1.23), (B.1.25), (B.1.26), (B.1.29), (B.1.34), (B.1.37), (B.1.38), (B.1.43) and (B.1.46); particularly selected from (B.1.5), (B.1.8), (B.1.10), (B.1.17), (B.1.22), (B.1.23), (B.1.25), (B.1.33), (B.1.34), (B.1.37), (B.138), (B.1.43) and (B.1.46).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from Delta14-reductase inhibitors in group B), more preferably selected from compounds (B.2.4), (B.2.5), (B.2.6) and (B.2.8); in particular (B.2.4).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from phenylamides and acyl amino acid fungicides in group C), more preferably selected from compounds (C.1.1), (C.1.2), (C.1.4) and (C.1.5); particularly selected from (C.1.1) and (C.1.4).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from other nucleic acid synthesis inhibitors in group C), more preferably selected from compounds (C.2.6), (C.2.7) and (C.2.8).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group D), more preferably selected from compounds (D.1.1), (D.1.2), (D.1.5), (D.2.4) and (D.2.6); particularly selected from (D.1.2), (D.1.5) and (D.2.6).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group E), more preferably selected from compounds (E.1.1), (E.1.3), (E.2.2) and (E.2.3); in particular (E.1.3).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group F), more preferably selected from compounds (F.1.2), (F.1.4) and (F.1.5).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group G), more preferably selected from compounds (G.3.1), (G.3.3), (G.3.6), (G.5.1), (G.5.2), (G.5.3), (G.5.4), (G.5.5), G.5.6), G.5.7), (G.5.8), (G.5.9), (G.5.10) and (G.5.11); particularly selected from (G.3.1), (G.5.1), (G.5.2) and (G.5.3).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group H), more preferably selected from compounds (H.2.2), (H.2.3), (H.2.5), (H.2.7), (H.2.8), (H.3.2), (H.3.4), (H.3.5), (H.4.9) and (H.4.10); particularly selected from (H.2.2), (H.2.5), (H.3.2), (H.4.9) and (H.4.10).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group I), more preferably selected from compounds (I.2.2) and (I.2.5).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group J), more preferably selected from compounds (J.1.2), (J.1.5), (J.1.8), (J.1.11) and (J.1.12); in particular (J.1.5).
Preference is also given to mixtures comprising as component 2) at least one active substance selected from group K), more preferably selected from compounds (K.1.41), (K.1.42), (K.1.44), (K.1.45), (K.1.47) and (K.1.49); particularly selected from (K.1.41), (K.1.44), (K.1.45), (K.1.47) and (K.1.49).
With due modification of the starting compounds, the procedures shown in the synthesis examples below were used to obtain further compounds I. The resulting compounds, together with physical data, are listed in Table I below.
HPLC-MS: HPLC-column Kinetex XB C18 1.7μ (50×2.1 mm); eluent: acetonitrile/water+0.1% TFA (5 gradient from 5:95 to 100:0 in 1.5 min at 60° C., flow gradient from 0.8 to 1.0 ml/min in 1.5 min). MS: Quadrupol Electrospray lonisation, 80 V (positive mode).
To a solution of 1.3 g 2,3-dibromo-5-cyanopyridine (5 mmol) and 1 g of 2-methyl-1-phenyl-propan-2-ol (7 mmol) in 20 ml of DCE at 0° C., 3 mL trifluoromethyl acid (33 mmol) were added. The reaction mixture was allowed to warm to rt overnight. Then, it was diluted with ethyl acetate and extracted with Na2CO3. The organic phase is washed with water, dried with Na2SO4 and concentrated. The crude was purified via HPLC (water/acetonitrile) to yield 1.33 g (26%) of the title compound as a colorless oil.
1H-NMR (CDCl3, δ in ppm): 8.5 (s, 1H); 8.2 (s, 1H); 7.5 (t, 1H); 7.3 (m, 2H); 7.1 (d, 1H); 2.8 (2, 2H); 1.3 (s, 6H).
To a solution of 1.73 g of 1-(5,6-dibromo-3-pyridyl)-3,3-dimethyl-4H-isoquinoline (3 mmol) in 20 mL of acetonitrile at rt, 1.53 ml of NEt3*3HF (9 mmol). After 1 h at 90° C., the reaction mixture was diluted with ethyl acetate and extracted with Na2CO3. The organic phase is washed with water, dried with Na2SO4 and concentrated. The crude was purified via HPLC (water/acetonitrile) to yield 990 mg (74%) of the title compound as a yellow oil
1H-NMR (CDCl3, δ in ppm): 8.5 (s, 1H); 8.2 (s, 1H); 7.8 (d, 1H); 7.7 (t, 1H); 7.5 (t, 1H); 7.3 (s, 1H); 1.4 (s, 6H).
To a solution of 2 g 1-(5,6-dibromo-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline (5 mmol) in 22 mL dioxane, 1.75 g of trimetylboroxin (14 mmol), 2.2 g of potassium carbonate (16 mmol) and 200 mg of palladium triphenylphosphine (0.2 mmol). The reaction was allowed to stir for 7 days at rt, after it was diluted with MTBE. The non-organic phase was extracted 2 times with MTBE. The combined organic phase were washed with water, dried with Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (heptane/EtOAc) to yield 1 g (72%) of the title compound as a white solid (m.p.: 103° C.)
1H-NMR (CDCl3, δ in ppm): 8.5 (s, 1H); 7.8 (d, 1H); 7.7-7.6 (m, 1H); 7.5 (t, 1H); 7.3 (d, 1H); 2.5 (s, 3H); 2.3 (s, 3H); 1.4 (s, 6H).
To a solution of 560 mg of 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline in 25 mL of MeOH at 0° C., 212 mg of NaBH4 (6 mmol) were added. The reaction mixture was allowed to warm to rt overnight. Then, it was diluted with ethyl acetate and extracted with Na2CO3. The organic phase is washed with water, dried with Na2SO4 and concentrated. The crude was purified via HPLC (water/acetonitrile) to yield 150 mg (26%) of the title compound as a yellow oil
1H-NMR (CDCl3, δ in ppm): 8.3 (s, 1H); 7.75 (d, 1H); 7.35 (t, 1H); 7.3 (t, 1H); 7.2 (s, 1H); 6.8 (d, 1H); 5.15 (d, 1H); 2.5 (s, 3H); 2.2 (s, 3H); 1.4 (s, 3H); 1.35 (s, 3H).
Alternatively, 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline can be also obtained from 1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethylisoquinoline
To a solution of 1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline (5 g, 13.5 mmol) in 170 mL NH4Cl sat. solution, carbonyl iron (0.09 g, 1.6 mmol) were added.
The reaction mixture was stirred overnight at 80° C., then water and MTBE were added. The mixture was filtered through celite, after separation the aq. phase was extracted 2 times with MTBE. The combined org. phases were washed with water, dried over MgSO4 and concentrated. The residue was purified via silica gel column chromatography (EtOAc, heptane) giving 1.2 g of the tittle compound (30%) as an orange oil.
1H-NMR (CDCl3, δ in ppm): 8.7 (s, 1H); 7.9 (d, 1H); 7.8 (s, 1H); 7.6 (t, 1H); 7.5 (t, 1H); 7.3 (d, 1H); 7.0 (s, 1H); 2.5 (s, 3H); 1.4 (s, 6H).
Alternatively, compound of 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline using intermediate B.
To a solution of 3,3-dimethyl-1-phenylsulfanyl-4H-isoquinoline (2.7 g. 10.06 mmol) and AlBN (0.17 g, 0,001 mmol) in 100 mL cyclohexan, NBS (4.1 g, 22.6 mmol) were added under nitrogen atmosphere. The reaction mixture was allowed to react at 65° C. for 2 h, then filtered and concentrated giving 4.3 g of the tittle compound (71%) as a yellow oil, which was used at the next step without further purification.
To a solution of 4,4-dibromo-3,3-dimethyl-1-phenylsulfanyl-isoquinoline (4.3 g, 0.007 mol) in 50 mL acetonitrile, Et3N*3HCl (3.5 mL, 0.021 mol) was added at rt. The reaction mixture was stirred overnight, before being quenched with a 20% NaOH sol. The aq. phase was extracted 3 times with MTBE, the combined org. phases were washed with brine, dried over Na2SO4 and concentrated. The crude was purified by silica gel column chromatography (EtOAc/heptane) giving 1.1 g of the tittle compound (49%) as a yellow oil.
1H-NMR (CDCl3, δ in ppm): 7.8 (d, 1H), 7.7 (d, 1H), 7.6 (m, 2H), 7.5 (m, 2H), 7.3 (m, 2H), 1.3 (s, 6H)
To a solution of magnesium (71.9 mg, 0.003 mol) and LiCl (125.3 mg, 0.003 mol) under Ar atmosphere in 0.5 mL THF, 0.7 mL of 1M DIBALH solution were added at 0° C. The reaction mixture was stirred for 10 min, 5-bromo-2,3-dimethylpyridine (500 mg, 2.7 mmol) was slowly added (exothermic reaction). After 2 h at rt, this mixture was added to a solution of 4,4-difluoro-3,3-dimethyl-1-phenylsulfanyl-isoquinoline (103.0 mg, 0.34 mmol) and 11 mg from NiCl2(PPh3)2 in 0.5 mL THF under Ar atmosphere at 0° C. The final mixture was allowed to react overnight at rt. Cold water and MTBE were added, the aq. phase was extracted 3 times with MTBE. The combined org. phase were dried over Na2SO4 and concentrated. The residue was purified by MPLC (water/acetonitrile) giving 26.3 mg of the titled compound (26%, 85% purity) as brown oil.
Synthesis of 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline using intermediate D
To a solution of 2,2-difluoro-2-phenyl-acetonitrile (0.1 g, 0.001 mol) in 2 mL THF at 0° C., methyl magnesium bromide (0.65 mL, 0.001 mol) was slowly added. After 10 min, titanium isopropoxide (0.19 g, 0.001 mol) was added. The reaction was allowed to react overnight at rt, then water was added. The aq. Phase was extracted 3 times with MTBE, the combined org. phases were washed with water, a NaCl solution, dried over Na2SO4 and concentrated. 0,093 g of the tittle compound were isolated (100%) and used at the next step without further purification.
1H-NMR (CDCl3, δ in ppm): 7.5-7.3 (m, 5H); 1.2 (s, 6H).
To a solution of 5,6-dimethylpyridine-3-carboxylic acid (0.6 g, 4.0 mmol) in 10 mL CH2Cl2, oxalyl chloride (1.5 mL, 0.006 mol) were added at 0° C. Slowly DMF was added, after a few minutes the reaction was finished. The reaction mixture was direct concentrated giving the tittle compound, which was used as the next step without further purification.
To a solution of 1,1-difluoro-2-methyl-1-phenyl-propan-2-amine (0,740 g, 0.004 mol) in 7 mL CH2Cl2, Et3N (2.5 mL, 0.01 mol) was added a 0° C. Then, a solution of 5,6-dimethylpyridine-3-carbonyl chloride (0.74 g, 0.004 mol) in 3 mL CH2Cl2 was added slowly. The reaction mixture was allowed to react overnight at rt, then water was added. The aq. phase was extracted 3 times with CH2Cl2. The combinaded org. phases were washed with water, a NaCl solution, dried over Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (MTBE/heptane) giving 0.67 g of the tittle compound (52%) as a brown oil.
1H-NMR (CDCl3, δ in ppm): 8.6 (s, 1H), 7.7 (s, 1H); 7.6-7.4 (m, 5H); 6.2 (br s, 1H); 2.6 (s, 3H); 2.3 (s, 3H); 1.6 (s, 6H).
To a solution of compound N-(2,2-difluoro-1,1-dimethyl-2-phenyl-ethyl)-5,6-dimethyl-pyridine-3-carboxamide (300 mg, 0.94 mmol) in 5 mL CH2Cl2, pyridine (1.2 mL, 1.13 mmol) was added. At −75° C., Tf2O (1.1 mL, 1.04 mmol) was added. The reaction mixture was allowed to warm to rt, after 5 h water was added and the aq. phase was extracted 3 times with CH2Cl2. The combinaded org. phases were washed with water, a NaCl solution, dried over Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (MTBE/heptane) giving 60 mg of the tittle compound (21%) as a solid.
Alternatively, compound 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-1,2-dihydroisoquinoline can also be synthesized (I-1)
To a solution of 1 g of 1-(5,6-dibromo-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline (2 mmol) in 10 mL of THF at −78° C., 1.6 mL of BuLi (1.6 M; 3 mmol) was added dropwise. After 30 min, the reaction mixture was diluted with a sat. solution NH4Cl and extracted with MTBE. The organic phase was dried over MgSO4 and concentrated. The crude was purified via HPLC (water/acetonitrile) to yield 0.8 g (24%) of the title compound as a solid (m.p: 103° C.) and 0.8 g (18%) of 1-(6-bromo-3-pyridyl)-3,3-dimethyl-4H-isoquinoline as an oil.
1H-NMR (CDCl3, δ in ppm): 8.4 (s, 1H); 7.9 (d, 1H); 7.8 (d, 1H); 7.7 (t, 1H); 7.5 (t, 1H); 7.3 (d, 1H); 2.5 (s, 3H); 1.4 (s, 6H).
To a solution of 0.3 g of 1-(6-bromo-5-methyl-3-pyridyl)-3,3-dimethyl-4H-isoquinoline (1 mmol) in 25 mL MeoH at 0° C., 350 mg of NaBH4 (10 mmol) were added. The reaction mixture was allowed to warm to rt overnight. Then, it was diluted with ethyl acetate and extracted with Na2CO3. The organic phase is washed with water, dried with Na2SO4 and concentrated. The crude was purified via HPLC (water/acetonitrile) to yield 302 mg (100%) of the title compound as a yellow oil
1H-NMR (CDCl3, δ in ppm): 8.2 (s, 1H); 7.8 (d, 1H); 7.5-7.2 (m, 3H); 6.8 (d, 1H); 7.3 (d, 1H); 5.2 (brs, 1); 2.3 (s, 3H); 1.3 (s, 3H); 1.2 (s, 3H).
To a 1.2 L solution of 3,3-dimethyl-4H-isoquinoline (30 g, 0.1888 mol) in cyclohexan, NBS (73.8, 0.4 mol) and AlBN (3.1 g, 0.019 mol) was added under nitrogen atmosphere. After 30 min at room temperature, the reaction mixture was warmed to 60° C., after 30 min it was concentrated and the filtrated was used in the next step directly.
To a 600 mL solution of 4,4-dibromo-3,3-dimethyl-isoquinoline (51.6 g, 0.13 mol) in acetonitrile, triethylamine*3HF (0.99 mL, 0.4 mol) was added dropwise. After 3 h at room temperature, the reaction mixture was allowed to react overnight at 80° C. After quenching with 300 mL 20% NaOH solution (pH=12-14), the aq. phase was extracted 3 times with ethyl acetate. The combined org. phase were washed, dried with Na2SO4 and concentrated. 31.6 g (900%) of the tittle compound were isolated as a brown oil and used in the next step after distillation.
1H-NMR (CDCl3, δ in ppm): 8.3 (s, 1H); 7.8 (d, 1H); 7.7 (m, 2H); 7.4 (d, 1H); 1.4 (s, 6H).
To a solution of 4,4-difluoro-3,3-dimethyl-isoquinoline (15 g, 70.7 mmol) in 300 mL MeOH at 0° C., sodium borohydride (4 g, 0.11 mol) was added slowly. The reaction mixture was stirred for 1 h, then concentrated. The rest was diluted in dichloromethane and water, the aq. Phase was extracted 3 times with dichloromethane. The organic phase was dried with Na2SO4 and concentrated. 13.9 g (100%) of the tittle compound were isolated as a brown oil and used a in the next step without any further purification.
1H-NMR (CDCl3, δ in ppm): 7.7 (d, 1H); 7.5-7.3 (m, 2H); 7.1 (d, 1H); 4.0 (br s, 2H); 2.0 (br s, 1H); 1.2 (s, 6H).
To a solution of 4,4-difluoro-3,3-dimethyl-1,2-dihydroisoquinoline (13.9 g, 70.5 mmol) in 300 mL MeOH at 0° C., sodium wolframat dehydrate (2.3 g, 7.0 mmol) was added. Then, a 30% hydrogen peroxide solution (28.8 mL, 281.9 mmol) was added over 5 min. The reaction mixture was allowed to warm to room temperature overnight. After cooling with a ice bath, 150 mL of sodium thiosulfate solution was added, 30 min later the aq. phase was extracted 3 times with dichloromethane. The combined organic phases were washed with a sodium thiosulfate solution, dried over Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (heptane/diisopropylether) to yield 11, 9 g (80%) of the title compound as a brown oil
1H-NMR (CDCl3, δ in ppm): 7.7 (d+s, 2H); 7.6-7.4 (m, 2H), 7.2 (dd, 1H); 1.6 (s, 6H).
To a flask with magnesium (0,387 g, 16 mmol) and LiCl (0.7 g, 16.0 mmol) under Ar atmosphere, 5 mL of 1M DIBALH solution were added. The reaction mixture was stirred for 10 min at 0° C., 5-bromo-2,3-dimethylpyridine (2.7 g, 14.5 mmol) was slowly added (exothermic reaction). The reaction mixture was allowed to warm to rt and stirred for 2 h. At rt, a 9 mL solution of 4,4-difluoro-3,3-dimethyl-isoquinoline 2-oxide (3.1 g, 14.5 mmol) in THF was added over the mixture, the reaction was controlled below 30° C. using an ice bath. After 1.5 h, a mixture of 150 mL cold water and 100 mL MTBE were added, the aq. phase was extracted 3 times with MTBE. The combined org. phase were filtrated throught celite, dried over Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (heptane/diisopropylether) to yield 2.2 g (48%) of the title compound as a brown oil
1H-NMR (CDCl3, δ in ppm): 8.3 (br s, 1H); 8.1 (s, 1H); 7.7 (d, 1H); 7.3 (dd, 1H), 7.2 (dd, 1H); 7.1 (s, 1H), 6.6 (d, 1H); 4.8 (d, 1H); 2.2 (s, 3H); 2.1 (s, 3H); 1.6 (s, 3H); 1.2 (s, 3H).
HPLC/MS: 0.884 min; M++H=319.0
To a solution of 5-bromo-2-(difluoromethyl)-3-methyl-pyridine (161 mg, 0.73 mmol) in 1 mL THF, turbo Grignard (0.8 mL, 1.04 mmol) was added at room temperature under Ar atmosphere. After 3 h at rt, a solution of 4,4-difluoro-3,3-dimethyl-2-oxido-isoquinolin-2-ium (168.5 mg, 1.04 mmol) in 1 mL THF was added dropwise. The reaction mixture was allowed to react overnight, then diluted with water. The aq. phase was extracted 3 times with MTBE, the combined organic phases were concentrated, and dried over Na2SO4. The crude was purified via MPLC (water/acetonitrile) to yield 50 mg (20%) of the title compound.
HPLC/MS: 1.179 min; M++H=355.1
To a solution of 5,6-dimethylpyridine-3-carbonitrile (50 g, 0.34 mol) in 500 mL acetic acid, potassium acetate (186 g, 1.9 mol) was added followed by trichloroisocyanuric acid (66 g, 0.28 mol). The reaction mixture was warmed to 50° C. for 7 h, then it was quenched with a 10% NaOH solution followed by addition of ethyl acetate. The org. phase was washed 2 times with 10% NaOH sol. Finally, the org. phase was dried over Na2SO4 and concentrated. 65.5 g of the titled compound (86%) were isolated as a white powder after crystallization (iisopropylether) as a white solid (see ref. JP2009/67682).
1H-NMR (CDCl3, route in ppm): 8.7 (s, 1H), 7.9 (s, 1H); 6.9 (s, 1H); 2.6 (s, 3H).
To 500 mL a solution of 6-(dichloromethyl)-5-methyl-pyridine-3-carbonitrile (50 g, 0.25 mol) and 2-methyl-1-phenyl-propan-2-ol (46.7 g, 0.31 mol) in dichloroethane in an ice bath, triflruoacetic acid (117.7 mL, 1.33 mol) were added dropwise added. After 3 h at rt, the reaction mixture was diluted with dichloromethane, and quenched with a 10% NaOH solution. The org.phase was washed with water, dried over Na2SO4 and concentrated. 33 g of the tittle compound (64%) was obtain after recrystallization (isopropylether) and silica gel column chromatography (ethyl acetate/heptane) as white solid.
1H-NMR (CDCl3, δ in ppm): 8.6 (s, 1H), 7.8 (s, 1H), 7.4 (t, 1H), 7.2 (m, 2H), 7.1 (d, 1H), 7.0 (s, 1H), 2.9 (s, 3H), 2.6 (s, 6H).
To a solution of 1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-3,3-dimethyl-4H-isoquinoline (5 g, 0.015 mol) in 250 mL EtOAc, AlBN (0.25 g, 0.002 mol) and NBS (11.2 g, 0.063 mol) were added. The reaction mixture was stirred at 80° C. for 2 h, then diluted with EtOAc and quenched with a 10% NaOH solution. The org.phase was washed with water, dried over Na2SO4 and concentrated. 5.1 g of the titled compound (45%) were isolated after crystallization (diisopropyl ether/pentane 1:1) as a white powder.
To a solution of 4,4-dibromo-1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-3,3-dimethyl-isoquinoline (1 g, 0.001 mol) in 6 mL triethylamine, Et3N*3HF (6 mL, 0.037 mol) was added. The reaction was stirred for overnight at 100° C., then quenched with ice followed by a 10% NaOH sol. and diluted with EtOAc. The org.phase was washed with water, dried over Na2SO4 and concentrated. 0.41 g of the title compound (69%) were isolated after silica gel column chromatography (EtOAc/heptane) as a yellow oil.
1H-NMR (CDCl3, δ in ppm): 8.7 (d, 1H), 7.8 (m, 2H), 7.7 (t, 1H), 7.5 (t, 1H), 7.0 (s, 1H), 6.8 (t, 1H), 2.7 (s, 3H), 1.4 (s, 6H).
To a solution of 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline (0.3 g, 0.001 mol) in 10 mL MeOH, 3 mL acetic acid and sodium cyanoborohydride (0.17 g, 0.003 mol) were added. The reaction mixture was allowed to react at rt overnight, then it was diluted with EtOAc, and washed with a Na2CO3 sol. The org. phase was washed again with water, dried over Na2SO4 and concentrated. The crude was purified via MPLC (water/acetonitrile) to give 247 mg of the titled compound (95%) as an oil.
1H-NMR (CDCl3, δ in ppm): 8.4 (s, 1H); 7.8 (d, 1H), 7.5-7.3 (m, 3H), 6.8 (d, 1H), 6.7 (t, 1H), 5.2 (d, 1H), 2, 5 (s, 3H), 1.7 (br s, 1H), 1.3 (s, 3H), 1.2 (s, 3H).
HPLC-MS: 0.864 min, M++H=321.0
Alternatively synthesis to 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline
To a solution of 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline (1 g, 0.003 mol) in 5 mL acetic esther, potassium acetate (1.6 g, 0.017 mol) and tribromoisocyanuric acid (0.58 g, 0.002 mol) were added at rt. The reaction mixture was stirred at 50° C. for 6 h, then it was diluted with ethyl acetate and quenched with a Na2CO3 solution. The org. phase was washed with water, dried over Na2SO4 and concentrated. The crude was purified via silica gel column chromatography (EtOAc/heptane) giving 1.11 g of the tittle compound (95%) as an aoil.
1H-NMR (CDCl3, δ in ppm): 8.7 (s, 1H); 7.9 (d, 1H); 7.8 (s, 1H); 7.6 (t, 1H); 7.5 (t, 1H); 7.3 (d, 1H); 7.0 (s, 1H); 2.5 (s, 3H); 1.4 (s, 6H).
A solution of 1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline (0,150 g, 0.4 mmol) in 9 mL Et3N*3HCl was allowed to react at 80° C. overnight. The reaction was diluted with EtOAc and extracted with 10% NaOH solution. The org.phase was washed with water, dried over Na2SO4 and concentrated. 75 mg of the title compound (55%) were obtained as a brown oil, which was used in the next step without purification.
In another hand, compound 1-[6-(dichloromethyl)-5-methyl-3-pyridyl]-3,3-dimethyl-4H-isoquinoline can also be obtained via 1-(5,6-dimethyl-3-pyridyl)-3,3-dimethyl-4H-isoquinoline using Intermediate B
To a solution of magnesium (71.9 mg, 0.003 mol) and LiCl (125.3 mg, 0.003 mol) under Ar atmosphere in 0.5 mL THF, 0.7 mL of 1M DIBALH solution were added at 0° C. The reaction mixture was stirred for 10 min, 5-bromo-2,3-dimethylpyridine (500 mg, 2.7 mmol) was slowly added (exothermic reaction). After 2 h at rt, this mixture was added to a solution of 3,3-dimethyl-1-methylsulfanyl-4H-isoquinoline (97.6 mg, 0.47 mmol) and 3.1 mg from NiCl2(PPh3)2 in 2.5 mL THF under Ar atmosphere at 0° C. The final mixture was allowed to react overnight at rt. Cold water and MTBE were added, the aq. phase was extracted 3 times with MTBE. The combined org. phase were dried over Na2SO4 and concentrated. 100 mg of the tittle compound were isolated (9%) as a brown oil
The synthesis of 3,3-dimethyl-1-methylsulfanyl-4H-isoquinoline is literature described (WO2015/117563)
To a solution of magnesium (71.9 mg, 0.003 mol) and LiCl (125.3 mg, 0.003 mol) under Ar atmosphere in 0.5 mL THF, 0.7 mL of 1M DIBALH solution were added at 0° C. The reaction mixture was stirred for 10 min, 5-bromo-2,3-dimethylpyridine (500 mg, 2.7 mmol) was slowly added (exothermic reaction). After 2 h at rt, this mixture was added to a solution of 3,3-dimethyl-1-phenylsulfanyl-4H-isoquinoline (97.6 mg, 0.37 mmol) and 2.4 mg from NiCl2(PPh3)2 in 2.5 mL TH F under Ar atmosphere at 0° C. The final mixture was allowed to react overnight at rt. Cold water and MTBE were added, the aq. phase was extracted 3 times with MTBE. The combined org. phase were dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc/Heptane) giving 40 mg of the titled compound (37%) as colorless oil.
For the synthesis of 3,3-dimethyl-1-phenylsulfanyl-4H-isoquinoline see reaction 5.9
To a solution of magnesium (53.9 mg, 0.002 mol) and LiCl (94, o mg, 0.002 mol) under Ar atmosphere in 0.5 mL THF, 0.5 mL of 1M DIBALH solution were added at 0° C. The reaction mixture was stirred for 10 min, 5-bromo-2,3-dimethylpyridine (375.1 mg, 2.0 mmol) was slowly added (exothermic reaction). After 2 h at rt, this mixture was added to a solution of 1-benzylsulfanyl-3,3-dimethyl-4H-isoquinoline (97.6 mg, 0.34 mmol) and 2.3 mg from NiCl2(PPh3)2 in 2.5 mL THF under Ar atmosphere at 0° C. The final mixture was allowed to react overnight at rt. Cold water and MTBE were added, the aq. phase was extracted 3 times with MTBE. The combined org. phase were dried over Na2SO4 and concentrated. 200 mg of the title compound (15%) were isolated and used at the next step without further purification.
For the synthesis of 1-benzylsulfanyl-3,3-dimethyl-4H-isoquinoline check reaction 5.10
To a solution of 14 mL sulfuric acid and 7.5 mL cyclohexan at 0° C., a solution of 2-methyl-1-phenyl-propan-2-ol (5 g, 0.033 mol) and phenylthiocyanate (4.1 g, 0.031 mol) in 7.5 mL cyclohexan was added dropwise during 30 min. The reaction was allowed to react overnight at rt, then it was diluted by addition of 100 mL water and quenched with a 40% K2CO3 sol. After separation, the aq. phase was extracted 2 times with MTBE, the combined org. phases were dried over Na2SO4 and concentrated. 7.2 g of the titled compound (88%) were isolated and used at the next step without further purification.
1H-NMR (CDCl3, δ in ppm): 7.7 (d, 1H), 7.5 (d, 1H), 7.4-7.2 (m, 6H), 7.1 (d, 1H), 2.7 (s, 2H), 1.1, (s, 6H).
To a solution of 15 mL sulfuric acid and 7.5 mL cyclohexan at 0° C., a solution of 2-methyl-1-phenyl-propan-2-ol (5 g, 0.033 mol) and benzylthiocyanate (4.1 g, 0.028 mol) in 7.5 mL cyclohexan was added dropwise during 30 min. The reaction was allowed to react overnight at rt, then it was diluted by addition of 100 mL water and quenched with a 40% K2CO3 sol. After separation, the aq. phase was extracted 2 times with MTBE, the combined org. phases were dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatograpy giving 4.3 g of the tittle compound (52%) as a light yellow oil.
1H-NMR (CDCl3, δ in ppm): 7.6 (d, 1H), 7.4 (t, 1H), 7.3-7.1 (m, 6H), 7.1 (d, 1H), 4.3 (s, 2H), 2.7 (s, 2H), 1.2 (s, 6H)
Alternative synthesis of compound 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline
To a solution of ethyl 3,3-dimethyl-4H-isoquinoline-1-carboxylate (20 g, 0.086 mol) in 250 mL HCCl3, NBS (33, 9 g, 0.19 mol) and AlBN (2.84 g, 0.017 mol) were added at rt. After 1 h, 200 mL heptane was added and 15 min later, 40 g of Ethyl 4,4-dibromo-3,3-dimethyl-isoquinoline-1-carboxylate (95%) were isolated by filtration and used in the next step without further purification.
To a solution of ethyl 4,4-dibromo-3,3-dimethyl-isoquinoline-1-carboxylate (40 g, 0.082 mol) in 100 mL acetonitrile, Et3N*3HF (80 mL, 0.43 mol) was added at rt. After 2 h at 80° C., the reaction mixture was allowed to cold to rt and quenched with a 20% NaOH sol. The aq. phase was washed 2 times with EtOAc, the combined org. phases were washed with a sat. NaCl sol., dried over Na2SO4. 12 g of the tittle compound were isolated (55%) after filtration and concentration of the crude. The compound was used in the next step without further purification.
1H-NMR (CDCl3, δ in ppm): 7.8 (d, 1H); 7.7 (d, 1H); 7.6-7.5 (m, 2H); 4.5 (q, 2H); 1.5 (t, 3H); 1.2 (s, 6H).
Ethyl 3,3-dimethyl-4H-isoquinoline-1-carboxylate can be synthesized following the literature (see Org. Lett. 2009, 11, 729-732).
A mixture of 12 g (0.045 mol), 100 ml isopropanol and 200 ml of 10% hydrochloric acid was heated to reflux for 1 hour. Afterwards the reaction mixture was concentrated under vacuum, 500 ml of toluene were added and the mixture was concentrated again. The residue was taken up in 500 ml of warm isopropanol and this solution was dried over molecular sieves. Subsequently 5,038 g (0.045 mol) potassium t-butanolate were added and the volatiles were evaporated yielding a solid residue. Methyl-t-butyl ether was added, the mixture was stirred and the crystalline title compound was filtered off (yield 5.5 g (44% of theorie)).
The compound was used in the next step without further purification.
A mixture of 7.3 g (0.026 mol) Ethyl 4,4-difluoro-3,3-dimethyl-isoquinoline-1-carboxylate and 1,143 g (0.027 mol) lithium hydroxide×H2O in 100 ml methanol was stirred for 2.5 hours at room temperature. Afterwards the volatiles were evaporated at room temperature, diethylether was added to the residue and the unsoluble crystals were filtered off yielding 6.3 g (99% of theory) of the title compound.
2,429 g (9,909 mmol) lithium 4,4-difluoro-3,3-dimethyl-isoquinoline-1-carboxylate and 2 g (8,738 mmol) 5-bromo-2-(difluoromethyl)-3-methyl-pyridine in 20 ml N-methyl-pyrrolidone and 30 ml toluene were heated at 70° C. under a stream of argon. Subsequently 0,194 g (1,351 mmol) copper(I)bromide and 0,122 g Pd(dppf)Cl2×CH2Cl2 have been added and the reaction mixture was heated at reflux over night. Afterwards the volatiles were evaporated under reduced pressure, the residue was taken up in MTBE and was filtered over a layer of silica. The silica layer was eluted with MTBE and the combined organic layers were extracted with ammonia- and lithium chloride-solution, dried over sodium sulfate and evaporated. The residue was purified via column chromatography over silica eluting with heptane/MTBE-mixtures yielding 2 g (5.9 mmol, 68% of theory) of the title compound as slightly brownish oil which slowly solidified.
1H-NMR (in CDCl3, δ in ppm): 8.6 (s, 1H); 7.88 (d, 1H); 7.84 (s, 1H); 7.67 (t, 1H); 7.56 (t, 1H); 7.26 (d, 1H); 6.77 (t, 1H); 2.58 (s, 3H); 1.4 (s, 6H).
Alternative synthesis of compound 1-(5,6-dimethyl-3-pyridyl)-3,3-dimethyl-4H-isoquinoline from ethyl 3,3-dimethyl-4H-isoquinoline-1-carboxylate
A solution of ethyl 3,3-dimethyl-4H-isoquinoline-1-carboxylate (20 g, 0.086 mol) in 100 mL EtOH and 200 mL HCl was heated 2 h at reflux. Afterwards the volatiles were evaporated and 200 mL EtOH and 400 mL iPrOH were added to the residue. Again the volatiles were evaporated and after cooling 250 mL iPrOH were added. The volatiles were evaporated again MTBE and KOtBu (14, 5 g, 0.13 mol) were added, the mixture was stirred, the crystalline solid was filtered off and washed with more MTBE. 19 g of the titled compound (91%) were isolated. The compound was used in the next step without further purification.
1H-NMR (D2O δ in ppm): 7.6 (t, 1H); 7.5-7.4 (m, 2H); 7.3 (d, 1H); 2, 8 (s, 2H); 1.1 (s, 6H).
To a solution of potassium 3,3-dimethyl-4H-isoquinoline-1-carboxylate (3.1 g, 12.9 mmol), 5-bromo-2,3-methyl-pyridine (2 g, 10.8 mmol), CuBr (0.23 g, 1.6 mmol) and Pd(dppf) Cl2 (0,157 g, 0.1 mmol) in 50 mL NMP, molecular sieves was added. After 20 h at 130° C., a NaHCO3 sol. and CH2Cl2 were added. The aq. phase was extracted with CH2Cl2 and EtOAc. The combined org. phases were washed with a sat. LiCl and sat. NaCl sol., dried and concentrated. 1.27 g of the titled compound (45%) were isolated.
To a solution of 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-1,2-dihydroisoquinoline (I-14) (0,375 g, 1.1 mmol) in 7.5 mL acetonitrile, formaldehyde (0.9 g, 11.1 mmol), NaBH3CN (0.21 g, 3.3 mmol) and 0.7 mL acetic acid were added. The reaction mixture was allowed to react overnight at rt, then it was diluted with EtOAc and quenched with a 1M NaOH sol. The org. phase was washed with Na2CO3 sol., water, dried and concentrated. 0.2 g of the tittle compound (49%) were isolated as a yellow oil.
1H-NMR (CDCl3, δ in ppm): 8.5 (s, 1H); 7.7 (d, 1H); 7.5 (s, 1H); 7.4-7.3 (m, 2H); 6.7 (t, 1H); 4.6 (d, 1H); 2.4 (s, 3H); 2.2 (s, 3H); 1.4 (s, 3H); 1.0 (s, 3H).
HPLC/MS: 1.275 min; M++H=3537. Synthesis of 1-[1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-1H-isoquinolin-2-yl]ethanone (I-20)
To a solution of 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-1,2-dihydroisoquinoline (I-14) (0,375 g, 0.001 mol) in 6 mL CH2Cl2, pyridine (5 mL, 0.006 mol) and acetyl chloride (3 mL, 0.003 moL) were added. The reaction was heated for 2 h at 90° C. in the microwave. The reaction mixture was diluted with EtOAc and quenched with NH4Cl sat. sol. The org. phase was washed with Na2CO3 sol., water, dried and concentrated. 0,184 g of the tittle compound (42%) were isolated as a yellow oil.
1H-NMR (CDCl3, δ in ppm): 8.4 (s, 1H); 7.8 (d, 1H); 7.7 (t, 1H); 7.6-7.5 (m, 2H); 7.3 (s, 1H), 6.7 (t, 1H); 6.1 (s, 1H); 2.5 (s, 3H); 2.2 (s, 3H); 2.0 (s, 3H); 1.5 (s, 3H); 1.2 (s, 3H).
HPLC/MS: 1.180 min; M++H=381.0
1H-NMR
1H-NMR (in
| Number | Date | Country | Kind |
|---|---|---|---|
| 17152578.5 | Jan 2017 | EP | regional |
| 17198548.4 | Oct 2017 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2018/050722 | 1/12/2018 | WO | 00 |
